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Abstract 
 
 Antibiotic resistance is a global public health problem, which is aggravated by the 
emergence and spread of multidrug resistant (MDR) bacteria, especially Gram-negative 
bacterial species. Bacteria can present intrinsically low susceptibility to antibiotics as a result 
of the presence of resistance determinants encoded in their genomes. Besides, they can also 
become resistant through the acquisition of resistance genes through horizontal gene transfer, 
as well as by the selection of genetic mutations. Transient resistance can also be achieved as a 
consequence of a temporal induction of the expression of some of these resistance mechanisms, 
such as MDR efflux pumps. 
 
Stenotrophomonas maltophilia is a Gram-negative opportunistic pathogen with an 
environmental origin and associated with infections in compromised patients, including those 
with cystic fibrosis and with other underlying pathologies. This bacterium exhibits an intrinsic 
low susceptibility to multiple antimicrobial compounds. Particularly, MDR efflux pumps from 
the resistance nodulation division (RND) family are among the most relevant determinants 
contributing to the intrinsic and acquired antibiotic resistance of S. maltophilia.   
 
The role of RND efflux pumps in transient resistance has not been studied in 
S. maltophilia in detail. Hence, in this thesis, we aim to analyse the contribution of two 
S. maltophilia RND efflux pumps in transient resistance to antibiotics. To that goal, two 
screenings using fluorescence-based strains and a broad variety of compounds have been 
performed in order to find inducers of the expression of SmeVWX and SmeYZ efflux pumps. 
Inducer compounds were identified for both efflux systems, pointing that smeVWX expression 
is likely induced by the thiol-reactivity of the compounds, while smeYZ is induced by molecules 
that inhibit protein synthesis. The role of these identified inducers in transient resistance to 
antibiotics was also confirmed. 
 
With the aim of defining new mechanisms involved in the acquisition of mutation-
driven resistance to antibiotics, as well as to decipher the evolutionary trajectories towards such 
resistance, S. maltophilia was submitted to experimental evolution in the presence of increasing 
concentrations of the antibiotics ceftazidime or tigecycline. Whole-genome sequencing of the 
final-step populations revealed that SmeH, the transporter protein of the SmeGH efflux pump, 
is an important contributor towards ceftazidime resistance acquisition. Amino acid substitutions 
Abstract 
 8 
in this efflux protein do not give rise to a fitness burden. However, they modify the 
susceptibility against other antimicrobials, possibly by producing changes in the access and 
binding of the substrate. Conversely, the first step towards the acquisition of tigecycline 
resistance is the overexpression of the SmeDEF efflux pump through mutations in the smeT 
gene, which encodes the transcriptional repressor of this efflux system. Besides, mutations in 
genes related to the ribosome (the tigecycline target), and to the lipopolysaccharide biosynthesis 
and membrane homeostasis, were also found mutated along the evolution period in the different 
evolved lineages. These mutations, which lead to cross-resistance to several antibiotics and 
collateral susceptibility to fosfomycin, impose a fitness cost for the S. maltophilia populations. 
 
Overall, the presented results highlight the relevance of the S. maltophilia RND efflux 
pumps, since they play a fundamental role not only in intrinsic resistance, but also in the 
acquired resistance through mutations and in transient resistance through their overexpression 
under specific stress conditions.   
Resumen 
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Resumen 
 
La resistencia a los antibióticos es un problema de salud global que se ha visto acentuado 
debido a la emergencia y diseminación de bacterias multirresistentes (MDR), en especial, 
bacterias Gram-negativas. Las bacterias pueden presentar, intrínsicamente, una baja 
sensibilidad a los antibióticos debido a la presencia de mecanismos de resistencia codificados 
en sus genomas. Además, la adquisición de genes de resistencia a través de eventos de 
transferencia horizontal de genes, así como de mutaciones genéticas, también pueden hacer que 
las bacterias se hagan resistentes. La resistencia transitoria a los antibióticos también puede 
ocurrir como consecuencia de una inducción temporal de la expresión de algunos de estos 
mecanismos de resistencia, como pueden ser las bombas MDR de expulsión múltiple de drogas. 
 
Stenotrophomonas maltophilia es un patógeno oportunista Gram-negativo de origen 
ambiental y asociado a infecciones en pacientes comprometidos, incluyendo aquellos que 
padecen fibrosis quística u otras patologías subyacentes. Esta bacteria es intrínsecamente poco 
sensible a múltiples compuestos antimicrobianos. Particularmente, las bombas de expulsión 
múltiple de drogas pertenecientes a la familia resistance nodulation division (RND) se 
encuentran entre los elementos más importantes que contribuyen a la resistencia intrínseca y 
adquirida de S. maltophilia.  
 
El papel de las bombas de expulsión de drogas RND en la resistencia transitoria no ha 
sido estudiado en detalle en S. maltophilia. Así pues, en esta tesis nos planteamos analizar la 
contribución de dos de las bombas RND de esta bacteria en la resistencia transitoria a los 
antibióticos. Para ello, se han llevado a cabo dos escrutinios utilizando cepas biosensoras y una 
amplia variedad de compuestos con el objetivo de encontrar inductores de la expresión de las 
bombas SmeVWX y SmeYZ. Se identificaron compuestos inductores para ambos sistemas de 
bombeo, cuyo modo de acción indica que la expresión de smeVWX es inducida, probablemente, 
por la capacidad de los compuestos de reaccionar con grupos tiol, mientras que la expresión de 
smeYZ es inducida por moléculas capaces de inhibir la síntesis de proteínas. El papel de los 
compuestos inductores identificados en la resistencia transitoria a los antibióticos también fue 
confirmado. 
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Con el fin de identificar nuevos mecanismos implicados en la adquisición de resistencia 
a los antibióticos mediante mutaciones, así como de determinar las trayectorias evolutivas hacia 
dicha resistencia, se han realizado evoluciones experimentales en presencia de concentraciones 
crecientes de los antibióticos ceftazidima o tigeciclina. La secuenciación masiva de los genomas 
pertenecientes a la última etapa de la evolución, reveló que SmeH, la proteína transportadora 
de la bomba SmeGH, es un importante contribuyente a la adquisición de resistencia a 
ceftazidima. Los cambios de aminoácido seleccionados en esta proteína no conllevan un coste 
de fitness. Sin embargo, modifican la sensibilidad bacteriana a otros compuestos 
antimicrobianos, posiblemente mediante cambios en el acceso y la unión del substrato. Por otro 
lado, el primer paso hacia la adquisición de resistencia a tigeciclina es la sobre-expresión de la 
bomba de expulsión de drogas SmeDEF debido a mutaciones en el gen smeT, el cual codifica 
para el represor transcripcional de este sistema de bombeo. Además, algunos genes 
relacionados con el ribosoma (diana de la tigeciclina), así como con la síntesis del 
lipopolisacárido y con la homeostasis de la membrana, también se encontraron mutados a lo 
largo del periodo de evolución de las diferentes poblaciones. Dichas mutaciones, las cuales 
conducen a la resistencia cruzada a varios antibióticos y a la sensibilidad colateral a 
fosfomicina, suponen un coste de fitness para las poblaciones evolucionadas de S. maltophilia.  
 
En conjunto, los datos presentados resaltan la importancia de las bombas de expulsión 
múltiple de drogas de la familia RND de S. maltophilia, debido a su contribución no sólo a la 
resistencia intrínseca, sino también a la resistencia adquirida mediante mutaciones, así como en 
la resistencia transitoria a través de su sobre-expresión ante condiciones de estrés específicas. 
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1. Introduction 
 
1.1. Antibiotic resistance: a global threat 
 
 Antibiotics are among the most successful compounds with a therapeutic application 
developed in the history of medicine. Since their discovery and introduction in the last century, 
they have saved countless lives by contributing not only to the treatment of life-threating 
infectious diseases, like pneumonia, meningitis or sepsis caused by wound infections, but also 
to prevent infections that might occur, for instance, after a surgical procedure 1. The “golden 
era” of antibiotics ranged from the 1950s to 1970s and gave rise to the discovery of many novel 
antibiotic classes 2. Unfortunately, shortly after the introduction of most antibiotics, resistant 
strains that were able to overcome the toxic effects of these compounds appeared (Figure 1).  
 
 
Figure 1. Timeline showing the introduction of several antibiotics and identification of resistance. For some of 
them, as methicillin, levofloxacin, linezolid, daptomycin or ceftaroline, resistance emerged little after the 
introduction of the antibiotic. Source: Centers for Disease Control and Prevention. 
 
Antibiotic resistance occurs when a drug loses its ability to inhibit the growth of a 
microorganism in an effective way 3. In the last decades, we have witnessed a significant 
increase in the emergence of antibiotic resistant bacterial strains. Although this resistance 
results mainly as a consequence of a selection pressure set on susceptible bacteria by the use of 
antimicrobial drugs, both for treating human infections and in animal production, several social 
and administrative factors, as noncompliance, self-medication, or the loss of interest in the 
discovery and introduction of new antimicrobial drugs by the pharmaceutical companies, have 
Introduction 
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also increased the problems associated with the emergence and spread of antibiotic 
resistance 4,5. The issue is more relevant because some bacterial pathogens have become 
resistant to many antimicrobial agents, showing a multidrug-resistant (MDR) phenotype 6,7. 
MDR bacteria have become one of the most important current threats to public health, being 
associated with high mortality rates. Considering Europe, it is estimated that MDR pathogens 
are responsible of 33,000 deaths per year 8. It is important to highlight the fact that MDR 
bacteria can be found across the animal, human and environmental settings, existing a 
continuous interchange of these pathogens among the three niches and a consequent spread of 
their resistance genes 9,10. The fact that some of these MDR bacteria are able to adapt to several 
hosts and survive in a broad range of potential niches is of utmost concern, and could increase 
their ability to acquire new resistance or virulence determinants while fitness is maintained 10.  
 
1.2. Definitions of antibiotic resistance 
 
Classically, antibiotic resistance has been defined from a practical point of view that 
categorize bacteria as susceptible or resistant on the basis of the feasibility of treating the 
infections they produce. Thus, from a clinical viewpoint, definition of resistance is based on 
the minimum inhibitory concentration (MIC) breakpoints, which are clinically relevant values 
when deciding which antibiotic to use in therapy 11. Nevertheless, this definition is not adequate 
for non-human-associated bacteria or other antimicrobial compounds that are not used in 
clinics, for which no established breakpoints are available. Besides, the clinical definition of 
resistance does not take into account low-level resistance, which can be also of importance 
during the first steps of high-level drug resistance acquisition 12. Therefore, in order to study 
different processes, as resistance evolution or functional genomics of antibiotic resistance, other 
more suitable definitions are employed.  
 
The epidemiological definition of antibiotic resistance is based on the epidemiological 
cut-off values for resistance (ECOFFs), which have been proposed by the European Committee 
on Antimicrobial Susceptibility Testing (EUCAST) to describe the upper MIC limit of the wild-
type population of a particular species 13,14. Those isolates whose MICs are above this 
breakpoint, are considered resistant even if the MICs do not reach the clinical breakpoint. This 
definition can be used to determine low-level resistance, as well as the breakpoints for other 
compounds different than antibiotics, as biocides, for which a clinical definition of resistance 
is not available 15. However, since this epidemiological definition is based on the analysis of a 
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large number of independent isolates, it is not appropriate for the study of single genes or 
mutations in a particular isolate.  
 
In these cases, a gene-centric definition of resistance (operational definition) is used 14. 
This third definition, which is the one that will be employed in this thesis when defining 
resistant or susceptible strains, is based on the comparison of a wild-type strain with a mutant 
strain, or with a strain that harbours a resistance gene acquired through horizontal gene transfer 
(HGT). If this strain has a MIC value higher than the one obtained for the parental strain for the 
same antimicrobial, it is considered resistant. Although this definition does not include 
predefined breakpoints, it is the most appropriate for the analysis of the role of a specific gene 
in the susceptibility to a given antibiotic 14,16.  
 
1.3. Types of antibiotic resistance and molecular mechanisms  
 
The inhibitory activity of a given antibiotic relies mainly on two basic parameters: the 
amount of antibiotic that reaches the target inside the cell, and the efficiency of the 
antibiotic/target interactions. Thus, antibiotic resistance can be achieved either by reducing the 
intracellular concentration of the drug, for instance, through the activity of MDR efflux pumps, 
antibiotic-modifying enzymes or alteration of the pathway for drug entrance; or by reducing 
the affinity of the interaction through target site alteration by mutations, among others 17. 
 
All of these mechanisms are involved in the intrinsic, acquired or adaptive resistance of 
bacterial pathogens (described hereunder), particularly in Gram-negative bacterial species that 
are resistant to several antibiotics and whose raise has become a serious challenge in all parts 
of the world 18,19. Some of these determinants can contribute to the three types of resistance, 
and it is not the presence of just one of them which renders bacteria less susceptible to 
antibiotics, but the interplay among several of these resistance mechanisms.  
 
1.3.1. Intrinsic resistance  
 
The recent use of antibiotics for human therapy and farming is not the unique driving 
force towards antibiotic resistance of human pathogens. Some bacterial species with an 
environmental origin (such as Pseudomonas aeruginosa or Stenotrophomonas maltophilia), 
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where the antibiotic load is not as high, as occurs in hospitals, present an intrinsic low 
susceptibility against several antibiotics 20.  
 
As discussed in the previous paragraph, bacteria are considered intrinsically resistant if 
the infections that they cause cannot be treated with a given antibiotic, based on the clinical 
definition 21. However, all the elements that directly or indirectly contribute to antibiotic 
susceptibility, regarding the epidemiological and the operational definitions as well, and whose 
presence is independent of prior antibiotic exposure or HGT, define the “intrinsic resistome” 16. 
All the chromosomally encoded genes that have been recently acquired as a consequence of the 
human use of antibiotics, are not encompassed in this definition 21. Although the intrinsic 
resistome of a given species comprises a wide variety of genes 16,22-25, the most relevant causes 
of intrinsic resistance in Gram-negative bacteria, from a clinical point of view, are low uptake 
of antibiotic, lack of the target or presence of an intrinsically resistant allele, antibiotic 
inactivation, and efflux of the antibiotic (Figure 2) 17.  
 
 
Figure 2. Schematic representation of the main intrinsic resistance mechanisms of Gram-negative bacteria. The 
presence of the lipopolysaccharide (LPS) in the bacterial outer membrane creates a barrier that prevents the passive 
diffusion of hydrophobic antibiotics. Those that manage to reach the periplasmic space, for instance, through 
membrane porins, can be counteracted by other mechanisms, such as inactivation by antibiotic modifying 
enzymes, or extrusion by multidrug resistance (MDR) efflux pumps.  
 
The membrane of Gram-negative bacteria consists in an asymmetric bilayer of 
lipopolysaccharides (LPS) and phospholipids where specialized protein channels are found 
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embedded 26. This LPS-structure confers the bacterial membrane a higher rigidity compared to 
a regular bilayer, which slows the passive diffusion of hydrophobic compounds, such as 
aminoglycosides, macrolides, rifamycins, novobiocin, fusidic acid and cationic peptides 26,27. 
Besides low uptake of the drug, the absence of the target of a specific antibiotic is also a 
common example of intrinsic antibiotic resistance. For instance, the antistaphylococcal agent 
daptomycin is not effective against Gram-negative bacteria since the content of negatively 
charged phospholipids, which allows the insertion of daptomycin into the cytoplasmic 
membrane, is substantially lower compared to Gram-positive bacteria 28. In other occasions, 
bacteria have the specific target for an antibiotic, but it is an intrinsically resistant allele, which 
makes this bacterial species resistant to such antibiotic. A good example for illustrating this 
situation is the MurA enzyme, involved in the bacterial cell wall peptidoglycan synthesis and 
the target of the antimicrobial agent fosfomycin 29. Bacterial species carrying a regular MurA 
enzyme with a cysteine in its active site, such as Escherichia coli, are susceptible to this 
antibiotic; however, other bacterial pathogens, such as Chlamydia and Borrelia burgdorferi, 
harbour MurA variants without a cysteine in the enzyme active site, without previous selection 
under fosfomycin exposure, that make these bacteria intrinsically resistant against this 
drug 30,31.  
 
Another effective way to resist the toxic effect of an antibiotic is through its inactivation. 
This can be achieved by both antibiotic hydrolysis performed by specific enzymes, such as 
beta-lactamases that hydrolytically cleave the beta-lactam ring of beta-lactam antibiotics 32, or 
by the modification of the drug through the addition of chemical groups, which results in 
structural alterations that impair target binding. This last category encompasses the group of 
transferases, including aminoglycoside acetyltransferases, macrolide kinases or 
nucleotidyltransferases 33. Although many of these antibiotic-modifying enzymes are 
associated with resistance plasmids, they can also be encoded by chromosomal genes, thus 
contributing to the bacterial intrinsic resistance. One example is the Acinetobacter baumannii 
non-inducible AmpC-type cephalosporinase that confers, at basal levels of expression, 
resistance against several beta-lactam drugs 34.  
 
Decreasing the intracellular concentration of an antibiotic is another common strategy 
that bacteria follow in order to prevent the toxic compound to efficiently reach its target, which 
is usually located inside the cell. In this respect, bacterial MDR efflux pumps are major 
contributors to the intrinsic resistance of Gram-negative bacteria since they actively extrude a 
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wide variety of antibiotics, as well as other toxic compounds, outside the cell 35. The resistance 
nodulation division (RND) family is the best characterized in Gram-negatives. The inner 
membrane protein (IMP) of these three-component complexes works in conjunction with an 
outer membrane protein (OMP), and a periplasmic membrane fusion protein (MFP) that links 
the IMP and the OMP 36. Some examples are MexAB-OprM from P. aeruginosa 37, AcrAB-
TolC from E. coli 38, or SmeYZ from S. maltophilia 39, whose basal levels of expression are 
sufficient for contributing to the intrinsic antimicrobial resistance of these microorganisms.  
 
1.3.2. Acquired resistance 
 
Acquisition of resistance to antibiotics can be mediated by chromosomal DNA 
mutations or by transfer and acquisition of new resistance genes from bacteria of the same or 
different genera or species (Figure 3) 40. Regarding genetic mutations, these can lead to 
modifications of the antibiotic target, so that the affinity between antibiotic and its target is 
diminished and the binding is not carried out. A common example of antibiotic target 
modification is the one occurring in the bacteria penicillin binding proteins (PBPs), leading to 
beta-lactams resistance. For instance, mutations in the Neisseria gonorrhoeae PBP 1-coding 
gene ponA, have been found in high-level penicillin-resistant clinical isolates 41.  
 
In addition to target modification, chromosomal mutations can alter the expression of 
several resistance determinants, as those happening in genes encoding the regulators of 
elements associated to antibiotic resistance, as MDR efflux pumps, antibiotic inactivating 
enzymes or porins 42. MDR efflux pumps, apart from contributing to the bacterial intrinsic 
resistance, can also acquire mutations that result in an ameliorated extrusion of the antibiotics, 
led by either an increase of their expression level or, less commonly, by structural changes that 
make the efflux more efficient. Overexpression of efflux pumps is achieved mainly through 
mutations in the genes encoding their transcriptional local regulators. Well-known examples 
are the P. aeruginosa Mex systems from the RND family, such as MexAB-OprM, whose 
overexpression, and the consequent resistance phenotype, is due to mutations in the genes 
encoding its repressors, specifically mexR, nalC or nalD 43-45. Similarly, acquisition of 
mutations in the S. maltophilia efflux pumps regulators smeT and smeRv, leads to the 
overproduction of the SmeDEF and SmeVWX systems, respectively, causing resistance to 
several antimicrobial agents 46,47. Although the vast majority of mutations affecting efflux 
pumps occur in regulatory elements, in some other cases, mutations arise in the transporter 
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protein of the efflux pump, making the antibiotic extrusion more efficient. Examples of these 
types of mutations have been described in AcrB from E. coli 48 or in MexY from 
P. aeruginosa 49.  
 
 
Figure 3. Schematic representation of the best studied acquired resistance mechanisms to antibiotics. Bacteria can 
acquire resistance through genetic mutations in the local transcriptional regulators of MDR efflux pumps, leading 
to the overexpression of these systems and antibiotic extrusion. Membrane porin-coding genes may also acquire 
mutations causing porin modification and prevention of antibiotic entrance. Mutations affecting the antibiotic 
target can also drive to antibiotic resistance caused by antibiotic-target binding inhibition. Acquisition of plasmids 
encoding resistance genes, such as antibiotic-modifying enzymes, is also an important mechanism of acquired 
resistance.  
 
Resistance mutations can also be acquired in the membrane porin-coding genes, 
decreasing or preventing the antibiotic entrance inside the cell. These mutations can affect the 
size of the porin, its expression level, or even can result in porin loss. For instance, E. coli 
isolates from a patient subjected to a treatment with various antibiotics present changes in the 
OmpC porin that result in the modulation of resistance to the beta-lactam cefotaxime 50. Besides 
these canonical mechanisms, several studies have demonstrated that resistance can be acquired 
through mutations in many more genetic elements, including transcriptional regulators, 
enzymes that participate in different bacterial processes, or motility-related genes, which can 
be involved, directly or indirectly, in the susceptibility to an antimicrobial compound  51-54.  
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Bacteria can also become resistant through the acquisition of different antibiotic 
resistance genes, either through transformation or via the interchange of genetic elements, such 
as plasmids 55,56, bacteriophages 57 and/or transposons 58 that carry antibiotic resistance 
determinants. Plasmids carrying extended-spectrum beta-lactamases (ESBLs) in different 
Enterobacteriaceae species 59, or the genomic islands present in Salmonella enterica that carry 
a class 1 integron containing transferable resistance genes 60, are examples of horizontal 
acquisition of resistance. Although the acquiring of external resistance genes is a very relevant 
mechanism concerning antibiotic resistance spread across different bacteria and ecosystems, it 
will not be discussed in this thesis. 
 
1.3.3. Transient resistance 
 
The third category of antibiotic resistance is transient resistance, also known as 
phenotypic or adaptive resistance. It can be defined as a temporary alteration in the bacterial 
physiology as a response to environmental signals/cues, conferring bacteria an increased 
capacity to overcome an antimicrobial challenge 42. In contrast with intrinsic and acquired 
resistance, which are stable and can be transmitted vertically or horizontally, respectively, to 
consecutive generations, transient resistance is not inheritable and generally reverts upon 
removal of the triggering signal or condition (Figure 4) 61. Transient resistance is particularly 
relevant since there are many signals that can act as inducers, including antimicrobials, 
oxidative or nitrosative stress, temperature, mode of growth (biofilm vs. planktonic), or even 
host-related compounds, compromising the course and treatment of bacterial infections 61-64.   
 
Several molecular mechanisms are known to be behind transient resistance. For 
instance, magnesium limitation can be sensed by the two-component system (TCS) PhoPQ in 
S. enterica, activating another TCS, PmrAB, which leads to the upregulation of a LPS-
modification operon (pmr). This transient upregulation reduces the net negative charge of the 
cell surface, thus limiting the interaction with positively charged antimicrobials and 
polymyxin B 65. MDR efflux pumps are also important transient resistance determinants since 
their expression can be triggered by a diverse range of molecules and conditions. Some 
examples are the RND efflux pumps AcrAB from E. coli, and CmeABC from Campylobacter 
jejuni, whose expression is triggered by bile salts, conferring resistance to diverse 
antibiotics 66,67. Similarly, expression of the S. maltophilia SmeDEF efflux system is induced 
by plant-derived flavonoids 68, as well as by the biocide triclosan, reducing the bacterial 
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susceptibility to quinolones 69. Inducible beta-lactamases are also a major mechanism involved 
in transient resistance in many Gram-negative bacteria. The expression of these enzymes, such 
as AmpC, can be induced indirectly by the action of particular beta-lactam antibiotics, leading 
to an unsuccessful therapeutic outcome 70. Other mechanisms, such as outer membrane 
modification through the modulation of porins expression, have also been reported to be 
involved in transient antibiotic resistance 71.  
 
 
Figure 4. Induction of transient resistance to antibiotics. Changes in several environmental conditions, such as the 
presence of antimicrobial molecules, induction of the stress response or growth conditions, can lead to the 
induction of transient resistance to antibiotics (dark blue rods). However, this phenotype is reversible when the 
triggering signal is removed, thus recovering the susceptible phenotype (light blue rods). 
 
Because of its temporary nature, transient resistance is difficult to detect and its 
investigations is limited to a few microorganisms and inducers/conditions. Nevertheless, since 
bacteria can encounter some of the above-mentioned inducer molecules or conditions during 
the course of an infection, which could lead to a transitory resistance situation, transient 
resistance study should not be disregarded.  
 
1.4. RND efflux pumps: functions and regulation 
 
Among all the resistance determinants, MDR efflux pumps are particularly relevant. 
There exist six major families of bacterial MDR efflux pumps: the ATP-binding cassette 
(ABC), the major facilitator superfamily (MFS), the multidrug and toxin extrusion (MATE), 
the small multidrug resistance (SMR), the proteobacterial antimicrobial compound efflux 
(PACE), and the previously mentioned resistance nodulation division (RND) family 72. The 
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latter family is specific to Gram-negative microorganisms and forms part of a tripartite complex 
which spans across the two membranes of these Gram-negative bacteria 73. RND efflux pumps 
are powered by the electrochemical potential of protons, or proton motive force, in order to 
transport the substrates across the cell membrane 74. It is proposed that RND membrane 
transporters, that is, the periplasmic proteins, can form homotrimers, and each monomer has 
varying conformations during substrate transport, named access, binding, and extrusion, as 
described for the E. coli AcrB transporter. Thus, the different compounds are exported 
following an orderly conformation change in the three monomers through a rotation mechanism 
that is driven by the protons translocation (Figure 5) 75. 
 
 
Figure 5. Schematic representation of the functional-rotation mechanism of substrate export mediated by the 
homotrimers of the RND transporter proteins. Each monomer (blue, green and yellow) changes its conformation 
going through three states: access, in which the substrate enters into the access pocket or vestibule of the 
transporter; binding, in which the substrate accommodates inside the binding pocket; and extrusion, in which the 
substrate exits through a funnel towards the outer membrane protein for being extruded outside of the cell. These 
conformational changes are coupled to the proton translocation (Adapted from Murakami, 2008 76). 
 
Although the majority of the studies regarding RND efflux pumps are focused on their 
role as antibiotic resistance determinants (they can contribute to the three types of resistance), 
these efflux systems are able to extrude other structurally unrelated compounds, including 
heavy metals, organic pollutants, or bacterial metabolites, among others. This fact highlights 
the role of efflux pumps in the detoxification of damaging endogenous and exogenous 
compounds 77. RND-type efflux pumps are also required for colonization and propagation 
during host infection, helping as well to extrude innate host defences. For instance, 
P. aeruginosa lacking MexAB-OprM efflux pump is unable to invade epithelial cells, a 
function that is restored after efflux pump complementation 78; and some Vibrio cholera RND 
efflux pumps are required for virulence factors’ production and intestinal colonization 79. Other 
important roles that have been identified are their involvement in the trafficking of quorum-
sensing signals 80, and in plant-bacteria interactions 81.  
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Since RND efflux pumps are involved in many physiological processes and demonstrate 
a wide substrate range, a regulatory control over the expression of these systems is to be 
expected. Modulation of the expression of RND efflux pumps is often mediated by local or 
global regulators, including TCSs, transcription and post-transcription factors (repressors and 
activators) 82, and even small proteins that can act as regulatory elements 83,84. Besides, certain 
environmental conditions, as stress situations, or the presence of particular signals/compounds, 
can also transiently regulate the expression of RND efflux pumps, as mentioned in the previous 
paragraph. Therefore, understanding RND efflux pump regulation is a noteworthy target to be 
addressed, since alterations in the regulatory systems, such as mutations in a transcriptional 
repressor, or the presence of inducer molecules, can lead to their overexpression and a 
consequent extrusion of antibiotics.  
 
1.5. Effects of the acquisition of antibiotic resistance on bacterial physiology 
 
1.5.1. Fitness cost 
 
It is generally accepted that genetic mutations and/or acquisition of antibiotic resistance 
determinants are associated with metabolic changes, including fitness cost. This vision is based 
on the fact that mutations that drive to resistance might occur in genes that are important for 
bacterial physiology 85,86. For instance, mutations can arise in genes that regulate the expression 
of antibiotic detoxification elements, such as MDR efflux pumps, as well as in the antibiotic 
targets or transporters. Since these elements are frequently well conserved and are important 
determinants for bacterial physiology, their mutation can lead to a poor functioning and, as a 
consequence, to a physiological burden that implies a disadvantage in comparison with the 
wild-type strain 87. Moreover, mutations leading to the overexpression of some antibiotic 
resistance determinants, as efflux pumps or antibiotic-inactivating enzymes, are physiologically 
costly, since, in a drug-free environment, a constant overproduction of these systems will drive 
to a non-needed metabolic burden 88.  Furthermore, acquisition of resistance genes, for instance, 
through HGT, could also imply a reduced bacterial fitness as a result of replication, 
transcription and translation of the newly-acquired genes 89. This fitness cost, usually observed 
as a reduction of growth rate, is a key biological parameter that determines the evolution of 
resistance.  
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1.5.2. Compensation mechanisms for fitness costs alleviation 
 
Since antibiotics act as a selective pressure towards resistance acquisition, the 
occurrence of a fitness cost associated with this resistance can lead to the idea that a reduction 
in the antibiotics usage would suppose an advantage for the fitter susceptible ancestor, which 
would replace the resistant strain in a drug-free environment 85,90. However, there exist some 
exceptions where resistance happens to be neutral or even beneficial 91,92. For instance, it has 
been reported that acquisition of resistance in P. aeruginosa, A. baumannii and V. cholerae is 
associated with an increased fitness in vivo in different infection settings 93.  
 
 
Figure 6. Compensation of fitness costs derived from antibiotic resistance. Acquisition of antibiotic resistance 
mutations may impose a fitness impairment in the absence of the selective pressure (antibiotic). These costs can 
be compensated, withouth compromising resistance, through the acquisition of compensatory mutations. An 
unlikely situation would be the reversion towards the wild-type susceptible genotype (dotted line).  
 
Although these no-cost mutations can contribute to the spread of some resistant mutants, 
other alternatives allow the resistant bacteria to remain even in the absence of selection. This 
can occur through a genetic reversion to the parental strain, although this is a rare event 85,94, or 
through the acquisition of second-site mutations that compensate the fitness costs imposed by 
a resistance mutation (Figure 6) 95,96. Compensation can occur through mutations that restore 
the fitness through the substitution of the affected function with an alternative activity, or by 
restoring, directly or indirectly, the efficiency of the concerned function 97,98. Thus, 
compensatory mutations can arise within the same gene that caused the resistance phenotype 
by recovering the protein functionality, or can occur in other genes. Compensatory evolution 
has been observed in both in vitro 95, in vivo 97,99, and in clinical studies 100, showing that 
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compensatory mutations are different according to each type of experimental model, thus 
demonstrating that fitness costs are highly dependent on the bacterial habitat 99.  
 
In occasions, compensation can also be caused by another resistance mutation. For 
instance, a mutation in rpsL, causing streptomycin resistance, can be compensated by different 
mutations that result in rifampicin resistance in E. coli. Besides conferring resistance to a new 
antibiotic, which would complicate the antibiotic treatment, the fitness of the double mutants is 
greater than the fitness of at least one of the single mutants 101. 
 
 Bacteria can also compensate the fitness costs associated with antibiotic resistance 
without the need of mutations. Examples of this situation are MDR efflux pump-overexpressing 
mutants of P. aeruginosa that are able to rewire their metabolism in order to avoid the fitness 
costs derived from the MDR efflux pumps overexpression 102; or overexpression of the rRNA 
methylase TlyA as a mechanism to increase fitness and reduce the deleterious effects of a 
resistance mutation in mycobacteria 103.  
 
1.5.3. Cross-resistance and collateral sensitivity 
 
Acquisition of antibiotic resistance, beyond involving eventually a fitness cost, is 
usually accompanied by other changes in response to certain environments. One phenomenon 
that might occur after acquiring resistance to one drug is the development of resistance, or the 
enhancement of sensitivity, to a different drug(s) simultaneously, which is called cross-
resistance or collateral sensitivity, respectively 104. These changes in the bacterial susceptibility 
to other antimicrobial compounds can be caused by various mechanisms. For instance, a 
mutation that alters the expression of an efflux pump, caused by the exposure to an specific 
antibiotic, would favour cross-resistance against other compounds that are substrates of such 
efflux pump, including clinically relevant antibiotics 105. While cross-resistance is a 
problematic outcome regarding the treatment of bacterial infections, collateral sensitivity in the 
clinics could be exploited through combination therapy or by the use of temporal cycling of 
different antibiotics. Thus, an understanding of how the evolution of resistance towards an 
antibiotic can affect the susceptibility to other drugs is of relevance 106.  
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1.6. Antibiotic resistance evolution 
 
As pointed out above, resistance can evolve rapidly and through several mechanisms, 
having important consequences for human health. Thus, predicting and understanding the 
factors that drive and constrain the evolution of resistance is essential for minimizing the 
probability that antibiotic resistance arises 107.  
 
1.6.1. Factors that determine the evolution of antibiotic resistance 
 
Bacteria possess an abundance of mechanisms that can potentially confer antibiotic 
resistance. However, the number of the resistance mechanisms that are finally selected is 
limited. This limitation, which is determined by the ecological dimension of resistance, defines 
the evolutionary trajectories towards antibiotic resistance 108. Evolutionary trajectories, as well 
as the spread and maintenance of antibiotic resistance in a bacterial population, are driven by 
the interplay of several factors (Figure 7) 109: i) the rate at which resistance and mutations arise 
in a population (mutation supply rate), which is determined by the population size, rate of 
mutation and HGT events; ii) the level of resistance that is conferred by the resistance 
mechanism, which depends on the resistance determinant itself and the conditions under which 
resistance is analysed. In some situations, the level of resistance changes is dependent on the 
environmental conditions 110. For instance, urine at neutral pH increases the MIC for 
fosfomycin in E. coli clinical isolates; however, acidic urine and anaerobiosis conditions render 
these isolates more susceptible to this antibiotic 111; iii) the relative fitness of the resistant 
mutant at different drug concentrations. As previously discussed, several antibiotic resistance 
mechanisms impose a fitness cost to the resistant mutant in the absence of the selective pressure, 
although some resistance mutations might be neutral or even beneficial 92. Thus, the relative 
fitness is a key parameter for assessing the evolutionary success of the resistant mutant in the 
host population or other environments 112; iv) the strength of the selective pressure, which 
would also have an influence on the rate of emergence of mutations and the type of mutants. 
For example, the mutations that are selected at high level of antibiotic concentrations would 
differ from those selected at non-lethal drug concentration 113.  
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Figure 7. Interplay between the factors that influence the evolution of antibiotic resistance. Four basic factors 
(mutation supply rate, level of conferred resistance by the resistance mechanism, relative fitness of the resistant 
mutant, and strength of the selective pressure) have a direct effect on the evolution of antibiotic resistance. These 
factors are in turn influenced by other determinants. The emergence of compensatory mutations, the presence of 
epistatic interactions or population bottlenecks are also main determinants in the evolution of resistance to 
antibiotics. 
 
In addition to these basic factors, other elements have also a strong impact on antibiotic 
resistance evolution. The genetic background has an influence on a mutation’s effect, meaning 
that the effect of a mutation in a specific gene can fluctuate drastically depending on the 
presence or absence of another mutation in another gene 114. This situation is referred to as 
“epistasis” or “epistatic interaction” and might have an effect on the level of resistance and on 
the relative fitness of the resistant mutant. Epistasis is considered positive, when the fitness of 
the double mutant is higher than the expected from the effects of the two single mutations; 
negative, when the fitness of the double mutant is lower than the expected from their effects 
when alone; or sign epistasis, in the case that the fitness of a mutation varies relying upon the 
genetic background 96. The fact that later mutations in evolution are dependent on the earlier 
ones, illustrates a feature known as contingency. Thus, a mutation may be contingent on prior 
mutations and could constrain future mutations along the evolutionary trajectory, owing to 
epistasis 115,116.   
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Compensatory mutations are also key factors for antibiotic resistance evolution since 
they can restore the bacterial fitness without a loss of resistance 109. The interactions between 
antibiotic resistance mutations and compensatory mutations are usually considered as sign 
epistasis, since these compensatory mutations are beneficial on the resistant strain but might be 
deleterious, or have no effect, on the parental strain background 117.  
 
Finally, population bottlenecks are also major determinants affecting the evolution of 
resistance. Bottlenecks are events that dramatically reduce the original population size, for 
instance, the inoculum of a bacterial population for starting an infection. In some cases, 
population bottlenecks can eliminate certain genotypes from a gene pool, even if these 
genotypes are not associated with a low fitness 118. Thus, these population-reducing events can 
constrain the evolutionary trajectories by restricting the mutation supply. The population size, 
the mutation rates and the fitness influence transmission bottlenecks 112.  
 
1.6.2. Experimental evolution for predicting antibiotic resistance  
 
If our purpose is to predict how resistance to an antibiotic will arise, it is necessary to 
know which resistance genes and mutations are most likely to confer resistance to the tested 
antibiotic. In addition, knowing which new genes might emerge and spread in the bacterial 
population, contributing to shorten the therapeutic lifetime of the antibiotic, is also required 107.   
 
A frequent method for analysing the mechanisms involved in the antibiotic resistance 
evolution is performing in vitro evolution experiments in the presence of antibiotics. By this 
approach, bacterial populations are exposed to a known drug concentration sufficient to 
partially inhibit the growth of the parental strain, but low enough to allow spontaneous resistant 
mutants to survive 54. In order to allow the selection of improved phenotypes, serial passages 
increasing the antibiotic concentration are performed for prolonged periods of time, that could 
range from days to years 54,119. The rate at which the antibiotic concentration is increased, which 
reflects the rate of resistance evolution, can vary in time and with the use of different drugs 54.  
 
With the aim of identifying the mutations involved in the acquisition of resistance, PCR 
amplification and sequencing of the suspected target genes can be performed; however, whole-
genome sequencing (WGS) allows to detect new resistance mechanisms (Figure 8) 119. Using 
this approach, it is possible to describe mutations that confer drug resistance before their 
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emergence in nature or clinics. Moreover, if these mutations appear in patients, their 
identification will allow to facilitate the diagnosis of resistant infections, as well as the measures 
for the most appropriate therapeutic treatment 120.  
 
 
Figure 8. Schematics of an experimental evolution assay in the presence of antibiotic. A bacterial population is 
initially grown at the maximum antibiotic concentration that allows bacterial growth. Serial passages are 
performed by inoculating a bacterial culture dilution into fresh media for several generations while antibiotic 
concentration is increased in order to promote selection. At the end of the experiment, antibiotic susceptibility is 
determined and bacterial genomic DNA is extracted and whole-genome sequenced (WGS) with the aim of 
identifying resistance mutations. 
 
Besides determination of resistance mutations, serial passages experiments are also 
useful for analysing and identifying compensatory mutations that ameliorate the fitness costs 
that might be imposed by other resistance mutations, as well as for the detection of epistatic 
interactions 119, which can strongly influence the evolution of resistance and thereby complicate 
its prediction 112. Multistep experimental evolution also reveals the evolutionary trajectories 
towards resistance to a given antibiotic. The ability to predict the order of appearance of the 
mutations during the experimental evolution is also crucial to assess the relative importance of 
each genetic change towards resistance. Recurrent evolutionary patterns, such as the emergence 
of mutations in a preferred order, can provide some degree of predictability to an evolutionary 
process that, at first sight, might seem stochastic 54.  
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1.7. Stenotrophomonas maltophilia: an opportunistic pathogen 
 
Among MDR Gram-negative bacteria, S. maltophilia has become a relevant nosocomial 
pathogen in the past years. Taxonomically, this bacterium belongs to a subclass of 
proteobacteria that was firstly described as Pseudomonas maltophilia at 1961 121. Further 
studies led to its reclassification as Xanthomonas maltophilia in 1983 122, and finally, to 
Stenotrophomonas maltophilia in 1993 123. 
 
 
 
Figure 9. S. maltophilia as a ubiquitous nosocomial pathogen. S. maltophilia has been isolated from both 
environmental (root plants, animals, wastewater plants, soil) and clinical-associated sources (catheters, sink drains, 
disinfectants, endoscopes).  
 
S. maltophilia is an environmental ubiquitous bacterium that has been isolated from 
several sources, both inside and outside the clinical setting (Figure 9). It has been recovered 
from habitats like plant roots 124, animals 125, wastewater plants 126, hand-washing soap 127 or 
food 128. S. maltophilia is characterized by its ability to form bacterial biofilms, colonizing both 
abiotic (catheters, nebulizers or prosthetic devices), and biotic surfaces, including lung 
cells 129,130. An interesting fact to have into account is that environmental and clinical 
S. maltophilia isolates do not form different phylogenetic branches and share a large core 
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genome where the distribution of antimicrobial resistance genes and virulence factors is similar. 
Besides, both clinical and environmental lineages present low susceptibility to antibiotics, 
supporting the idea that environmental strains are potential opportunistic resistant 
pathogens 131.  
 
Although it is not considered as a highly virulent bacterium, it is an important 
opportunistic pathogen in clinical environments, being responsible for various infectious 
diseases. S. maltophilia infections can occur in the general population at the hospital setting, 
being most frequently associated with respiratory infections, followed by bloodstream 
infections, and, rarely, soft tissue and skin infections 132. These diseases are usually associated 
with high mortality, particularly in immunocompromised individuals and in patients with 
underlying pathologies, as cystic fibrosis or cancer, as well as in those who have been under 
previous therapy with broad-spectrum antibiotics 129,132.  
 
1.7.1. Antibiotic resistance mechanisms in S. maltophilia 
 
The World Health Organization (WHO) lists S. maltophilia as one of the leading drug-
resistant pathogens of greatest public health concern in hospitals worldwide 133. This 
opportunistic pathogen shows an intrinsic low susceptibility to many antibiotics, including 
those that are commonly used to treat the infections that it causes. S. maltophilia isolates have 
demonstrated resistance against beta-lactams, cephalosporins, macrolides, fluoroquinolones, 
aminoglycosides, and carbapenems 134.  
 
The low susceptibility displayed by this bacterium against antibiotics is due to the 
interplay of several resistance mechanisms 134,135. Among them, S. maltophilia possesses two 
chromosomal-encoded inducible beta-lactamases, namely L1 and L2, which contribute to beta-
lactams resistance. Expression of both enzymes is indirectly induced by beta-lactam antibiotics 
and controlled by the transcriptional regulator AmpR 136,137.  
 
Regarding aminoglycoside resistance, S. maltophilia genome encodes several known 
and putative aminoglycoside-modifying enzymes, such as AAC(6’)-Iz, an aminoglycoside 
acetyltransferase that confers resistance against amikacin, tobramycin, netilmicin and 
sisomicin 138; APH(3’)-IIc, an aminoglycoside phosphotransferase that contributes to 
kanamycin, neomycin, paromomycin and butirosin 139; and a more recently 
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identified  AAC(6’)-Iak 140. Further, susceptibility to aminoglycosides can vary in a transient 
manner depending on growth temperature as a consequence of outer membrane lipids alteration, 
being more susceptible to these antibiotics at 37 C than at 30 C 141. 
 
Besides, S. maltophilia chromosome encodes the SmQnr protein, which contributes to 
low-level intrinsic resistance to quinolones 142. Since qnr genes are usually plasmid-associated, 
it has been proposed that S. maltophilia isolates that harbour Smqnr genes may act as a reservoir 
for the potential dissemination of these quinolone resistance elements to other 
Enterobacteriaceae 143.  
 
1.7.2. MDR efflux pumps  
 
Major contributors to the S. maltophilia low susceptibility to antibiotics are MDR efflux 
pumps belonging to the RND family. Eight RND-type systems that are encoded in the 
S. maltophila genome have been identified: SmeABC, SmeDEF, SmeGH, SmeJK, SmeMN, 
SmeOP, SmeVWX, and SmeYZ (Table 1) 135. Regulation of these RND efflux pumps occurs 
at different levels, making S. maltophilia a suitable model for the study of these resistance 
determinants. The expression of some of them is modulated by local regulators, such as 
SmeDEF efflux pump, which is down-regulated by the TetR-family SmeT repressor 46, or 
SmeVWX, whose expression is controlled by the LysR-type transcriptional regulator 
SmeRv 144. In other cases, TCSs are the regulators of S. maltophilia efflux pumps, as in SmeYZ, 
whose expression is controlled by the SmeRySy system 145, or SmeABC, regulated by the 
SmeRS TCS 146. 
 
As previously stated, RND efflux pumps can be contributors to intrinsic, acquired or 
transient resistance. In S. maltophilia, the role of six of them (SmeABC, SmeDEF, SmeGH, 
SmeIJK, SmeOP, SmeVWX, and SmeYZ) in intrinsic, acquired and/or transient resistance has 
been previously analysed (Table 1) 39,146-151. For instance, smeYZ is constitutively expressed at 
a significant level, thus playing an important role in the intrinsic resistance to several 
antibiotics, including aminoglycosides 39. Antibiotic resistance can be also achieved through 
the overexpression of these efflux systems, which can be accomplished by the acquisition of 
mutations usually in the regulatory elements that control their expression. In the case of 
S. maltophilia, the most prevalent cause of acquired resistance to quinolones is the 
overproduction of MDR efflux pumps, particularly SmeDEF and SmeVWX, associated with 
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mutations in their respective transcriptional regulators 47,152. Regarding transient resistance, the 
role of the S. maltophilia RND efflux pumps has not been studied in detail and just SmeDEF 
efflux pump has been reported to contribute to transient antibiotic resistance 68,69. Thus, 
overexpression of RND efflux pumps leading to a transient situation of antibiotic resistance can 
also be achieved by changes in the expression of these systems caused by particular 
physiological situations or as a response to effectors 77. Knowing the inducers of S. maltophilia 
efflux pumps would help to characterize these systems, not only regarding their ecological or 
functional role, but also for predicting situations of transient antibiotic resistance induction.  
 
Table 1. Overview of the identified S. maltophilia RND efflux pumps and their role in antibiotic resistance 
Efflux 
Pump 
Antibiotic Resistance IR AR TR Ref. 
SmeABC Aminoglycosides, beta-lactams, 
fluoroquinolones. 
No Yes ND 
146 
SmeDEF Tetracycline, chloramphenicol, 
macrolides, fluoroquinolones, 
sulfamethoxazole, trimethoprim, 
trimethoprim/sulfamethoxazole. 
Yes Yes Yes 147,150,
153,154 
SmeGH Unknown ND Yes ND 135,151 
SmeIJK Aminoglycosides, tetracycline, 
minocycline, ciprofloxacin, 
levofloxacin, leucomycin 
Yes Yes ND 148,155 
SmeMN Unknown ND ND ND 135 
SmeOP Nalidixic acid, doxycycline, 
aminoglycosides, macrolides 
Yes No ND 149 
SmeVWX Quinolones, chloramphenicol, 
trimethoprim/sulfamethoxazole 
No Yes ND 47,150,1
52 
SmeYZ Aminoglycosides, tetracycline, 
leucomycin, 
trimethoprim/sulfamethoxazole 
Yes Yes ND 39 
IR: intrinsic resistance; AR: acquired resistance; TR: transient resistance; ND: not determined 
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1.7.3. Therapeutic strategies for the treatment of S. maltophilia infections 
 
The intrinsic low susceptibility of S. maltophilia against antibiotics limits the 
antimicrobial options and complicate the treatment of its infections. The combination 
trimethoprim/sulfamethoxazole (SXT) is currently the most effective drug of choice 156. It can 
also be used in combination with other agents, such as ciprofloxacin 157.  Nevertheless, the use 
of this antimicrobial is limited due to intolerance, allergic reactions and resistance mechanisms, 
such as sul1, sul2 and dfrA genes, or the expression of MDR efflux pumps 150,158-161.  Thus, 
alternative therapeutic options are required to combat S. maltophilia infections.  
 
Among them, the use of ceftazidime, a third-generation cephalosporin, mainly in 
combination with other antimicrobial agents, has been proposed as a potential treatment, since 
many S. maltophilia clinical isolates are susceptible to this beta-lactam 156,162-164. Despite the 
fact that S. maltophilia possesses a large set of antibiotic resistance genes, the potential 
mechanisms that could challenge a ceftazidime-based treatment, besides beta-lactamase 
overproduction 165, have not been sufficiently studied.  
 
Tigecycline, which belongs to a new group of tetracyclines called glycylcyclines, also 
appears as a suitable option for the treatment of S. maltophilia severe infections, mostly those 
with a nosocomial origin 166, being also effective against SXT-resistant S. maltophilia 
isolates 167,168. Although the mechanisms of acquisition of resistance to tigecycline have been 
described for other bacterial species, in S. maltophilia the resistance mechanisms against this 
antibiotic are not well established.  
 
In the course of this PhD thesis, we have focused our attention on the study of the role 
of S. maltophilia RND efflux pumps in transient resistance to antibiotics through the 
identification of molecules and/or signals that induce their expression, an issue that is still 
hardly explored. In addition, we aim to elucidate new potential mechanisms involved in the 
acquisition of ceftazidime and tigecycline resistance, two of the antibiotics of choice that are 
currently under study for the treatment of S. maltophilia infections, after experimental evolution 
in the presence of these antibiotics, as well as the effects of the selected mutations on bacterial 
physiology aspects, such as fitness cost. Consequently, in this PhD thesis, we have addressed 
the following objectives.
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2. Objectives 
 
 
I. Study of the role of RND efflux pumps in the inducible resistance to antibiotics of 
S. maltophilia 
 
a. To develop YFP-based reporters of the expression of SmeVWX and SmeYZ efflux 
pumps.  
b. To perform a screening of potential inducer compounds that trigger the expression 
of either smeVWX and/or smeYZ. 
c. To analyse the effect of the identified inducer compounds on the transient antibiotic 
resistance of S. maltophilia. 
 
II. Study of the acquisition of resistance during experimental evolution in 
S. maltophilia  
 
a. To perform experimental evolution assays in the presence of the antibiotics 
ceftazidime and tigecycline.  
b. To unveil the genetic mechanisms underlying the acquisition of resistance to both 
antibiotics. 
c. To assess how the acquisition of resistance influences cross-resistance and collateral 
sensitivity against other antibiotics, and on fitness cost.  
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3. Results 
 
The results of this PhD thesis have been published in peer-reviewed journals with the 
following titles: 
 
I. Vitamin K3 Induces the Expression of the Stenotrophomonas maltophilia SmeVWX 
Multidrug Efflux Pump.  
II. Biolog Phenotype Microarray Is a Tool for the Identification of Multidrug Resistance 
Efflux Pump Inducers.  
III. Involvement of the RND Efflux Pump Transporter SmeH in the Acquisition of 
Resistance to Ceftazidime in Stenotrophomonas maltophilia.  
IV. Mechanisms and Phenotypic Consequences of Tigecycline Resistance Acquisition in 
Stenotrophomonas maltophilia. 
 
All the mentioned papers are completely reported hereunder, along with a brief 
introduction and the corresponding supplementary information. 
  
The PhD candidate contributed to the experimental design of each study, development of 
the experiments, interpretation of the results and writing of the manuscripts, together with the 
other authors. 
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Article I 
 
Vitamin K3 Induces the Expression of the Stenotrophomonas maltophilia SmeVWX 
Multidrug Efflux Pump 
 
P. Blanco, F. Corona, M. B. Sánchez, J. L. Martínez 
 
Antimicrobial Agents and Chemotherapy. 61:e02453-16 (2017) 
 
Multidrug (MDR) efflux pumps are major contributors to S. maltophilia antibiotic 
resistance, being the resistance nodulation division (RND) family the best characterized. 
Although their expression is usually controlled by specific transcriptional regulators, some 
situations, as the presence of certain effectors in the environment or particular physiological 
conditions, can induce the expression of these efflux systems, which might lead to a situation 
of transient resistance to antibiotics that are substrates of such efflux pumps. Thus, the 
knowledge of the effectors (or situations) that are able to trigger the expression of these 
resistance determinants is fundamental, not only to predict situations of transient antibiotic 
resistance, but also to understand the functional role of S. maltophilia MDR efflux pumps 
besides antibiotics extrusion.  
 
In the present work, we carried out a screening of potential inducer compounds of the 
S. maltophilia SmeVWX RND efflux pump, proved to contribute to the acquisition of resistance 
against quinolones, chloramphenicol and trimethoprim/sulfamethoxazole (SXT). Therefore, we 
developed a yellow fluorescent protein (YFP)-based sensor and tested a variety of compounds 
in order to measure the fluorescence given by the expression of YFP under the control of the 
smeVWX promoter. Among the tested compounds, we found vitamin K3, or menadione, as an 
inducer of the expression of smeVWX. Besides, the presence of this compound, which is 
produced by plants and is present in some haemostatic drugs, renders S. maltophilia less 
susceptible to ofloxacin and chloramphenicol, two of the SmeVWX antibiotic substrates.  
 
 
Vitamin K3 Induces the Expression of the
Stenotrophomonas maltophilia SmeVWX
Multidrug Efﬂux Pump
P. Blanco, F. Corona, M. B. Sánchez, J. L. Martínez
Centro Nacional de Biotecnología, CSIC, Madrid, Spain
ABSTRACT Stenotrophomonas maltophilia is an opportunistic pathogen with in-
creasing prevalence, which is able to cause infections in immunocompromised pa-
tients or in those with a previous pathology. The treatment of the infections caused
by this bacterium is often complicated due to the several intrinsic antibiotic resis-
tance mechanisms that it presents. Multidrug efﬂux pumps are among the best-
studied mechanisms of S. maltophilia antibiotic resistance. Some of these efﬂux
pumps have a basal expression level but, in general, their expression is often
low and only reaches high levels when the local regulator is mutated or bacteria
are in the presence of an effector. In the current work, we have developed a yel-
low ﬂuorescent protein (YFP)-based sensor with the aim to identify effectors able
to trigger the expression of SmeVWX, an efﬂux pump that confers resistance to
quinolones, chloramphenicol, and tetracycline when it is expressed at high lev-
els. With this purpose in mind, we tested a variety of different compounds and
analyzed the ﬂuorescence signal given by the expression of YFP under the con-
trol of the smeVWX promoter. Among the tested compounds, vitamin K3, which
is a compound belonging to the 2-methyl-1,4-naphthoquinone family, is pro-
duced by plants in defense against infection, and has increasing importance in human
therapy, was able to induce the expression of the SmeVWX efﬂux pump. In addition, a
decrease in the susceptibility of S. maltophilia to oﬂoxacin and chloramphenicol was ob-
served in the presence of vitamin K3, in both wild-type and smeW-deﬁcient strains.
KEYWORDS inducible resistance, SmeVWX, Stenotrophomonas maltophilia,
biosensors, efﬂux pumps
Stenotrophomonas maltophilia is an emerging multidrug-resistant opportunistic patho-gen involved in an increased number of infections (1). Among these infections, we can
highlight septicemia, urinary infections, endocarditis, and respiratory infections in immu-
nocompromised patients and in those with cystic ﬁbrosis (2). In general, clinical isolates of
S. maltophilia present low susceptibilities to a wide range of antibiotics, including macro-
lides, -lactams, cephalosporins, trimethoprim-sulfamethoxazole, tetracyclines, polymyxins,
aminoglycosides, chloramphenicol, carbapenems, and ﬂuoroquinolones, making the infec-
tions caused by this bacterium difﬁcult to treat (1). This low susceptibility to antibiotics is
associated with several intrinsic resistance elements, such as antibiotic-modifying enzymes,
low membrane permeability, the quinolone resistance protein SmQnr, and multidrug
resistance (MDR) efﬂux pumps (3, 4).
Eight MDR efﬂux pumps (SmeABC, SmeDEF, SmeGH, SmeIJK, SmeMN, SmeOP,
SmeVWX, and SmeYZ) belonging to the resistance-nodulation-cell division (RND) family
have been identiﬁed in S. maltophilia K279a (4). The roles of six of them (SmeABC,
SmeDEF, SmeIJK, SmeOP, SmeVWX, and SmeYZ) in intrinsic and acquired resistance to
antibiotics have been analyzed (5–14).
The expression of MDR efﬂux pumps is generally tightly downregulated by speciﬁc
transcriptional regulators, likely because their overexpression might compromise bac-
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terial physiology (15). However, transient higher expression levels can be reached due
to some particular physiological situations, as a response to stress or in the presence of
effectors, including host-produced anti-infective molecules, such as bile, cationic pep-
tides, or fatty acids (16–18), as well as agents used for therapeutic purposes, some of
which might be relevant in the course of an infection (19). Knowing these effectors can
be useful for understanding the role of these MDR efﬂux pumps besides resistance to
antibiotics, as well as for predicting situations of transient antibiotic resistance that may
occur in vivo (20).
RND efﬂux pump substrates are very diverse and include antibiotics, biocides, bile
salts, detergents, aromatic hydrocarbons, homoserine lactones, and dyes (21); however,
the number of known inducers that can trigger their expression is lower in comparison
(20). In the present study, we have carried out a screening in order to identify potential
effectors of the S. maltophilia RND efﬂux pump SmeVWX, using a yellow ﬂuorescent
protein (YFP)-based sensor. The operon encoding this MDR efﬂux system is composed
of a membrane fusion protein gene (smeV), an inner membrane transporter gene
(smeW), and an outer membrane protein gene (smeX). smeVWX genes are coexpressed
with two short-chain-dehydrogenase/reductase (SDR) genes, which are located up-
stream smeV (smeU1) and between smeW and smeX (smeU2). The operon is regulated
by the LysR-type transcriptional regulator SmeRv (11). SmeVWX does not participate in
S. maltophilia intrinsic resistance, likely because its expression levels are too low (11);
nevertheless, it is known that this efﬂux pump contributes to the acquisition of
resistance mediated by mutations in the transcriptional regulator SmeRv, leading to the
overexpression of the efﬂux system (22). Further, quinolone-resistant clinical isolates
overexpressing this efﬂux pump have been found, indicating that SmeVWX overex-
pression may have clinical relevance (12, 22).
Among the compounds tested in this study, we have found that vitamin K3 (vitK3),
also known as menadione (2-methylnaphtalene-1,4-dione), acts as an inducer and is
likely a substrate of the SmeVWX efﬂux system. In addition to developing a biosensor
for tracking inducers of the expression of SmeVWX and since vitK3 is present in some
hemostatic drugs and is also becoming an important candidate for anticancer therapy,
our study provides information about the potential implications that using vitK3 during
the course of an infection caused by S. maltophilia might have.
RESULTS AND DISCUSSION
Reporter construction. Fluorescent protein-based sensors have been extensively
used for different purposes due to their high reliability, sensitivity, and simplicity in
operation (23). In the current work, a YFP-based reporter was constructed in order to
identify potential inducers of the expression of the S. maltophilia SmeVWX efﬂux pump,
which are unknown so far. To carry this out, a DNA fragment containing the promoter
sequence of smeVWX was ampliﬁed and cloned into the pSEVA237Y plasmid, which
harbors the yellow ﬂuorescent protein (YFP) (24), giving rise to the pPBT04 plasmid, as
described in Materials and Methods. This allows the quantiﬁcation of the expression of
smeVWX through the ﬂuorescence given by YFP. Using tripartite conjugation, the
plasmid pPBT04 was introduced in S. maltophilia D457, with the resultant strain dubbed
PBT02, and in S. maltophilia MBS287, the resultant strain was dubbed PBT06. The
MBS287 strain, a mutant derived from the wild-type S. maltophilia D457 strain, consti-
tutively expresses high levels of smeVWX due to a mutation (Gly266Asp) in the gene
encoding its local regulator SmeRv. This strain can be used as a control for measuring
the expression levels of smeVWX when the efﬂux pump is overexpressed (22). To test
the smeVWX sensor, the ﬂuorescence levels given by the PBT02 and PBT06 strains
and the growth of both strains were measured for 18 h. As mentioned above, the
expression levels of SmeVWX are very low; consequently, it is expected that the
ﬂuorescence given by the expression of YFP under the control of the smeVWX promoter
in the PBT02 strain is lower than the one obtained in the overexpressing derivative
strain PBT06. As shown in Fig. 1, higher levels of ﬂuorescence given by the YFP are
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obtained in the case of the PBT06 strain than with PBT02 during growth, validating the
smeVWX sensor developed in this work.
Vitamin K3 induces smeVWX expression. Multidrug efﬂux pumps are relevant
elements in the development of antibiotic resistance in bacterial populations.
Expression of these determinants is usually repressed by speciﬁc regulators en-
coded by genes located upstream of the operons that contain the structural genes
for these efﬂux pumps (19). In the opportunistic pathogen S. maltophilia, some of
these RND multidrug efﬂux pumps, such as SmeDEF, SmeIJK, SmeOP, and SmeYZ,
contribute to bacterial intrinsic resistance (4, 6, 9, 14), while others, such as
SmeVWX, have very low levels of expression and its overexpression alone leads to
acquired resistance (11, 22). In addition to genetic alterations, resistance can also be
achieved by the presence of effectors or conditions that trigger the expression of
multidrug efﬂux pumps, leading to the acquisition of transient phenotypic antibi-
otic resistance (25–27). A wide range of MDR efﬂux pump substrates are known.
However, the number of known effectors that regulate their expression is lower in
comparison (28). For instance, the AcrAB-TolC system in Escherichia coli can be
induced by bile salts (29), and in Pseudomonas aeruginosa, the MexXY-OprM system
is induced in response to antibiotics that target the ribosome and under oxidative
stress conditions (30, 31). In the case of S. maltophilia, the SmeDEF efﬂux pump is
induced by triclosan and some plant-produced compounds, which bind its local
repressor SmeT, so that smeDEF transcription becomes activated (26, 32). To date,
it is not known if there is any compound able to induce the expression of the
SmeVWX efﬂux pump; consequently, we carried out a screening of such potential
effectors in S. maltophilia PBT02 using compounds belonging to different categories,
including antibiotics, compounds that produce oxidative stress, chelating agents, biocides,
etc. The concentrations were chosen taking into consideration the MIC values of each
compound.
None of the tested compounds gave a clear increase in ﬂuorescence levels,
except vitK3, which caused an increment in the ﬂuorescence obtained by YFP
FIG 1 Fluorescence levels and growth of the sensor strains PBT02 and PBT06. The ﬂuorescence of both
strains was measured using a plate reader for 18 h in LB medium. The YFP levels given by the expression
of smeVWX in PBT06 are higher than in the D457-derivative strain PBT02, since it overexpresses the efﬂux
pump due to a mutation in the regulator SmeRv. There are not signiﬁcant differences in the growth of
both strains. Error bars indicate standard deviations of the results from three independent replicates.
RFU, relative ﬂuorescence units.
Induction of MDR Pump SmeVWX by Vitamin K3 Antimicrobial Agents and Chemotherapy
May 2017 Volume 61 Issue 5 e02453-16 aac.asm.org 3
 o
n
 April 9, 2019 by guest
http://aac.asm
.org/
D
ow
nloaded from
 
expression under control of the smeVWX promoter. The ﬂuorescence levels were
measured in both PBT02 and PBT06. As shown in Fig. 2, the ﬂuorescence levels
given by PBT02, when cells reached exponential phase (optical density at 600 nm
[OD600], 0.6), are higher in the presence of 1 mM vitK3 than those obtained in the
absence of any compound. To analyze whether or not the effect of vitK3 was
speciﬁc and determine the minimal concentrations that may trigger smeVWX
induction, a more detailed analysis was performed using as potential inducers vitK3,
its structural analogues vitamin K2 (vitK2) and plumbagin, and the generator of
oxidative stress, tert-butyl hydroperoxide. As shown in Fig. 3, vitK3 remains the best
smeVWX inducer, even at concentrations as low as 4 M, whereas a modest
induction in the presence of vitK2 and plumbagin can be seen, and tert-butyl
hydroperoxide does not induce the expression of smeVWX; this indicates that
oxidative stress is not the cause (at least the unique cause) of the induction of
smeVWX expression in the presence of vitK3.
In order to further address whether or not vitK3 induces the expression of smeVWX,
smeV mRNA levels were measured by real-time reverse transcription-PCR (RT-PCR) in
the presence and absence of vitK3. As shown in Fig. 4, the expression levels of smeV are
increased by 105-fold in the presence of vitK3 in the wild-type strain D457 in compar-
ison with those levels obtained without this compound. In S. maltophilia MBS287,
where smeVWX is overexpressed, the smeV levels are increased by 286-fold in compar-
ison with those of the wild-type strain D457. These data show that vitK3 increases the
expression of smeVWX mRNA, a feature in agreement with the results obtained using
the above-described ﬂuorescent reporter, indicating that the sensor is valid for the
detection of inducer compounds.
Vitamin K3 might be extruded by SmeVWX efﬂux pump. As described above,
vitK3 is able to induce smeVWX expression, and it is possible that this compound is a
substrate of the efﬂux pump. To test this possibility, a D457-derivative mutant with a
partial deletion in smeW (MBS704) was constructed by homologous recombination, as
described in Materials and Methods. Both strains, the wild type (D457) and the smeW
mutant (MBS704), were grown in the presence and absence of vitK3 (1 mM) for 20 h at
FIG 2 Effect of vitK3 on smeVWX expression. The ﬂuorescence levels obtained by smeVWX expression
when OD600 of 0.6 is reached in PBT02 strain, PBT02 strain after incubation with 1 mM vitK3, and PBT06
strain are shown. vitK3 increases YFP expression in comparison with the untreated strain, although the
level reached is lower than in PBT06. Error bars indicate standard deviations of the results from three
independent replicates.
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37°C, and the optical density at 600 nm was measured every 10 min using a Tecan
Inﬁnite 200 plate reader (Tecan). As shown in Fig. 5, in the absence of vitK3, the two
strains exhibit similar growth; however, when vitK3 is added to the medium, the
MBS704 strain growth is impaired in comparison with D457. This result suggests that
SmeVWX extrudes vitK3, and in the absence of this efﬂux pump, this compound inhibits
S. maltophilia growth.
vitK3 is an analogue of vitamins K1 and K2, with all of them belonging to the
2-methyl-1,4-naphthoquinone family (33, 34). vitK3 is also known as menadione, a
compound that has been isolated from fungi and phanerogams (35), where it was ﬁrst
studied as a plant regulator (36). The function of menadione in the defense against
plant pathogens has been shown in several studies (37–39). This contribution can be
carried out in two ways: ﬁrst, vitK3 is able to increase the activity of the H-ATPase in
plant cells due to its redox properties, contributing to the immune response against
phytopathogens (40, 41); second, vitK3 itself is toxic for bacteria as a result of its
capability of generating reactive oxygen species (ROS), elevating the intracellular
production of O2 and H2O2 (42).
S. maltophilia is an ubiquitous bacterium which has been isolated from several
sources, including those associated with the plant rhizosphere (1, 43). One of the roles
of MDR efﬂux pumps is the prevention of the accumulation of toxic compounds inside
the cell by extruding them (44). Since S. maltophilia is a rhizosphere-related bacterium,
the SmeVWX efﬂux pump is likely involved in nature in the detoxiﬁcation of vitK3 and
its analogues, which might be produced by plants during S. maltophilia root coloniza-
tion.
Vitamin K3 decreases S. maltophilia antibiotic susceptibility even in the ab-
sence of smeW. It is known that the SmeVWX efﬂux pump is able to extrude
quinolones and chloramphenicol, and its overexpression causes resistance to these
antibiotics (11, 12). Since vitK3 is able to induce smeVWX expression, it is possible that
the susceptibility to such antibiotics decreases in the presence of this agent. To analyze
this hypothesis, a susceptibility assay using either an oﬂoxacin disc (5 g) or a
FIG 3 Effects of different compounds on smeVWX expression. Fluorescence levels for: vitamin K3 (A), vitamin K2 (B), plumbagin (C), and
tert-butyl hydroperoxide (D) given by the expression of smeVWX in PBT02 strain when OD600 of 0.6 is reached at several concentrations.
Plumbagin and vitamin K2 slightly increase the YFP levels in comparison with vitamin K3 (A to C); tert-butyl hydroperoxide does not cause
any changes (D). Error bars indicate standard deviations of the results from three independent replicates.
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chloramphenicol disc (30 g) placed next to a vitK3-containing disc (2 mol) was
carried out. The inhibition halos around the antibiotic discs present deformations in the
region nearby the vitK3 disc (not shown), indicating that this compound decreases S.
maltophilia susceptibility to antibiotics. To further conﬁrm that vitK3 decreases suscep-
tibility to antibiotics, a checkerboard assay was performed. A 96-well microtiter plate
containing serial concentrations of either oﬂoxacin or chloramphenicol (also a substrate
of SmeVWX) in combination with vitK3 was inoculated with cultures of S. maltophilia
D457 or the smeW-defective mutant MBS704 at an OD600 of 0.01. After 24 h of
incubation at 37°C, the OD600 was measured in each well. The fractional inhibitory
concentration (FIC) values are shown in Table 1. Noteworthy, the effect of vitK3 was
antagonistic in all cases, independently of the type of the antibiotic used and of the
presence or the absence of smeW. This indicates that the effect of vitK3 on S. malto-
philia goes beyond the induction of smeVWX, a topic that is currently under study in our
laboratory.
Concluding remarks. Resistance to antibiotics has become an increasing problem
in public health, with MDR efﬂux pumps being relevant elements in the development
of this resistance. As mentioned above, MDR efﬂux pump expression is usually re-
pressed by speciﬁc transcriptional regulators (15). Expression of MDR efﬂux pumps is
likely induced under physiological conditions when their activity is required, and
bacteria can determine this need by detecting growing conditions or compounds in the
environment that act as effectors. However, antibiotics are not usually good inducers of
efﬂux pumps, whereas nonantibiotic compounds can induce such expression (21).
In this study, we have developed a ﬂuorescent biosensor useful for detecting
inducers of the S. maltophilia SmeVWX MDR efﬂux pump. Using this biosensor, we have
determined that vitK3 (a potential substrate of this efﬂux pump involved in the defense
of plants against pathogens) is able to induce the expression of the S. maltophilia
SmeVWX efﬂux pump. Vitamin K is an essential nutrient which acts as a cofactor in the
production of some factors of blood coagulation in mammals, such as factors II
(prothrombin), VII (proconvertin), IX, and X (33). vitK3 has improved antihemorrhagic
FIG 4 vitK3 increases smeV mRNA levels. smeV mRNA levels were measured by real-time RT-PCR in the
presence of vitK3 in the wild-type D457 strain and in the MBS287 strain, which overexpresses smeVWX.
The data show that expression of smeV is induced by vitK3. Fold changes were estimated with respect
to the value given by strain D457 in the absence of vitK3. Error bars indicate standard deviations of the
results from three independent experiments.
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activity compared with the natural vitamin K, so it is used as an agent of choice for the
treatment of vitamin K deﬁciency, hemorrhagic diathesis, and hypoprothrombinemia,
prophylactically before and after surgery to prevent bleeding, and it is administered to
newborns with low levels of prothrombin to prevent hemorrhagic diseases (45).
Besides, vitK3 is gaining importance as an anticancer agent because of its cytotoxic
effect against cancer cells (34, 46). Recent work has shown that the plasma concentra-
tion of menadione upon the administration of 10 mg of menadiol sodium diphosphate
to healthy subjects can reach a peak of 3 M (47), within the concentration range at
which we begin to observe induction of smeVWX expression.
S. maltophilia mainly causes nosocomial infections (48), although community-
acquired infections can also occur (49). The population at risk is mostly composed of
immunocompromised hosts, including intensive care unit (ICU) patients, patients with
dialysis catheters, hematological diseases, and cystic ﬁbrosis, and those treated with a
wide spectrum of antibiotics (50–53). Although our results indicate that vitK3 might
induce the expression of the smeVWX efﬂux pump even at low concentrations and
antagonizes the effects of oﬂoxacin and chloramphenicol against S. maltophilia, both in
the presence and in the absence of this efﬂux pump, the clinical signiﬁcance of these
ﬁndings remains to be clearly established.
In addition, the fact that vitK3 is produced by plants and that S. maltophilia is a
common plant inhabitant (54) strongly suggests that SmeVWX might be involved in
FIG 5 vitK3 might be extruded by the SmeVWX multidrug efﬂux pump. The growth in the presence and
absence of 1 mM vitK3 in D457 strain and MBS704 (ΔsmeW) was measured. In the presence of vitK3, the
smeW mutant presents a diminished growth in comparison with the wild-type strain D457, suggesting
that vitK3 might be extruded by the SmeVWX MDR efﬂux pump. Error bars indicate standard deviations
of the results from three independent replicates.
TABLE 1 FIC values of vitK3 in combination with either chloramphenicol or oﬂoxacina
Strain
Chloramphenicol  vitK3 Oﬂoxacin  vitK3
CvitK3 MICvitK3 Cchlor MICchlor FIC CvitK3 MICvitK3 Coﬂox MICoﬂox FIC
D457 2.56 2.56 16 16 2 5.12 5.12 6 4 2.5
MBS704 5.12 2.56 16 12 3 2.56 2.56 6 3 3
aSee FIC index analysis in Materials and Methods for details on the terms used here. chlor,
chloramphenicol; oﬂox, oﬂoxacin.
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bacterium-plant interactions in nature, a functional role that has been already demon-
strated for the S. maltophilia SmeDEF efﬂux pump (32).
MATERIALS AND METHODS
Bacterial strains and growing conditions. All bacterial strains and plasmids used in this study are
listed in Table 2. Cells were grown in LB medium at 37°C, unless otherwise stated. When required, the
following antibiotics were added: ampicillin (Ap; 100 g/ml) for Escherichia coli harboring the pGEM-T
Easy vector and the pPBT02 and pBS51 plasmids, and kanamycin (Km; 50 g/ml and 500 g/ml) for E.
coli and S. maltophilia D457, respectively, for pSEVA237Y and pPBT04 plasmid selection. Km at 50 g/ml
was added to LB liquid medium to maintain pSEVA237Y and pPBT04 plasmids in both E. coli and S.
maltophilia; tetracycline (Tc; 10 g/ml) was added in the case of E. coli harboring pEx18Tc and pBS52
plasmids. Tc at 10 g/ml and imipenem (Imp; 20 g/ml) were added for the selection of S. maltophilia
D457 exconjugants. Medium was supplemented with 80 g/ml 5-bromo-4-chloro-3-indolyl--D-
galactopyranoside (X-Gal) and 0.5 mM isopropyl--D-thiogalactopyranoside (IPTG) for the detection of
-galactosidase production.
Reporter construction. S. maltophilia D457 genomic DNA was extracted according to the Gnome
DNA kit protocol (MP Biomedicals). The 384-bp region between the smeRv gene (SMD_1762) and the
smeU1 gene (SMD_1763), which contains the smeVWX promoter region, was ampliﬁed using the FailSafe
PCR system (Epicentre) with primers SmeVWX_F (5=-GAATTCGATCCTGGACGTCG-3=, EcoRI site under-
lined) and SmeVWX_R (5=-AAGCTTGACATTTCCTCCCAAATC-3=, HindIII site underlined). The thermocycler
was programmed for 25 cycles of 94°C for 30 s of denaturation, 56°C for 30 s of annealing, and 72°C for
a 36-s extension, with an initial denaturation at 94°C for 5 min and a ﬁnal extension at 72°C for 7 min.
The PCR product was ligated into pGEM-T Easy vector (Promega), according to the manufacturer’s
instructions, obtaining the pPBT02 plasmid, which was introduced by transformation into E. coli Omni-
MAX (Invitrogen). The construction was veriﬁed by DNA sequencing. The pPBT02 plasmid was extracted
with the QIAprep Spin miniprep kit 250 (Qiagen), according to the manufacturer’s instructions, and
digested with EcoRI and HindIII restriction enzymes (New England BioLabs). The product corresponding
to the smeVWX promoter region was puriﬁed with the puriﬁcation kit (GE Healthcare) from a 1% agarose
gel and cloned into pSEVA237Y using the same restriction enzymes and the T4 DNA ligase (New England
BioLabs). The obtained plasmid, pPBT04, was introduced by transformation in E. coli OmniMAX (Invitro-
gen) competent cells. The presence of the plasmid was conﬁrmed by PCR, as described above, with
primers pSEVA227Y_F (5=-GCGGATAACAATTTCACACA-3=) and pSEVA227Y_R (5=-TTGCTCACCATATGTTTT
TCC-3=).
The pPBT04 plasmid was introduced by transformation in E. coli CC118pir. Afterwards, the plasmid
was introduced into the S. maltophilia D457 and MBS287 strains by tripartite matting using the strains
E. coli CC118pir (donor cell), E. coli 1047/pRK2013 (helper cell), and S. maltophilia (receptor cell), in a 4:2:1
proportion (receptor:donor:helper). Kanamycin (500 g/ml) was added for selecting the S. maltophilia
clones containing the pPBT04 plasmid, and imipenem (20 g/ml) was added for eliminating the E. coli
TABLE 2 Bacterial strains and plasmids
Strain or plasmid Descriptiona Source or reference
Bacterial strains
E. coli
OmniMAX Strain used in transformation; F= {proAB lacIq lacZΔM15 Tn10(Tetr)} mcrA Δ(mrr-hsdRMS-mcrBC)
80(lacZ)ΔM15 Δ(lacZYA-argF) U169 endA1 supE44 thi-1 gyrA96 relA1 deoR tonA panD
Invitrogen, Life
Technologies
TGI Strain used in transformation; supE thi-1 Δ(lac-proAB) Δ(mcrB-hsdSM)5 (rK mK) [F= traD36 proAB
lacIq ZΔM15]
61
CC118pir Donor cell in conjugation; strain CC118 lysogenized with  pir phage (Tc=) Δ(ara-leu) araD ΔlacX74
galE galK phoA20 thi-1 rpsE rpoB argE (Am) recA1
56
1047 (pRK2013) Helper cell in conjugation harboring pRK2013 (Kanr) plasmid 62
S. maltophilia
D457 Clinical strain 63
MBS287 D457-derived mutant (SmeRv G266N) overexpressing SmeVWX efﬂux pump 22
MBS704 D457 ΔsmeW This work
PBT02 D457 with pPBT04 plasmid This work
PBT06 MBS287 with pPBT04 plasmid This work
Plasmids
pGEM-T Easy vector Cloning vector, Ampr Promega
pSEVA237Y Plasmid containing YFP; replication origin pBBR1; Kanr 24
pPBT02 pGEMT-derived plasmid containing smeVWX promoter region This work
pPBT04 pSEVA237Y-derived plasmid containing smeVWX promoter region This work
pEX18Tc Gene replacement vector; sacB, Tcr 23
pBS51 pGEMT-derived plasmid containing the 5= and 3= regions of smeW gene This work
pBS52 pEX18Tc-derived plasmid containing the 5= and 3= regions of smeW gene This work
aTetr, tetracycline resistance; Kanr, kanamycin resistance; Ampr, ampicillin resistance.
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strains. For plasmid conﬁrmation, PCR was performed as described above with primers pSEVA227Y_F and
pSEVA227Y_R.
Deletion of the smeW gene. An S. maltophilia D457 mutant with a partial deletion of smeW gene
was generated by homologous recombination. A fragment homologous to both the 5= end (498 bp) and
the 3= end (513 bp) of the smeW gene was obtained by overlapping PCR, using the PCR master mix
(Promega). In the ﬁrst PCR, the primers SmeWA (5=-CGGGATCCTTAGCTGCCGGCGCCAG-3=, BamHI site
underlined) and SmeWB (5=-CAGGATCTTCTGCGTAGTCA-3=) for the 5= end and SmeWC (5=-CAGGATCTT
CTGCGTAGTCA-3=) and SmeWD (5=-CCCAAGCTTGATGCATGCCTTGTGG3=, HindIII site underlined) for the
3= end were used. The PCR products were puriﬁed with the QIAquick PCR puriﬁcation kit (Qiagen),
according to the manufacturer’s instructions, and used as the template for a second PCR with SmeWA
and SmeWD primers. The PCR product, puriﬁed from an agarose gel with the QIAquick gel extraction kit
(Qiagen), was cloned in pGEM-T Easy vector (Promega), generating pBS51 plasmid, which was introduced
in E. coli TG1. The right sequence was conﬁrmed by sequencing, and the fragment containing the 5= and
3= ends of the smeW gene was cloned into the suicide vector pEX18Tc (55) using the BamHI-HindIII sites,
generating the pBS52 plasmid. This plasmid was introduced into E. coli CC118pir and mobilized
afterwards into S. maltophilia D457 by tripartite conjugation (56). The exconjugants containing pBS52
were selected on LB agar containing 10 mg/ml tetracycline and 20 mg/ml imipenem. Tetracycline-
resistant colonies were streaked onto 10% sucrose-LB agar to select double recombinants with the partial
deletion of the smeW gene. S. maltophilia D457 ΔsmeW (MBS704) was conﬁrmed by PCR, with external
(SmeWA/SmeWD) and internal (SmeW5 [5=-GAACCGTTGCCGAACAGC-3=]/SmeW6 [5=-GACAGGCCTTCCT
CGATG-3=]) primers to the smeW gene.
Screening of potential inducers of the expression of smeVWX. Different compounds from
different categories were used in this assay at serial concentrations. Among them were the antibiotics
erythromycin (512, 256, and 128 g/ml), gentamicin (32, 16, and 8 g/ml), co-trimoxazole (trimethoprim-
sulfamethoxazole, 1:5) (1, 0.5, and 0.25 g/ml), chloramphenicol (16, 8, and 4 g/ml), tobramycin (512,
256, and 128 g/ml), oﬂoxacin (4, 2, and 1 g/ml), kanamycin (512, 256, and 128 g/ml), tetracycline (4,
2, and 1 g/ml), polymyxin B (2, 1, and 0.5 g/ml), and colistin (24, 12, and 6 g/ml); heavy metals ZnSO4
(5, 2.5, and 1.25 mM), CuSO4 (5, 2.5, and 1.25 mM), CdSO4 (5, 2.5, and 1.25 mM), CoSO4 (5, 2.5, and 1.25
mM), and FeCl3 (5, 2.5, and 1.25 mM); oxidative stress compounds paraquat (5, 2.5, and 1.25 mM), vitamin
K3 (2, 1, and 0.5 mM), and tert-butyl hydroperoxide (1, 0.5, and 0.25 mM); biocides triclosan (10, 5, and
2.5 g/ml) and hexachlorophene (100, 50, and 25 g/ml); plant-produced ﬂavonoids phloretin (10, 5, and
2.5 g/ml), quercetin (10, 5, and 2.5 g/ml), and genistein (10, 5, and 2.5 g/ml); detergents SDS (200,
100, and 50 mM) and Tween 20 (200, 100, and 50 mM); chelating agents EDTA (2, 1, and 0.5 mM) and
EGTA (2, 1, and 0.5 mM); the analgesic metamizol (10, 5, and 2.5 mg/ml); and the inhibitor of oxidative
phosphorylation carbonyl cyanide m-chlorophenyl hydrazone (CCCP; 20, 10, and 5 M). The compounds
vitamin K3, vitamin K2, plumbagin, and tert-butyl hydroperoxide were studied in more detail using a
wider range of concentrations.
The stock solutions of the different compounds were diluted in LB medium to obtain the required
concentrations. The assay was performed in Corning Costar 96-well black clear-bottom plates (Corning
Incorporated). Ten microliters of cell culture was inoculated in 140 l of medium in each well to a ﬁnal
OD600 of 0.01. Bacteria were grown at 37°C for 18 h, and growth (OD600) and ﬂuorescence were measured
every 10 min (although data are represented on an hourly basis) using a Tecan Inﬁnite 200 plate reader
(Tecan) set with an excitation wavelength at 508 nm and emission wavelength at 540 nm for YFP
detection.
Assays of induction of antibiotic resistance. Two hundred microliters of S. maltophilia D457 culture
at an OD600 of 0.01 was seeded in an agar-LB medium plate. A 9-mm sterile disc (Macherey-Nagel) was
placed in the plate with vitK3 (2 mol). An oﬂoxacin (5 g) or a chloramphenicol disc (30 g) (Oxoid) was
placed 18 mm from the vitK3 disc. The plate was incubated for 24 h at 37°C.
The effect of vitK3 on the susceptibility of S. maltophilia to oﬂoxacin or chloramphenicol was
analyzed using the checkerboard technique in a 96-well microtiter plate, where 10 l of bacterial culture
of D457 or MBS704 strain was added to each well to a ﬁnal OD600 of 0.01. Eleven vitK3 concentrations
were combined with 7 oﬂoxacin or chloramphenicol concentrations to carry out this assay. The plates
were incubated at 37°C, and the OD600 was recorded after 24 h using a Tecan Inﬁnite 200 plate reader
(Tecan).
FIC index analysis. The fractional inhibitory concentration (FIC) index (57) was determined for each
strain in order to deﬁne if there is some interaction between the antibiotics and vitK3. The sum of the
FICs is deﬁned as FIC  FICA  FICB  (CA/MICA)  (CB/MICB), where A is vitK3 and B is oﬂoxacin or
chloramphenicol. The MIC is deﬁned as the minimum inhibitory concentration of the compounds alone,
and C is deﬁned as the MIC of the compounds in combination. Synergy is deﬁned as an FIC of 0.5, an
FIC value between 0.5 and 2 is considered indifferent, and antagonism is deﬁned as an FIC value of 2.
RNA preparation and real-time RT-PCR. Two ﬂasks containing 20 ml of LB medium were inoculated
with an overnight culture of S. maltophilia D457 to a ﬁnal OD600 of 0.01 and were incubated until
exponential phase was reached (OD600, 0.6). This step was repeated, inoculating two new ﬂasks with
culture from the previous ones. When the culture reached an OD600 of 0.6, vitK3 (1 mM) was added to
one of the ﬂasks and cells were incubated for a further 30 min. Ten milliliters of each culture was
centrifuged at 8,000 rpm and 4°C for 20 min. Five hundred seventy microliters of TE buffer (10 mM
Tris-HCl, 1 mM EDTA [pH 8.0]) and 30 l of lysozyme (Sigma) from a 20 mg/ml stock, for a ﬁnal
concentration of 1 mg/ml, were added to each sample. Afterwards, the samples were mixed by vortexing
for 10 s and were incubated at room temperature for at least 10 min with regular vortexing. A volume
of 2,100 l of buffer RLT (Qiagen) was added, and samples were sonicated twice for 5 to 10 s (constant
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frequency, 0.45 Hz). Then, 1,410 l of ethanol was added and the protocol continued using the RNeasy
minikit (Qiagen), according to the manufacturer’s instructions. In order to eliminate any residual DNA, a
DNase I (Qiagen) treatment was carried out, according to the manufacturer’s instructions. A second
treatment was performed using Turbo DNA-free (Ambion). RNA integrity was veriﬁed on a 1% agarose
gel, and the absence of DNA was conﬁrmed by PCR using primers sme27 and sme48, which amplify a
347-bp fragment belonging to the smeT gene from strain D457 (58). cDNA was obtained from 10 g of
RNA using the High-Capacity cDNA reverse transcription kit (Applied Biosystems). Real-time RT-PCR was
performed using the Power SYBR green PCR master mix (Applied Biosystems) in the ABI Prism 7500
real-time system (Applied Biosystems). The ﬁrst denaturation step, 95°C for 10 min, was followed by 40
temperature cycles (95°C for 15 s, 60°C for 1 min) for ampliﬁcation and quantiﬁcation. Fifty nanograms
of cDNA was used in each reaction. Primers SmeV-RT.fw and SmeV-RT.rv, which amplify the smeV gene
(22), were used at 400 nM. Primers FtsZ1 and FtsZ2 were used to amplify the housekeeping gene ftsZ (22).
Differences in the relative amounts of mRNA were determined according to the 2ΔΔCT method (59, 60).
In all cases, the mean values for relative mRNA expression were obtained from three independent
experiments.
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Article II 
 
Biolog Phenotype Microarray Is a Tool for the Identification of Multidrug Resistance 
Efflux Pump Inducers 
 
P. Blanco, F. Corona, J. L. Martínez 
 
Antimicrobial Agents and Chemotherapy. 62:e01263-18 (2018) 
 
 S. maltophilia RND efflux pumps present diverse regulation patterns, which causes that 
each efflux pump contributes differently to resistance. While SmeVWX, regulated by the LysR-
type regulator SmeRv, is expressed at very low levels at laboratory conditions and hence, does 
not contribute to the bacterial intrinsic resistance, the SmeYZ efflux is controlled by the two-
component system (TCS) SmeRySy and is constitutively expressed, being an intrinsic 
resistance determinant against aminoglycosides.  As discussed in Article I, an increased 
expression of these efflux systems can be induced by environmental signals/cues. 
 
With the aim of extending our knowledge about the effectors that are able to trigger the 
expression of the S. maltophilia efflux pumps, we developed a YFP-based sensor corresponding 
to the SmeYZ efflux pump. In this case, we used the Biolog phenotype microarrays as a high-
throughput methodology for the identification of inducer molecules of smeYZ, as well as for 
searching new potential inducers of smeVWX. Among all the tested compounds, we found that 
iodoacetate, clioquinol, and sodium selenite are able to induce smeVWX, while boric acid and 
the antibiotics erythromycin, chloramphenicol, and lincomycin, trigger smeYZ expression. The 
mechanisms of action of the identified compounds suggest that smeVWX induction might be 
associated with the thiol-reactivity of the inducer molecules, while ribosome-stalling stress 
could be the signal that triggers smeYZ expression. We also analysed the effect of the exposure 
to the inducers sodium selenite and lincomycin on the transient resistance to antibiotics, finding 
that both molecules are able to promote transient resistance to ofloxacin (substrate of 
SmeVWX) and amikacin (substrate of SmeYZ), respectively. 
Biolog Phenotype Microarray Is a Tool for the Identiﬁcation of
Multidrug Resistance Efﬂux Pump Inducers
P. Blanco,a F. Corona,a J. L. Martíneza
aCentro Nacional de Biotecnología, CSIC, Madrid, Spain
ABSTRACT Multidrug resistance efﬂux pumps frequently present low levels of basal
expression. However, antibiotic-resistant mutants that overexpress these resistance
determinants are selected during infection. In addition, increased expression of ef-
ﬂux pumps can be induced by environmental signals/cues, which can lead to situa-
tions of transient antibiotic resistance. In this study, we have applied a novel high-
throughput methodology in order to identify inducers able to trigger the expression
of the Stenotrophomonas maltophilia SmeVWX and SmeYZ efﬂux pumps. To that
end, bioreporters in which the expression of the yellow ﬂuorescent protein (YFP) is
linked to the activity of either smeVWX or smeYZ promoters were developed and
used for the screening of potential inducers of the expression of these efﬂux pumps
using Biolog phenotype microarrays. YFP production was also measured by ﬂow cy-
tometry, and the levels of expression of smeV and smeY in the presence of a set of
selected compounds were also determined by real-time reverse transcription-PCR
(RT-PCR). The expression of smeVWX was induced by iodoacetate, clioquinol, and sel-
enite, while boric acid, erythromycin, chloramphenicol, and lincomycin triggered
smeYZ expression. The susceptibility to antibiotics that are known substrates of the
efﬂux pumps decreased in the presence of the inducers. However, the analyzed mul-
tidrug efﬂux systems did not contribute to S. maltophilia resistance to the studied
inducers. To sum up, the use of ﬂuorescent bioreporters in combination with Biolog
plates is a valuable tool for identifying inducers of the expression of bacterial multi-
drug resistance efﬂux pumps, and likely of other bacterial systems whose expression
is regulated in response to signals/cues.
KEYWORDS antibiotic resistance, efﬂux pumps, induction of resistance, phenotype
microarrays, phenotypic resistance, Stenotrophomonas maltophilia
Multidrug resistance (MDR) efﬂux pumps constitute a group of antibiotic resistancedeterminants able to reduce the activity of antimicrobial agents through their
active transport outside the cell (1–3). Expression of efﬂux pumps is usually tightly
downregulated at several levels and frequently involves the participation of global and
local transcriptional regulators (4). Depending on their basal level of expression, some
efﬂux pumps contribute to intrinsic resistance, while the contribution of others to this
phenotype is low (3, 5, 6). In addition to their contribution to intrinsic resistance to
antimicrobials, MDR-overexpressing mutants presenting decreased susceptibility
(cross-resistance) to different clinically useful antibiotics (7) are isolated from infected
patients (8) and selected in vitro upon antibiotic selective pressure (9). Five different
families of MDR efﬂux pumps have been described so far (6). Among them, the
resistance-nodulation-division (RND) MDR efﬂux pumps family stands as the most
relevant one in Gram-negative bacteria (10, 11).
Stenotrophomonas maltophilia is an opportunistic pathogen, with environmental
origin (12), which produces nosocomial infections as well as chronic infections in cystic
ﬁbrosis patients (13, 14). S. maltophilia is considered a prototype of intrinsically resistant
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pathogens (15). The characteristic low susceptibility of S. maltophilia to a wide range of
antibiotics is due to the reduced permeability of the cell envelope as well as to the
expression of several antibiotic resistance determinants encoded in its genome, includ-
ing at least eight RND efﬂux pumps (15–17). The expression of each S. maltophilia RND
efﬂux pump is regulated at different levels, which makes this organism a suitable model
for the investigation of these systems. Among them, SmeYZ and SmeVWX are good
examples of the transcriptional regulatory diversity present among S. maltophilia RND
efﬂux pumps. The regulation of the expression of smeYZ is modulated by the two-
component system (TCS) SmeRySy (18), while smeVWX expression is regulated by the
LysR-type regulator SmeRv (19). In addition, whereas smeYZ is constitutively expressed
at a signiﬁcant level, hence contributing to the intrinsic resistance of S. maltophilia to
aminoglycosides (20, 21), the level of smeVWX expression is not high enough to
contribute to the intrinsic resistance of this microorganism (19) and SmeVWX-mediated
antibiotic resistance is achieved only through its overexpression, as the consequence of
mutations in its regulator, SmeRv (22).
As above stated, overexpression of MDR efﬂux pumps (and consequently antibiotic
resistance) can be achieved through mutations in the regulatory elements controlling
their expression. However, it is important to recall that there are occasions in which
these antibiotic resistance determinants can be overexpressed without the need for a
genetic change. Indeed, efﬂux pumps are expected to be expressed, when needed, in
response to speciﬁc signals/cues (10). Consequently, there are situations and com-
pounds capable of triggering the expression of these MDR systems, leading bacteria to
display a phenotype of transient antibiotic resistance (23, 24). It is worth mentioning
that besides their function as antibiotic resistance determinants, RND efﬂux pumps
present a range of functions (11, 25–27) that include, among others, the bacterial
response to host defenses (28–31), the modulation of the quorum-sensing (QS) signal-
ing network (32–34), and the response to general stress situations (e.g., oxidative and
nitrosative stress), acting as escape valves for the accumulation of toxic compounds or
stress by-products (35).
RND efﬂux pumps are known to extrude a wide range of structurally different
compounds, some of which are well characterized, especially in the case of clinically
relevant antimicrobials (36). However, less is known about the efﬂux pump effectors.
Given the above-mentioned functions of efﬂux pumps, most of the RND effectors
already known have been discovered through the study of speciﬁc physiological
processes wherein efﬂux pumps participate, such as the colonization of particular
niches or the extrusion of a particular toxic compound (31, 37, 38). Expanding the
knowledge of the set of RND inducer molecules could thus help in the characterization
of MDR efﬂux systems, getting novel insights on their functional and ecological roles.
Besides, the characterization of these effectors might also be useful for detecting
possible situations of induced antibiotic resistance in vivo, which would not be de-
tected by classical laboratory susceptibility tests.
Biolog phenotype microarrays consist of 96-well microplates developed for the
determination of the bacterial response to a wide variety of chemical agents and
nutrients, allowing testing nearly 2,000 phenotypes (39), which may help among
several applications, including bioﬁlm formation or the response to stressors, to deci-
pher the phenotypes modulated by gene regulatory networks (40–48). In the current
study, we have employed for the ﬁrst time a different approach, based on the use of
ﬂuorescent reporters of the RND efﬂux pumps SmeVWX and SmeYZ, which present
different levels of expression as well as different regulation patterns, to perform a wide
screening of efﬂux pumps’ inducer molecules, which could be applied as well to any
other study on the regulation of gene expression. In addition, we have analyzed the
effect of the induction of the expression of smeVWX and smeYZ on S. maltophilia
susceptibility to the inducer compounds and to antibiotics currently used in clinical
practice. Overall, our work provides new insights on the regulation of the expression
and the role of the studied efﬂux pumps in the physiology of S. maltophilia.
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RESULTS
Characterization of reporter strains PBT03 (PEM7) and PBT10 (PYZ). In a previous
study, we developed the reporter strain PBT02, which expresses a yellow ﬂuorescent
protein (YFP) under the control of the smeVWX promoter, in order to identify potential
inducers of smeVWX expression (49). In the present work, two new YFP-based reporter
strains have been developed as described in Materials and Methods: one containing the
promoter of smeYZ, for measuring smeYZ expression (PBT10), and another which
contains the constitutive promoter PEM7 (50) as a control for the normalization of the
results (PBT03).
In order to test the proper functioning of the reporter strains, bacterial growth and
YFP levels were determined. The ﬂuorescence levels shown by the PBT10 strain were
higher than those already described for the PBT02 strain (see Fig. S1 in the supple-
mental material), conﬁrming that smeYZ is constitutively expressed in the wild-type S.
maltophilia strain (20), while smeVWX expression was low, as reported previously (19).
The YFP level shown by the PBT03 (PEM7) strain was also assessed, and as expected, the
expression was constitutive and suitable to be used as a positive control of ﬂuorescence
as well as for normalization purposes (Fig. S1).
Screening of inducers of MDR efﬂux pumps expression using Biolog phenotype
plates. Biolog plates contain four different quantities (in different wells) of each tested
compound. Nevertheless, information on these quantities is not available for users. The
four wells for each of the tested compounds were named A, B, C, and D, with A being
the well containing the highest amount of each compound. In the current work, plates
PM11 to PM16 were chosen, making a total of 144 analyzed compounds (see Table S1).
S. maltophilia reporter strains grew in at least one concentration for 142 of the tested
compounds (Fig. S2). Those wells where S. maltophilia did not grow were discarded for
further analysis.
The growth and the YFP ﬂuorescence were recorded and analyzed in the presence
of each of the tested compounds to obtain a proxy value of the transcriptional activity
of the analyzed promoters. In the ﬁrst step, the maximum speciﬁc rate of ﬂuoresce
production () was determined as described in Materials and Methods for each
promoter-compound-concentration combination (VWX, YZ, and EM7). In the second
step, the obtained values were normalized to those of the constitutive promoter and
the values of normalized ﬂuorescence production driven by each of the two analyzed
promoters (VWX/EM7 and YZ/EM7) were represented for every compound concen-
tration in a box plot (Fig. 1). From these analyses, the upper whiskers of each
distribution were used to establish the thresholds deﬁning those situations where
smeVWX and smeYZ were considered to be overexpressed. These thresholds were 0.14
FIG 1 Normalized ﬂuorescence production. Shown is a box plot representing the values of RND/EM7 for
all Biolog compounds and concentrations tested in plates PM11 to PM16 where there was observable
growth. The upper whisker delimits the threshold above which outlier transcription activity is deﬁned for
smeVWX or smeYZ promoters and therefore efﬂux pump overexpression.
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for VWX/EM7 and 0.89 for YZ/EM7, respectively. All the compounds and concentra-
tions that led to the overexpression of smeVWX or smeYZ following these rules are listed
in Table 1. In the case of the SmeVWX efﬂux pump, the value of VWX/EM7 for 23
compounds and 34 concentrations was found to exceed the threshold, while the value
of YZ/EM7 was above the threshold in the case of the SmeYZ efﬂux pump for 22
compounds and 39 concentrations.
Conﬁrmation of the increased expression of smeVWX and smeYZ in the pres-
ence of potential inducers. Among those Biolog compounds that increased the YFP
levels for each of the studied efﬂux pumps, some of those for which the induction was
higher in order to validate the results were selected. As possible inducers of smeVWX,
iodoacetate, clioquinol (5-chloro-7-iodo-8-hydroxyquinoline), and sodium selenite were
TABLE 1 Normalized ﬂuorescence production of PVWX and PYZ with Biolog compounds
Efﬂux pump, promoter
analyzed Plate Compound
Fluorescence production of promoter
normalized to that of EM7 in wella:
A B C D
SmeVWX, VWX 11 Chlortetracycline 0.23 0.34
Cloxacillin 0.25
Erythromycin 0.15
12 D,L-Serine hydroxamate 0.17
Penimepicycline 0.28
5-Fluoroorotic acid 0.21
Dodecyltrimethylammonium bromide 0.17
Spiramycin 0.16
Vancomycin 0.15
13 Thallium (I) acetate 0.17
Manganese chloride 0.19 0.65
Potassium chromate 0.42
Tylosin 0.30
14 Iodoacetate 0.50 0.22
15 Menadione 0.38 0.59
5,7-Dichloro-8-hydroxyquinaldine 0.27 0.51
Methyl viologen 0.18
Nordihydroguaiaretic acid 0.18
16 Sodium selenite 1.14 1.30 1.40 1.40
5-Chloro-7-iodo-8-hydroxyquinoline 0.22 0.46 0.45 0.38
Cinoxacin 0.19
Cetylpyridinium chloride 0.16
Protamine sulfate 0.18
SmeYz, YZ
11 Chloramphenicol 1.06 0.99
Erythromycin 0.96 1.22 1.27
Lincomycin 0.98 1.30 1.49
12 5-Fluoroorotic acid 1.18 1.08 0.95 0.98
D,L-Serine hydroxamate 1.02
Penimepicycline 1.09
Spiramycin 0.93 0.97 1.42
Sulfadiazine 0.98
Sulfathiazole 1.12
13 Azlocillin 0.90
Dequalinium chloride 0.92
Rolitetracycline 1.03
Tylosin 1.40 1.58
Boric acid 0.96
14 Chloramphenicol 1.13 1.06
Sodium metaborate 0.99
Fusidic acid 1.12 0.92
15 Oleandomycin 1.11 1.04
Puromycin 0.91
16 Cetylpyridinium chloride 0.98
Cinoxacin 1.46
Protamine sulfate 1.28 1.41 1.47 1.55
aA, B, C, and D refer to the four wells per compound, with A being the well with the highest concentration and D the well with the lowest concentration of each
compound.
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selected; boric acid, chloramphenicol, erythromycin, and lincomycin were chosen as
potential smeYZ inducers. Since the quantity of the inducing compounds present in the
Biolog plate was unknown, we ﬁrst determined the MICs of the potential inducers in
order to establish the right concentrations to be used in the next studies. These
concentrations were as follows: iodoacetate, 1 mM; clioquinol, 0.065 mM; sodium
selenite, 200 mM; boric acid, 25 mM; erythromycin, 256 g/ml; chloramphenicol, 4
g/ml; and lincomycin, 4,096 g/ml. Three concentrations below the MIC value were
selected to further study the role of these compounds as inducers of the expression of
the tested efﬂux pumps.
To carry out the experiment, the reporter strains PBT02 (PVWX) and PBT10 (PYZ) were
incubated with their respective putative inducers for 20 h. The PBT03 (PEM7) strain was
also incubated with all the compounds and results were used as ﬂuorescence controls.
Figure 2 shows the YFP values and growth obtained for the PBT02 and PBT10 strains,
using the concentration for which the highest induction was obtained and bacterial
growth was less compromised in each case. These concentrations were 0.5 mM sodium
selenite, 78 M clioquinol, 0.5 mM iodoacetate, 6.25 mM boric acid, 8 g/ml of
erythromycin, 1 g/ml of chloramphenicol, and 128 g/ml of lincomycin. In agreement
with the data obtained using the Biolog plates, iodoacetate, clioquinol, and sodium
selenite increased YFP production through the induction of the smeVWX promoter in
the PBT02 strain, in comparison with the ﬂuorescence observed in control medium
without inducer (Fig. 2A). Meanwhile, erythromycin, boric acid, chloramphenicol, and
lincomycin increased the production of YFP through the induction of the smeYZ
promoter in the PBT10 strain, compared with the strain grown in the control medium
(Fig. 2B). PBT03 did not show any difference in YFP production when incubated with
and without the different compounds (Fig. 2C). These results conﬁrm that the observed
ﬂuorescence increase observed in the Biolog plates for both reporter strains PBT02 and
PBT10, when grown in the presence of the above-mentioned potential effectors, is due
to the induction of the promoters of the tested efﬂux pumps.
Single-cell analysis of the induction of the expression of MDR efﬂux pumps. In
order to examine the induction of smeVWX and smeYZ expression at the single-cell
level, we measured by ﬂow cytometry the YFP values of the two reporter strains PBT02
FIG 2 Growth and ﬂuorescence values produced by the reporter strains PBT02 (PVWX), PBT10 (PYZ), and PBT03 (PEM7) after incubation
with the selected putative inducers. (A) Expression of smeVWX during 20 h of incubation in the presence of iodoacetate (0.5 mM),
clioquinol (78 M), or sodium selenite (0.5 mM). (B) Expression of smeYZ during 20 h of incubation in the presence of erythromycin
(8 g/ml), boric acid (6.25 mM), chloramphenicol (1 g/ml), or lincomycin (128 g/ml). (C) PEM7 expression during 20 h of incubation
with all the compounds at the above-mentioned concentrations. Error bars show SDs from three independent replicates. FU,
ﬂuorescence units; CQ, clioquinol; IA, iodoacetate; SE, sodium selenite; BA, boric acid; CM, chloramphenicol; EM, erythromycin; LCM,
lincomycin.
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and PBT10 after 90 min of incubation with their respective inducers when cells reached
exponential growth phase (optical density at 600 nm [OD600]  0.6) (Fig. 3). Measuring
induction at exponential growth phase lessens potential interferences with the ﬂuo-
rescence signal, growth phase, or compound degradation that could happen over time.
PBT03 was also treated with the entire set of compounds as a control (Fig. 3C and D).
As shown in Fig. 3A, the expression of smeVWX in the PBT02 population was higher in
the presence of clioquinol, iodoacetate, or sodium selenite than in the untreated
population. The same results were obtained when the PBT10 strain was incubated with
boric acid, erythromycin, chloramphenicol, or lincomycin, showing that smeYZ expres-
sion is increased in the presence of these compounds (Fig. 3B). For all the compounds,
FIG 3 Population analysis of smeVWX and smeYZ expression in the presence of the selected putative inducers. YFP
production was analyzed by ﬂow cytometry. (A) Expression proﬁle of the smeVWX promoter in strain PBT02 treated
with clioquinol (78 M), iodoacetate (0.5 mM), or sodium selenite (0.5 mM). (B) Expression proﬁle of the smeYZ
promoter in strain PBT10 treated with erythromycin (8 g/ml), boric acid (6.25 mM), chloramphenicol (1 g/ml),
or lincomycin (128 g/ml). (C and D) Expression proﬁle of the PEM7 promoter in strain PBT03 treated with all the
different compounds at the above-mentioned concentrations. Gray populations represent in all cases the basal
promoters’ expressions in the absence of any compound. Geometric mean (GMean) and standard deviation (StDev)
were calculated for each population using Kaluza 1.5 software.
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a unimodal distribution of the level of YFP was seen in the population, indicating that
all cells presented an increased expression of the corresponding efﬂux pump in the
presence of the inducers. In addition, the averages of ﬂuorescence corresponded with
those obtained when induction was measured along the growing cycle (see above),
showing that induction of the analyzed efﬂux pumps is produced at mid-exponential
growth phase.
Analysis of the expression of efﬂux pumps in the presence of inducers at the
mRNA level. For further conﬁrmation of the results, the mRNA levels of smeV and smeY
were quantiﬁed by real-time reverse transcription-PCR (RT-PCR) in the wild-type strain
S. maltophilia D457 in the presence of the different inducer compounds. As shown in
Fig. 4A, smeV expression increased 764-, 4,402-, and 8,972-fold in the presence of
clioquinol, iodoacetate, and sodium selenite, respectively. The same effect can be
observed in Fig. 4B, where smeY expression increased 6-, 47-, 71-, and 102-fold in the
presence of boric acid, chloramphenicol, erythromycin, and lincomycin, respectively.
These data conﬁrm that the compounds selected from the analysis using Biolog plates,
namely, clioquinol, iodoacetate, and sodium selenite, are smeVWX inducers, and boric
acid and the antibiotics chloramphenicol, erythromycin, and lincomycin are able to
trigger smeYZ expression.
Deletion of either smeW or smeZ does not alter the susceptibility of S. malto-
philia to their corresponding inducers. Since the smeVWX and smeYZ inducers
described here are antimicrobials, we wanted to elucidate whether these compounds
were also substrates of their respective efﬂux pumps. To test this, the growth of D457
and MBS704 (ΔsmeW) in the presence of clioquinol (78 M), iodoacetate (0.5 mM), or
sodium selenite (0.5 mM) was recorded. The same experiment was performed for smeYZ
inducers, growing D457 and PBT100 (ΔsmeZ) strains in the presence of boric acid (6.25
mM), chloramphenicol (1 g/ml), erythromycin (8 g/ml), or lincomycin (128 g/ml). If
these compounds are extruded through the efﬂux pumps, it is expected that both
smeW- and smeZ-defective mutants should have an increased deﬁciency in their growth
in the presence of inducers compared with the wild-type strain. As shown in Fig. 5, no
relevant growth differences were observed between the wild-type and the efﬂux
pump-defective strains in the presence of the different inducer compounds, despite the
fact that all the analyzed compounds impaired bacterial growth. It is generally assumed
that efﬂux pump inducer molecules are also extruded by the efﬂux system; the efﬂux
pump hence confers resistance to such effectors if they are toxic (51–54). However, the
data obtained in this work suggest that efﬂux pumps do not always confer resistance
FIG 4 Effect of putative inducers on the mRNA levels of smeV and smeY. Expresion of smeV and smeY was measured
in the presence and in the absence of their potential inducers by real-time RT-PCR. (A) smeV expression in strain
D457 after 90 min of incubation with clioquinol (78 M), iodoacetate (0.5 mM), or sodium selenite (0.5 mM). (B)
smeY expression in D457 after 90 min of incubation with boric acid (6.25 mM), chloramphenicol (1 g/ml),
erythromycin (8 g/ml), or lincomycin (128 g/ml). Fold changes were estimated with respect to the values
obtained for the untreated D457 strain. Error bars show SDs derived from three independent experiments.
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to their inducers, likely because in this case, these compounds are not substrates of the
efﬂux systems they induce.
The overexpression of MDR efﬂux pumps promotes transient resistance to
antibiotics. It is known that overexpression of smeVWX contributes to the acquired
resistance to chloramphenicol and quinolones of S. maltophilia (19), while SmeYZ is
able to extrude aminoglycosides, contributing to intrinsic resistance to them (20, 21).
Since new inducer compounds have been identiﬁed for both RND efﬂux pumps, we
wondered whether the susceptibility of S. maltophilia to known antibiotic substrates of
these MDR determinants would be altered in the presence of these putative effectors.
In order to test the contribution of the SmeVWX efﬂux pump to transient resistance,
bacterial growth was measured in the presence and in the absence of oﬂoxacin, and
with or without the inducer sodium selenite, using both D457 and MBS704 (ΔsmeW)
strains. As shown in Fig. 6A and B, sodium selenite, at the tested concentration, did not
FIG 5 Effects of smeW and smeZ on the susceptibility of S. maltophilia to the inducers of these efﬂux pumps. The strains
D457, MBS704 (ΔsmeW), and PBT100 (ΔsmeZ) were grown in LB medium as a control (H). D457 and MBS704 were grown
in the presence of clioquinol (78 M) (A), iodoacetate (0.5 mM) (B), and selenite (0.5 mM) (C). D457 and PBT100 were grown
in the presence of boric acid (6.25 mM) (D), chloramphenicol (1 g/ml) (E), erythromycin (8 g/ml) (F), and lincomycin (128
g/ml) (G). Represented values correspond to the means calculated from three independent replicates.
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compromise the growth of either strain signiﬁcantly, whereas oﬂoxacin impaired the
growth of both D457 and MBS704. However, the combination of oﬂoxacin together
with sodium selenite did not impede growth of D457. With the aim of assessing
whether SmeYZ may contribute to transient resistance during growth in the presence
of its potential effectors, a similar experiment was performed in which the D457 and
PBT100 (ΔsmeZ) strains were grown in the presence or absence of the efﬂux pump
substrate amikacin, with or without the inducer lincomycin. As shown in Fig. 6C and D,
lincomycin slightly reduced the growth of both strains due to its toxic effect. At the
tested concentration of amikacin, the growth was compromised for both strains;
however, the presence of lincomycin diminished the inhibitory effect of amikacin.
These data suggest that both MDR pumps are involved in transient resistance to
antibiotics when inducers are present, since sodium selenite and lincomycin are able to
induce smeVWX and smeYZ, respectively, changing the susceptibility of D457 to their
antibiotic substrates.
DISCUSSION
The conditions that lead to the induction of the expression of MDR efﬂux pumps,
which consequently could give rise to transient antibiotic resistance, have not been
FIG 6 Effects of the inducer compounds sodium selenite and lincomycin in the transient resistance of S. maltophilia
to antibiotics. Growth curves were performed in the presence of oﬂoxacin (OFX), sodium selenite (SE), and both
oﬂoxacin and sodium selenite for strains D457 (A) and MBS704 (ΔsmeW) (B). Growth curves were also performed
in the presence of amikacin (AMK), lincomycin (LCM), and both amikacin and lincomycin in strains D457 (C) and
PBT100 (ΔsmeZ) (D). Growth in LB medium was used as a control. Error bars show SDs derived from three
independent replicates.
Discovering Novel Effectors of Multidrug Efﬂux Pumps Antimicrobial Agents and Chemotherapy
November 2018 Volume 62 Issue 11 e01263-18 aac.asm.org 9
 o
n
 April 9, 2019 by guest
http://aac.asm
.org/
D
ow
nloaded from
 
fully explored, and their detection through the use of classical susceptibility methods
is usually difﬁcult (6, 23).
In a previous screening using the PBT02 (PVWX) strain, we determined that vitamin
K3, among 30 tested compounds, was an inducer of the SmeVWX system (49). In the
current study, around 40 compounds were selected as potential candidates for being
smeVWX or smeYZ inducers after screening of 144 compounds employing Biolog
phenotype microarrays. Among all the potential inducer compounds derived from the
Biolog data analysis, clioquinol (5-chloro-7-iodo-8-hydroxyquinoline), iodoacetate, and
sodium selenite (smeVWX inducer candidates) and boric acid, chloramphenicol, eryth-
romycin, and lincomycin (smeYZ inducer candidates) were selected for further analysis.
The ﬂuorescence data obtained through the use of Biolog plates were conﬁrmed by
testing cognate concentrations of the selected agents, as well as by ﬂow cytometry at
mid-exponential growth phase and by RT-PCR after exposure to the corresponding
compounds, obtaining similar results for the expression level. Hence, the Biolog tech-
nology linked to the use of ﬂorescence reporters has allowed us to successfully identify
a set of inducer molecules of the expression of RND efﬂux pumps.
Although the main purpose of the current work was to identify RND efﬂux pumps’
inducers, the combination of Biolog microarrays and ﬂuorescent reporters could also be
employed for the search of inhibitors of the expression of these efﬂux systems, which
would help to reduce the emergence and spread of antibiotic resistance. Moreover, our
approach could be broadly used in the screening of effector molecules for any
transcriptional regulatory system (55).
Besides contributing to antibiotic resistance, MDR efﬂux pumps are involved in
different aspects of bacterial physiology, including bacterial interaction with hosts
(human, animals, and plants) or detoxiﬁcation of cellular toxic metabolites (26). MDR
efﬂux pumps can also take part in general mechanisms of response to cellular stress
that contribute to ameliorate the adverse effects caused by stressor agents or stress
by-products (e.g., oxidative stress or envelope stress) (35, 56). We hypothesize that
when MDR efﬂux systems participate in this global cellular stress response, a general
common inducer mechanism of stress could be identiﬁed through the analysis of their
inducer compounds, despite their structural diversity. As described here, clioquinol,
iodoacetate, and sodium selenite have been identiﬁed as smeVWX inducers, in addition
to the previously described vitamin K3 (49). Although these compounds generate
oxidative stress (57–60), except iodoacetate (61), we determined in our previous work
that tert-butyl hydroperoxide, another oxidative stress agent, was not able to induce
smeVWX expression (49). However, all of the identiﬁed inducer compounds are asso-
ciated with thiol reactivity. Iodoacetate is an alkylating reagent that modiﬁes thiol
groups in proteins by S-carboxymethylation (61); selenite is known to catalyze the
oxidation of thiol groups and to induce protein aggregation (62); clioquinol, as a Cu
ionophore, can deliver metal ions into cells, where it exerts its activity through the
interaction with thiol and amino groups (63); and, ﬁnally, vitamin K3 (menadione)
contributes to redox cycling and has alkylating properties, reacting as well with thiol
groups (60). All of this evidence suggests that the smeVWX induction mechanism might
be related, at least in part, to the thiol reactivity of the inducer compounds.
In the case of the SmeYZ efﬂux pump, boric acid, erythromycin, chloramphenicol,
and lincomycin were identiﬁed as inducers. Erythromycin targets the 50S subunit of the
bacterial ribosome and inhibits the nascent chain elongation (64). Chloramphenicol
targets the 50S subunit of the ribosome by its binding to the peptidyl transferase center
(PTC), where peptide bond formations happen (65). Both erythromycin and chloram-
phenicol are also known to directly inhibit the biogenesis of the ribosomal 50S subunit
(66). The third identiﬁed antibiotic inducer, lincomycin, also targets the 50S subunit of
the ribosome by inhibiting peptide bond formation (67). smeYZ was also found to be
induced by boric acid, which is not an antibiotic but impairs the acylation of tRNAs and
inhibits protein synthesis (68). All of these compounds share a mechanism of action,
suggesting that SmeYZ mechanism of induction might be related to protein synthesis
inhibition. Supporting this possibility, other compounds present in the Biolog plates,
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such as oleandomycin, spiramycin, tylosin, penimepiclyne, and fusidic acid, whose
mechanism of action is also the inhibition of protein synthesis, were found to increase
the YFP levels produced by the PBT10 strain (Table 1). These data reinforce the
hypothesis that ribosome-stalling stress could be a signal that triggers smeYZ expres-
sion, as happens with other RND efﬂux pumps, such as MexXY of Pseudomonas
aeruginosa (69).
It has been described that RND efﬂux pumps extrude several of their known
inducers, such as aminoglycosides in the case of MexXY-OprM in P. aeruginosa (70),
or triclosan in the case of SmeDEF in S. maltophilia (51), a protection mechanism
against these toxic agents. However, in this work, we have shown that the lack of
either SmeVWX or SmeYZ does not affect the growth of S. maltophilia in the
presence of their toxic inducers (Fig. 5). Different circumstances might explain this
apparent contradiction; one possibility is that the concentration for induction is
lower than or similar to the toxic concentration of the tested compound, not
allowing detection of an effect (45). Also, the bacterium can exhibit more efﬁcient
mechanisms, (e.g., other efﬂux pumps) able to extrude or detoxify the same
compounds, in which case these mechanisms must be removed for analyzing the
less proﬁcient ones (71). In addition, the possibility that an effector is not extruded
by the efﬂux pump it induces cannot be disregarded. In this respect, it is worth
noticing that the substrates and the inducers of a given efﬂux pump are frequently
structurally diverse (26), although they can interfere with the same cell machinery
or target. Indeed, we propose two common mechanisms of stress generated by a
set of RND inducers, each one inducing the expression of an efﬂux pump. It is
important to consider that RND efﬂux pumps mainly extrude substrates that are
located in the periplasm or in the bacterial inner membrane (72), while the
regulation of these systems takes place in the cytoplasm (73). This differentiated
compartmentalization may justify the possibility that RND inducers might not
always be substrates of efﬂux pumps. This means that in some situations, MDR
efﬂux pumps might be overexpressed despite the fact that there is no apparent
advantage for bacteria. However, the presence of the inducer may imply a situation
of transient resistance to other toxic compounds, which represents a beneﬁt under
some conditions. We have assessed this situation for clinically useful antibiotics that
are RND efﬂux pumps substrates using sodium selenite and lincomycin, the stron-
gest inducers of SmeVWX and SmeYZ efﬂux pumps, respectively. Both inducer
molecules were able to promote transient reduced susceptibility to oﬂoxacin
(SmeVWX substrate) or amikacin (SmeYZ substrate).
This is a fact to take into account regarding clinical situations, since some of these
inducer molecules could be provided during treatment of S. maltophilia infection. For
instance, sodium selenite has been recently administered during a phase I clinical trial
in terminal cancer patients (74) due to its cytotoxic effect on proliferating cancer cells.
Since these patients are very vulnerable to infections caused by MDR Gram-negative
bacteria, such as S. maltophilia (75), the use of sodium selenite could lead to the
overexpression of smeVWX and thus transient resistance to its substrates. The clinical
consequences of this situation need to be further investigated.
Through the combination of Biolog phenotype microarrays and ﬂuorescence-based
reporter strains, we have developed a new high-throughput methodology to identify
MDR efﬂux pump inducer compounds. The common mechanism of action of the
detected inducer molecules has allowed us to establish possible mechanisms of
induction of both smeVWX and smeYZ in S. maltophilia. smeVWX is likely induced by
compounds related to thiol reactivity, while smeYZ is induced by agents that target the
ribosome, suggesting a relationship between the expression of the efﬂux pump and the
inhibition of protein synthesis. Together with already published works (76, 77), these
results indicate that MDR efﬂux pump expression is triggered not always by a speciﬁc
compound but by stress signals generated by certain molecules with similar mecha-
nisms of action.
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MATERIALS AND METHODS
Bacterial strains and growth conditions. All plasmids and strains derived from this study are listed
in Table 2. All experiments were performed using LB medium at 37°C. The following antibiotics were
added when required: streptomycin (50 g/ml) for Escherichia coli harboring the pSEVA4413 plasmid,
ampicillin (100 g/ml) for E. coli containing the pGEM-T Easy vector and the pGEM-T-derived plasmids
pPBT02 and pPBT11, and kanamycin (50 g/ml and 500 g/ml) for E. coli and S. maltophilia, respectively,
for the selection of pSEVA237Y and the derived plasmids pPBT04, pPBT05, and pPBT08. Medium was
supplemented with 0.5 mM isopropyl--D-thiogalactopyranoside (IPTG) and 80 g/ml of 5-bromo-4-
chloro-3-indolyl--D-galactopyranoside (X-Gal) for the induction and detection of -galactosidase pro-
duction.
Plasmid constructions. The PBT10 strain, which harbors the reporter plasmid pPBT08 containing the
smeYZ promoter region, was obtained as described previously (49) using the primers SmeYZ_F (5=-GA
ATTCGGCGGGGCCGTAAG-3=; EcoRI site underlined) and SmeYZ_R (5=-AAGCTTTGCTGTGCACAATG-3=;
HindIII site underlined). In order to obtain the PBT03 strain, which harbors the pPBT05 plasmid with the
constitutive promoter PEM7, the pSEVA4413 plasmid was digested with PacI and HindIII (New England
BioLabs). The product corresponding to the PEM7 promoter was puriﬁed from a 1% agarose gel using a
DNA puriﬁcation kit (GE Healthcare) and cloned into the pSEVA237Y plasmid, previously digested with
the same restriction enzymes. The resulting plasmid, pPBT05, was introduced by transformation in E. coli
CC118pir. Then pPBT05 was introduced into S. maltophilia D457 by tripartite mating as previously
described (49).
Biolog phenotype microarray assay. The 96-well plates PM11 to PM16 from the Biolog phenotypic
microarray (PM) system (Biolog), which contain a variety of chemical agents (listed in Table S1), including
antimicrobials (78), were used for the screening. To carry out the experiment, 100 l of LB medium was
added to each well and plates were incubated at room temperature under constant shaking for 2 h in
order to dissolve the different dried compounds in the medium before inoculating the bacterial cells. Ten
microliters of an overnight cell culture was added to each well to a ﬁnal OD600 of 0.01. Plates were then
incubated at 37°C for 20 h in a Tecan Spark 10M plate reader (Tecan). Growth (OD600) and ﬂuorescence
(excitation wavelength at 508 nm and emission wavelength at 540 nm) were measured every 10 min.
Plates were shaken for 5 s before each measurement.
Normalization of the results. The obtained time courses of ﬂuorescence determinations (see above)
were ﬁtted to a ﬁrst-order differential equation, analogously to the one that represents bacterial growth,
F (t)  F0 e t [where F (t) is ﬂuorescence across the time, F0 is initial ﬂuorescence,  is maximum speciﬁc
rate of ﬂuorescence production (per hour), and t is time (in hours)]. Using this equation,  was obtained
for every promoter-compound-concentration combination, giving rise to a set of YZ, VWX, and EM7
values. Afterwards, the normalized values of ﬂuorescence production (VWX/EM7 and YZ/EM7) were
obtained, dividing YZ and VWX by EM7 for each compound and concentration. This step is required to
avoid any effect of the toxic compound on the ﬂuorescence signal, which may be caused by itself or by
its action on the growth rate, being inversely related to the ﬂuorescence signal (79). To set a threshold
of the normalized values of ﬂuorescence production, which could indicate that the expression is
increased (overexpression), a box plot of every normalized value of ﬂuorescence production for all the
compounds and concentrations was obtained. Then the threshold to deﬁne outlier values, and therefore
values which could indicate overexpression, was set according to the formula Q3  1.5  IQR, where Q3
is the upper quartile and IQR the interquartile range of each data set. These values were 0.14 for
VWX/EM7 and 0.89 for YZ/EM.
Conﬁrmation of the induction of gene expression. Sodium selenite, clioquinol (5-chloro-7-iodo-
8-hydroxyquinoline), and iodoacetate were selected as possible inducers of the SmeVWX efﬂux pump,
while boric acid and the antibiotics erythromycin, chloramphenicol, and lincomycin were chosen as
possible inducers of the SmeYZ efﬂux pump. First, the MIC was determined for each compound by
microdilution using 96-well plates (Nunclon Delta Surface). Ten microliters of each overnight cell culture
were added to 140 l of medium containing different concentrations of the selected compound to a ﬁnal
OD600 of 0.01. Plates were incubated at 37°C for 20 h without shaking. The MIC value was deﬁned as the
lowest concentration at which bacterial growth was not observed in the presence of the tested
compound.
Three concentrations of each compound were chosen for the induction assay considering the
obtained MIC values, as follows: sodium selenite, 0.25, 0.5, and 1 mM; clioquinol, 78, 156, and 312 M;
iodoacetate, 0.25, 0.5, and 1 mM; boric acid, 3.125, 6.25, and 12.5 mM; erythromycin, 4, 8, and 16 g/ml;
chloramphenicol, 0.5, 1, and 2 g/ml; and lincomycin, 64, 128, and 256 g/ml. Ten microliters of each
bacterial culture was added to 140 l of medium to a ﬁnal OD600 of 0.01 using Corning Costar 96-well
black clear-bottom plates (Corning Incorporated). Plates were incubated at 37°C for 20 h, and growth
(OD600) and ﬂuorescence were monitored every 10 min in the Tecan Spark 10M plate reader (Tecan).
Plates were shaken for 5 s every 10 min before each measurement. An excitation wavelength at 508 nm
and emission wavelength at 540 nm were set for YFP detection.
Flow cytometry assays. S. maltophilia reporter strains PBT02 (PVWX), PBT03 (PEM7), and PBT10 (PYZ)
were inoculated in 100-ml Erlenmeyer ﬂasks with 20 ml of LB medium to a ﬁnal OD600 of 0.01 and
incubated at 37°C with shaking. When bacterial cultures reached mid-exponential growth phase
(OD600 0.6), induction with the different compounds was tested using the following concentrations: 0.5
mM sodium selenite, 78 M clioquinol, 0.5 mM iodoacetate, 6.25 mM boric acid, 8 g/ml of erythro-
mycin, 1 g/ml of chloramphenicol, and 128 g/ml of lincomycin. A bacterial culture with no compound
was used as a control. Cells were then incubated with shaking for 90 min at 37°C. One milliliter of each
culture was centrifuged at 13,000 rpm for 1 min at room temperature. Cells were washed with 500 l of
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phosphate-buffered saline (PBS) and centrifuged as indicated above. The bacterial pellets were sus-
pended with 300 l of 0.4% paraformaldehyde and incubated at room temperature for 10 min. Cells were
then centrifuged as indicated above and suspended in 1 ml of PBS. In order to avoid false-positive
signals, all the media and buffers employed were ﬁltered through 0.22-m-pore ﬁlters (Corning Incor-
porated). With the aim of measuring YFP production at the single-cell level, samples of each reporter
strain containing 20,000 cells were analyzed using a Gallios ﬂow cytometer (Beckman Coulter). Data
processing was accomplished with Kaluza 1.5 software (Beckman Coulter).
RNA preparation and real-time RT-PCR. RNA was obtained as described previously, with some
modiﬁcations (49). Brieﬂy, a 100-ml Erlenmeyer ﬂask with 20 ml of LB medium was inoculated with an
overnight culture of S. maltophilia D457 to reach a ﬁnal OD600 of 0.01. Cell cultures were incubated at
37°C in agitation until they reached mid-exponential growth phase (OD600  0.6). At this point, the
induction assay was performed, adding the different compounds at the concentrations required: 0.5 mM
sodium selenite, 78 M clioquinol, 0.5 mM iodoacetate, 6.25 mM boric acid, 8 g/ml of erythromycin, 1
g/ml of chloramphenicol, and 128 g/ml of lincomycin. A bacterial culture with no compound was used
as a control. Cultures were incubated with shaking for 90 min. Ten milliliters of each culture was taken
and centrifuged at 8,000 rpm for 20 min at 4°C. RNA extraction was performed as described previously
(49), and cDNA was obtained using a high-capacity cDNA reverse transcription kit (Applied Biosystems).
One hundred nanograms of cDNA was used for each reaction. Real-time RT-PCR was performed in an ABI
Prism 7500 real-time system (Applied Biosystem) using the Power SYBR green PCR master mix (Applied
Biosystem). Primers RT-SmeV.L (5=-GTCGACTTCCTCGACAACC-3=) and RT-SmeV.R (5=-TTGCCATCCTTGTCT
ACCAC-3=) were used to amplify smeV, primers RT-SmeY.L (5=-CATTGGTGACCGAAGGTG-3=) and RT-
SmeY.R (5=-TTGATACCGGAGAACAGCAG-3=) were used to amplify smeY, and primers RT-ftsZ.L (5=-ATGG
TCAACTCGGCAGTG-3=) and RT-ftsZ.R (5=-CGGTGATGAACACCATGTC-3=) were used to amplify the
housekeeping gene ftsZ. Relative changes in gene expression were determined according to the
threshold cycle (2ΔΔCT) method (80). Mean values were obtained from three independent replicates in
each experiment.
Deletion of smeZ. A partial deletion of the smeZ gene was performed in S. maltophilia D457 through
homologous recombination. To that end, 545-bp (ZA) and 549-bp (ZB) fragments from the 5= end and
3= end of the smeZ gene, respectively, were ampliﬁed by PCR using primers ZAF (5=-GAATTCATGGCAC
GTTTCTTCATCGATCGCCCGGTGTTCGC-3=; EcoRI site underlined) and ZAR (5=-ATCGACAACAACAGCAGCC
ATGCTCGGCACCGAACAACTG-3=) and primers ZBF (5=-CAGTTGTTCGGTGCCGAGCATGGCTGCTGTTGTTGT
CGAT-3=) and ZBR (5=-GAATTCTCAACGATGTTCCGTTCCATCCACGGTTCCTCCCGGC-3=; EcoRI site underlined). An
overlapping PCR was performed with ZA and ZB fragments as the template using ZAF and ZBR primers,
yielding a 1,000-bp fragment (ZAB). The ZAB fragment was puriﬁed from a 1% agarose gel using a DNA
puriﬁcation kit (GE Healthcare) and cloned into pGEM-T Easy (Promega) following the manufacturer’s
protocol. The sequence was conﬁrmed by DNA sequencing. Afterwards, this plasmid was digested using
EcoRI (New England BioLabs) and the resulting ZAB fragment was cloned into the suicide vector pEX18Tc
(81), obtaining the pZAB7 plasmid, which was introduced by transformation into CC118pir. Selection
was performed using tetracycline (4 g/ml). pZAB7 was introduced by tripartite mating into S. malto-
philia D457 (82), and selection was performed on LB agar plates with tetracycline (12 g/ml) and
imipenem (20 g/ml). Tetr colonies were streaked onto 12-g/ml tetracycline plates and 10% sucrose
plates. Tetr and Sacs colonies were streaked onto 10% sucrose plates and incubated at 30°C overnight.
From the sucrose plates, Sacr colonies were streaked onto 12-g/ml tetracycline plates and 10% sucrose
in order to obtain double recombinants with a partial deletion of the smeZ gene. Deletion was conﬁrmed
in the PBT100 strain using primers FragZAB_L (5=-GTGCAGAACCGGATCAAG-3=) and FragZAB_R (5=-CGA
ACTCGACAATGAGGAT-3=) and primers InternoSmeZ_F (5=-CGGTGTCGATCCTGTTCT-3=) and InternoS-
meZ_R (5=-TGGATCGAGGTCATGAAATA-3=).
Determination of transient resistance to antibiotics. In order to determine the contribution of
SmeVWX and SmeYZ to transient resistance to antibiotics, the respective inducer molecules of each efﬂux
pump, sodium selenite and lincomycin, were chosen to measure bacterial growth in the presence of
antibiotics. D457 and MBS704 (ΔsmeW) strains were grown in oﬂoxacin (2 g/ml), sodium selenite (0.5
mM), or oﬂoxacin and sodium selenite in combination at the same concentrations. D457 and PBT100
(ΔsmeZ) strains were grown in the presence of amikacin (16 g/ml), lincomycin (128 g/ml), or amikacin
and lincomycin in combination at the same concentrations. Ten-microliter volumes of overnight cultures
of the three S. maltophilia strains were added to 140 l of LB medium containing the different
compounds to a ﬁnal OD600 of 0.01 in 96-well plates (Nunclon Delta Surface). Plates were incubated at
37°C for 20 h using a Tecan Spark 10M plate reader (Tecan), and growth (OD600) was recorded every 10
min. Plates were shaken for 5 s before every measurement.
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Supplemental material 
Table S1. Biolog phenotype microarray tested compounds 
PM11 PM12 PM13 
Amikacin Penicillin G Ampicillin 
Chlortetracycline Tetracycline Dequalinium chloride 
Lincomycin Carbenicillin Nickel chloride 
Amoxicillin Oxacillin Azlocillin 
Cloxacillin Penimepicycline 2, 2’-Dipyridyl 
Lomefloxacin Polymyxin B Oxolinic acid 
Bleomycin Paromomycin 6-Mercaptopurine 
Colistin Vancomycin Doxycycline 
Minocycline D, L-Serine hydroxamate Potassium chromate 
Capreomycin Sisomicin Cefuroxime 
Demeclocycline Sulfamethazine 5-Fluoroacil 
Nafcillin Novobiocin Rolitetracycline 
Cefazolin 2,4-Diamino-6,7-
diisopropylpteridine 
Cytosine-1-beta-D-
arabinofuranoside 
Enoxacin Sulfadiazine Geneticin (G418) 
Nalidixic acid Benzethonium chloride Ruthenium red 
Chloramphenicol Tobramycin Cesium chloride 
Erythromycin Sulfathiazole Glycine 
	   2	  
Neomycin 5-Fluorootic acid Thallium (I) acetate 
Ceftriaxone Spectinomycin Cobalt chloride 
Gentamicin Sulfamethoxazole Manganese chloride 
Potassium tellurite L-Aspartic-β-hydroxamate Trifluoperazine 
Cephalothin Spiramycin Cupric chloride 
Kanamycin Rifampicin Moxalactam 
Ofloxacin Dodecyltrimethylammonium 
bromide 
Tylosin 
   
PM14 PM15 PM16 
Acriflavine Procaine Cefotaxime 
Furaltadone Guanidine hydrochloride Phosphomycin 
Sanguinarine Cefmetazole 5-Chloro-7-iodo-8-
hydroxyquinoline 
9-Aminoacridine D-Cycloserine Norfloxacin 
Fusaric acid EDTA Sulfanilamide 
Sodium arsenate 5,7-Dichloro-8-hydroxyquinaldine Trimethoprim 
Boric acid 5,7-Dichloro-8-hydroxyquinoline Dichlofluanid 
1-Hydroxypyridine-2-thione Fusidic acid Protamine sulphate 
Sodium cyanate 1,10-Phenanthroline Cetylpyridinium chloride 
Cadmium chloride Phelomycin 1-Chloro-2,4-dinitrobenzene 
Iodoacetate Domiphen bromide Diamide 
Sodium dichromate Nordihydroguaia retic acid Cinoxacin 
Cefoxitin Alexidine Streptomycin 
Nitrofurantoin 5-Nitro-2-furaldehyde 
semicarbazone 
5-Azacytidine 
Sodium metaborate Methyl viologen Rifamycin SV 
	   3	  
Chloramphenicol 3,4-Dimethoxy-benzyl alcohol Potassium tellurite 
Piperacillin Oleandomycin Sodium selenite 
Sodium metavanadate Puromycin Aluminum sulphate 
Chelerythrine CCCP Chromium chloride 
Carbenicillin Sodium azide Ferric chloride 
Sodium nitrite Menadione L-Glutamic-g-hydroxamate 
EGTA 2-Nitroimidazole Glycine hydroxamate 
Promethazine Hydroxyurea Chloroxylenol 
Sodium orthovanadate Zinc chloride Sorbic acid 
 
  
	   4	  
 
Figure S1. Growth and fluorescence values produced by sensor strains PBT03 (PEM7), 
PBT10 (PYZ) and PBT02 (PVWX). Error bars show standard deviations from three 
independent replicates. FU, fluorescence units. 
  
	   5	  
 
 
Figure S2. Compounds concentrations where S. maltophilia growth is detected. 
Compounds are divided in five categories. A-B-C-D compounds represent those agents where 
S. maltophilia growth is observable in all concentrations. A-B-C compounds are those where 
S. maltophilia grows only in A, B and C concentrations. The same reasoning for A-B and A 
compounds. No growth was observed for – compounds.  
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Article III 
 
Involvement of the RND Efflux Pump Transporter SmeH in the Acquisition of Resistance 
to Ceftazidime in Stenotrophomonas maltophilia 
 
P. Blanco, F. Corona, J. L. Martínez 
 
Scientific Reports. 9: 4917 (2019) 
 
 The low susceptibility to antibiotics that characterizes S. maltophilia limits the 
therapeutic options for the treatment of the infections that it causes. Although the combination 
treatment trimethoprim/sulfamethoxazole remains as the best drug of choice, other alternatives 
are also being evaluated. Among them, the use of ceftazidime, mainly in combination with other 
antibiotics, has been proposed as a treatment for S. maltophilia infections, although this 
treatment might be challenged due to the acquisition of resistance. Besides beta-lactamase 
overexpression, little information is available about other potential resistance mechanisms that 
might have an effect on S. maltophilia susceptibility to ceftazidime. 
 
 In the current work, we performed experimental evolution studies, followed by whole-
genome sequencing, using increasing concentrations of ceftazidime with the purpose of 
identifying the genetic mechanisms and mutational trajectories involved in the acquisition of 
resistance to this beta-lactam drug. Among the identified mutations, we could determine a new 
mechanism in the acquisition of ceftazidime resistance: two amino acid substitutions in the 
transporter protein of the SmeGH RND efflux pump, SmeH, being the first report of mutations 
selected in an efflux pump transporter, and not in the efflux pump regulatory genes, in 
S.  maltophilia. The analysis of the mutational trajectories shows that mutations in SmeH are 
the first step towards ceftazidime resistance in all the replicates. We also recreated both 
mutations in the wild-type strain D457, showing that they contribute to cross-resistance towards 
other beta-lactams as well, and that they do not compromise S. maltophilia fitness in an 
antibiotic-free medium. The structure prediction analysis of both amino acids residues in the 
transporter protein shows that the observed resistance phenotype can be due to changes in the 
access and binding pockets of the efflux pump transporter protein.  
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Involvement of the RND efflux 
pump transporter SmeH in the 
acquisition of resistance to 
ceftazidime in Stenotrophomonas 
maltophilia
Paula Blanco, Fernando Corona & José Luis Martínez  
The emergence of antibiotic resistant Gram-negative bacteria has become a serious global health issue. 
In this study, we have employed the intrinsically resistant opportunistic pathogen Stenotrophomonas 
maltophilia as a model to study the mechanisms involved in the acquisition of mutation-driven 
resistance to antibiotics. To this aim, laboratory experimental evolution studies, followed by 
whole-genome sequencing, were performed in the presence of the third-generation cephalosporin 
ceftazidime. Using this approach, we determined that exposure to increasing concentrations of 
ceftazidime selects high-level resistance in S. maltophilia through a novel mechanism: amino acid 
substitutions in SmeH, the transporter protein of the SmeGH RND efflux pump. The recreation of these 
mutants in a wild-type background demonstrated that, in addition to ceftazidime, the existence of 
these substitutions provides bacteria with cross-resistance to other beta-lactam drugs. This acquired 
resistance does not impose relevant fitness costs when bacteria grow in the absence of antibiotics. 
Structural prediction of both amino acid residues points that the observed resistance phenotype could 
be driven by changes in substrate access and recognition.
The evolution and dissemination of antibiotic resistance has become one of the major threats for public health 
worldwide, being the spread of multidrug resistant (MDR) Gram-negative bacteria one of the main problems 
nowadays1. Stenotrophomonas maltophilia is an opportunistic nosocomial pathogen responsible for causing a 
variety of infections, with high morbidity and mortality especially in patients with underlying pathologies, as 
cystic fibrosis, and in those who are immunocompromised2–4. One of the main characteristics of this bacterium 
is its low susceptibility to a broad range of antibiotics, which entails a difficulty in the treatment of the infections 
that it causes5,6.
Among the elements that determine the intrinsic low susceptibility of S. maltophilia to antibiotics, it is impor-
tant to highlight the low permeability of its membrane, as well as the presence in its genome of a number of intrin-
sic resistance genes that encode antibiotic-modifying enzymes, the quinolone resistance protein SmQnr and MDR 
efflux pumps, being of higher relevance those belonging to the resistance nodulation division (RND) family7–11. 
Few therapeutic options are currently in use for treating S. maltohilia infections. Among them, combinations 
of antibiotics including classical ones, as trimethoprim/sulfamethoxazole, are in use12–15. Despite S. maltophilia 
contains in its genome two intrinsic beta-lactamases, dubbed L19 and L210, they are not particularly active against 
ceftazidime at the level they are expressed in several clinical S. maltophilia isolates16–18. Consequently, use of 
ceftazidime, mainly in combination with other antibiotics, has been suggested for treating S. maltophilia infec-
tions19–23, although the success of these treatments might be challenged given the large number of antibiotic 
resistance genes that S. maltophilia harbours. Indeed, it has been shown that mutants overexpressing L1 and L2 
beta-lactamases and presenting a reduced susceptibility to ceftazidime can be easily selected in vitro17,24. Further, 
recent work has shown that S. maltophilia beta-lactamase-overexpressing ceftazidime-resistant mutants lacking a 
functional Mpl are frequently selected in clinics25. Despite these findings, little is still known about other potential 
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resistance mechanisms, besides beta-lactamase overexpression, that might impact not only S. maltophilia suscep-
tibility to ceftazidime, but to other antibiotics as well. To analyze this possibility, we challenged S. maltophilia with 
increasing concentrations of ceftazidime and analyzed the mutations that arised after this selection. Notably, we 
found that one of the first mutations to be selected was located in smeH, which encodes the transporter protein 
of the SmeGH RND efflux pump. RND efflux pumps are involved in the intrinsic resistance to several antibiotics 
when expressed at a basal level and their induction by environmental signals or conditions sensed by bacteria can 
lead to transient antibiotic resistance26,27. In addition, mutants overexpressing these efflux pumps are selected by 
antibiotics in vitro and are regularly isolated from infected patients28–34.
Although some few publications address that mutations in the structural elements of efflux pumps can alter 
their specificity and hence contribute to antibiotic resistance35–40, most works analyzing the role of efflux pumps 
in acquired antibiotic resistance focus on their level of expression41–50, and not on the allelic variations in the 
genes encoding the efflux pump. Herein, we show that changes in the structure of SmeH, without the need of its 
overexpression, reduce the susceptibility of S. maltophilia to different antibiotics, including ceftazidime.
Results
Experimental evolution upon ceftazidime challenge leads to high levels of resistance in S. 
maltophilia populations. In order to elucidate how ceftazidime challenge impacts the acquisition of cef-
tazidime resistance, four independent S. maltophilia D457 cultures were serially passaged during 30 days of evo-
lution in the presence of increasing concentrations of ceftazidime, reaching 32-fold the starting concentration 
at the end of the experiment. Four control cultures were also performed in the absence of antibiotic to track the 
selection of medium-adaptive mutations, not involved in resistance to ceftazidime challenge. Prior to the final 
evaluation of the evolved populations’ susceptibility to ceftazidime, serial daily passages in LB medium without 
ceftazidime were performed for 3 days in order to exclude a possible induction of resistance caused by the previ-
ous ceftazidime exposure. Ceftazidime susceptibility was then evaluated in the four evolved populations (A, B, C 
and D) by Etest. As shown in Fig. 1, all the populations reached high levels of ceftazidime resistance after 30 days 
of evolution in comparison with the parental strain D457.
Selected mutations and temporal dynamics of S. maltophilia evolution in the presence of cef-
tazidime. With the aim of assessing the genetic mechanisms involved in ceftazidime resistance, the genomic 
DNAs of the evolved populations in presence of ceftazidime and the controls, grown in absence of antibiotics as 
well as of the parental strain, were extracted and sequenced. The coverage of the sequence was 106 on average, 
ranging from 90 to 113. The presence of mutations was determined in all populations as described in Methods, 
and confirmed by PCR amplification and Sanger sequencing. Only those mutations that were selected upon 
antibiotic selective pressure, but were absent in the populations evolved in the absence of selection, were taken 
into consideration. Table 1 shows those genetic changes that were identified after the whole genome sequencing 
(WGS) data analysis, and subsequently confirmed by Sanger sequencing, present in the ceftazidime-treated pop-
ulations and absent in controls. In total, changes were found in 11 different genes. Most mutations were single 
nucleotide polymorphisms (SNPs) leading to amino acid substitutions. Among them, mutations in smeH were 
found in the four evolved populations, whereas mutations in phoQ were selected in three of them. Mutations 
in the penicillin binding protein (PBP) ftsI in population A, or in genes encoding for hypothetical proteins, as 
SMD_2719 also in population A, and SMD_0260 in population B, were also selected. Insertions or deletions 
Figure 1. MICs for ceftazidime of the four S. maltophilia evolved populations. MIC was determined after 30 
days of experimental evolution in the presence of increasing concentrations of ceftazidime in the populations A, 
B, C and D. The parental strain D457 was used as a reference. MIC, minimum inhibitory concentration.
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leading to frame shifts were also found in other genes. For instance, a 188-bp deletion in the lipopolysaccharide 
biosynthesis regulator yciM was detected in population C, and a 10-bp deletion in the permease component yrbE 
of an uncharacterized ABC transporter was selected in population D. In addition, an insertion sequence (IS) 
belonging to the IS5 family was also involved in the disruption of the gene smd_0534, which encodes a hypothet-
ical protein, in population A. Noteworthy, and although every independent population seems to have a different 
resistance pattern, it was possible to find in the four antibiotic-evolved populations the same amino acid substitu-
tion (P326Q) in SmeH, the transporter protein of the SmeGH RND efflux pump.
The temporal dynamics of the different genetic changes were determined by amplifying and sequencing each 
of the mutated genes from stored samples of the four populations at days 5, 10, 15, 20, 25 and 30 (Table 1). The 
most remarkable aspect from these dynamics is the detection of the amino acid substitution P326Q in SmeH at 
day 5 of evolution in the four treated populations, when the ceftazidime concentration was 1 µg/ml. Further, in 
populations B and C, the following substitution in emerging was a second amino acid change in SmeH, Q663R, 
which was detected at day 20 when the ceftazidime concentration was 8 µg/ml. The remaining acquired genetic 
changes were found between days 20 and 30 of evolution.
Effect of SmeH substitutions on resistance and fitness. Since smeH mutations were found in the four 
ceftazidime-exposed populations and there are no previous studies regarding the contribution of the SmeGH 
efflux pump to antibiotic resistance, we decided to determine the role of both P326Q and Q663R substitutions 
in S. maltophilia ceftazidime resistance. In order to do this, both mutations were recreated in the parental strain 
D457, either together or separately, obtaining the strains PBT101 (P326Q), PBT102 (Q663R) and PBT103 
(P326Q; Q663R). The MIC of ceftazidime was determined for the three recreated strains, as well as for the paren-
tal strain D457. While P326Q substitution was able to increase more than 5-fold the ceftazidime MIC (4 µg/ml), 
the second substitution Q663R did not lead to a change in the susceptibility by itself (0.75 µg/ml). Nevertheless, 
the presence of both mutations led to a 10-fold change in the MIC levels (8 µg/ml).
To explore whether the ceftazidime resistance mutations in smeH lead to cross-resistance and/or collateral 
sensitivity to other antibiotics, changes in the susceptibility to several classes of antibiotics were measured in the 
strains PBT101, PBT102 and PBT103 using the parental strain D457 as a reference. The MICs of the different anti-
biotics are shown in Supplementary Table S1. As observed in Fig. 2, a two-fold increase in the MIC was obtained 
for the beta-lactams cefazolin and aztreonam in the PBT101 strain. In the case of the PBT103 strain, the fold 
change for these antibiotics was 2-fold and 6-fold, respectively. Further, cross-resistance in this strain was also 
observed for cefotaxime (2-fold change) and the quinolone norfloxacin (3-fold change). As happened with cef-
tazidime, no changes in the MICs for beta-lactams were observed in the PBT102 strain; however, a 4-fold change 
in the MIC was obtained for tetracycline. No collateral sensitivity was observed for any of the tested antibiotics.
In order to study in more detail the observed resistance to beta-lactams in the PBT101 and PBT103 strains, a 
more sensitive method based on bacterial growth was applied. The OD600 was recorded in the presence of ceftazi-
dime, cefotaxime and cefoxitin for 20 h. Strains D457, PBT102 and PBT104 were also included in the experiment. 
Data shown in Fig. 3B, C and D, proved that only mutants PBT101 and PBT103 were able to grow in the presence 
of the three selected antibiotics, being the resistance of the PBT103 strain higher than that of PBT101. Meanwhile, 
Population Gene Localization Type Nucleotide change
Amino acid 
change Frequency (%)
Detected day 
of emergence
A
smeH 3061160 SNV C → A P326Q 98.7 5
SMD_2719 3026930 SNV A → C V232G 51.6 20
phoQ 315221 SNV T → A I76N 100 25
ftsI 736289 SNV C → A A592D 100 25
SMD_0534 613290 Ins Ins of 1.037 bp V398fs — 30
B
smeH 3061160 SNV C → A P326Q 100 5
smeH 3062171 SNV A → G Q663R 100 20
SMD_0260 314100 SNV A → G K88R 70.1 25
C
smeH 3061160 SNV C → A P326Q 100 5
yrbC 4744239 SNV C → T Q126* 32.3 30
yciM 2035186 Del Del of 188 bp A206fs — 30
phoQ 315914 SNV C → T S307L 41.2 30
phoQ 315965 SNV C → T P324L 37.5 30
D
smeH 3061160 SNV C → A P326Q 100 5
smeH 3062171 SNV A → G Q663R 100 20
phoQ 315236 SNV C → T P81L 99.2 20
yrbE 4742678 Del ATCGCCGTCG → — I49fs 65.3 30
SMD_1278 14224481 Ins — →TGACTT F91_G92insDF 57.1 30
mrkC 685444 Del GGCTTC → — G187_F188del 76.3 30
Table 1. WGS-identified mutations in ceftazidime-evolved populations. SNV: single nucleotide variant; Ins: 
insertion; Del: deletion; Frequency (%): percentage of reads that contain the variation within a heterogeneous 
population; * STOP codon.
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Figure 2. Susceptibility of the S. maltophilia mutants to different antibiotics. MICs were measured in the 
three recreated mutants PBT101 (P326Q), PBT102 (Q663R) and PBT103 (P326Q; Q663R). Fold changes were 
determined using the MIC values of the wild-type strain D457 as reference (dotted line). MIC, minimum 
inhibitory concentration; CAZ, ceftazidime; CTX, cefotaxime; FOX, cefoxitin; CFZ, cefazolin; ATM, aztreonam; 
OFX, ofloxacin; NOR, norfloxacin; NAL, nalidixic acid; CHL, chloramphenicol; TET, tetracycline; TGC, 
tigecycline; PMB, polymyxin B.
Figure 3. Effect of beta-lactams on the growth of S. maltophilia strains. Growth curves were performed for 
the three S. maltophilia recreated mutants PBT101 (P326Q), PBT102 (Q663R) and PBT103 (P326Q; Q663R), 
the smeH-defective strain PBT104 and the parental strain D457 in the absence (A) or presence of ceftazidime 
(4 µg/ml) (B), cefotaxime (256 µg/ml) (C) and cefoxitin (128 µg/ml) (D) during 20 h. Error bars show standard 
deviations from three independent experiments.
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the PBT102 mutant displayed a growth similar to the observed for the wild-type strain in all conditions, confirm-
ing the above-obtained MIC results. We also evaluated the effect of these mutations on fitness cost. As shown in 
Fig. 3A, the strains PBT101, PBT102 and PBT103 had no growth defect in comparison with the parental strain in 
LB medium; only the PBT104 strain, which lacks smeH, showed a slight growth impairment. These results point 
that fitness is not compromised in an antibiotic-free medium when smeH mutations are present.
Role of SmeGH efflux pump in the intrinsic resistance and the physiology of S. maltophilia. 
Besides studying its contribution to the acquisition of resistance, we decided to assess the role of the SmeGH 
efflux pump in the S. maltophilia intrinsic resistance through the generation of a smeH-deficient mutant. In addi-
tion, we wanted to address whether the original substrates of the wild-type allele of the efflux pump are the same 
as those of the selected mutants and hence the amino acid substitutions just modify the efficiency; or they are 
different and the mutations alter the substrates specificity of SmeH. The MICs for ceftazidime, as well as for the 
other antibiotics, were determined in the PBT104 (ΔsmeH) strain and are shown in Supplementary Table S1. 
As shown in Fig. 4, the smeH-deficient mutant PBT104 showed an increased susceptibility to ceftazidime and to 
almost all tested antibiotics, excepting chloramphenicol and tigecycline, in comparison with the wild-type strain. 
In the case of cefoxitin, no changes in the MIC were observed; however, as shown in Fig. 3D, the PBT104 mutant 
presents a more impaired growth, as compared to the wild-type strain, in the presence of this beta-lactam. These 
results suggest that these antibiotics could be substrates of the SmeGH efflux pump, which would then be involved 
in S. maltophilia intrinsic resistance.
In addition to commonly-used antibiotics, we evaluated the implication of the SmeGH efflux pump in the sus-
ceptibility to other antimicrobial toxic compounds. As shown in Table 2, the smeH-deficient strain PBT104 was 
more susceptible than the parental strain to the oxidative stress-generating compounds menadione and tert-butyl 
hydroperoxide, as well as to the biocide benzalkonium chloride and to the plant-derived compound naringenin. 
Changes in the MICs were also observed for some of the compounds in the smeH-mutant alleles selected in pres-
ence of ceftazidime. A two-fold increase in the MIC was observed in the PBT101 (P326Q) strain for all the tested 
biocides (hexachlorophene, benzalkonium chloride and triclosan). Further, a higher susceptibility to menadione 
was detected in the PBT102 (Q663R) and PBT103 (P326Q; Q663R) strains, and a lower MIC was also obtained 
for tert-butyl hydroperoxide in the PBT103 strain. These data suggest that, besides its contribution to antibiotics 
resistance, SmeGH might be involved in the detoxification of some other toxic compounds and the amino acid 
substitutions in SmeH selected in presence of ceftazidime could have different effects on the capability of this 
efflux pump for extruding other compounds.
The role of SmeGH in S. maltophilia physiology was also studied through the evaluation of virulence-related 
characteristics, as biofilm formation and swimming motility. As shown in Fig. 5A, the PBT104 (ΔsmeH) strain 
Figure 4. Susceptibility of the S. maltophilia smeH-defective mutant to different antibiotics. MICs were 
measured in the PBT104 strain (ΔsmeH) and the fold changes were determined using the MIC values of the 
wild-type strain D457 as reference (dotted line). MIC, minimum inhibitory concentration; CAZ, ceftazidime; 
CTX, cefotaxime; FOX, cefoxitin; CFZ, cefazolin; ATM, aztreonam; OFX, ofloxacin; NOR, norfloxacin; NAL, 
nalidixic acid; CHL, chloramphenicol; TET, tetracycline; TGC, tigecycline; PMB, polymyxin B.
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presented an enhanced ability to form biofilm in comparison with the parental strain D457, while no significant 
differences in the swimming ability were detected among the different strains (Fig. 5B).
Ceftazidime-selected SmeH substitutions are likely located in the vicinity of the access and 
deep binding pockets of the transporter protein. With the purpose of elucidating the molecular basis 
behind the phenotype conferred by both SmeH mutations, a structural alignment of the S. maltophilia SmeH 
transporter was performed with the Escherichia coli AcrB efflux protein sequence, showing that both proteins 
are homologous (Template modeling score 0.97, sequence identity 0.51, coverage 0.98). The alignment showed 
that residue P326 is conserved in both transporter proteins (Supplementary Fig. S1); consequently, the available 
crystal structure of AcrB (PDB ID code 4DX7.B37) was used for predicting the effect of the mutation P326Q in S. 
maltophilia. It has been described that AcrB monomers can adopt one of three conformations, labeled as loose 
(L), tight (T) and open (O), depending on the step of the drug export process (access, binding, and extrusion, 
respectively)51. Using these templates, the P326 residue was predicted to be located in the proximities of the deep 
binding pocket in the tight (T), or binding, monomer of AcrB (Fig. 6A). Q663, which corresponds to the V672 
in AcrB, was also represented in the AcrB crystal structure (PDB ID code 4DX7.A37), and it was mapped at the 
bottom of the access pocket of the efflux protein (Fig. 6B).
Since P326 is conserved in both species, we wanted to study the effect of the P326Q substitution in the AcrB 
crystal in its doxorubicin-bound form (PDB ID code 4DX7.B37) in order to have a reference of the deep binding 
pocket conformation when a known substrate is bound inside. In its wild-type form, the protamine residue is 
mapped under the deep binding pocket of the transporter protein, but contactless (Fig. 7A). However, when 
Q326 is represented, the glutamine residue can be found pointing into the deep binding pocket cavity (Fig. 7B). 
Although in this simulation the glutamine residue does not seem to interact with the cocrystallized substrate 
directly, it might establish contact with other residues that are part of the binding pocket and change in some way 
the affinity for the antibiotic.
Discussion
Experimental evolution studies provide important information on the genetic adaptive changes underlying the 
acquisition of different phenotypes by bacterial populations52, including antibiotic resistance53. In the current 
work, we have used such approach for analyzing the evolutionary trajectories of the relevant nosocomial patho-
gen S. maltophilia towards ceftazidime resistance. As it happens in the case of other studies on evolution towards 
Strain MD (mM) TBHP (mM) NGEN (mM) HCP (μg/ml) BAC (μg/ml) TRI (μg/ml)
D457 1.25 0.62 25 2 6.25 25
PBT101 (P326Q) 1.25 0.62 25 4 12.5 50
PBT102 (Q663R) 0.62 0.62 25 2 6.25 25
PBT103 (P326Q; Q663R) 0.50 0.31 25 2 6.25 25
PBT104 (ΔsmeH) 0.12 0.31 3.12 2 1.56 25
Table 2. MICs of antimicrobial compounds for S. maltophilia strains. MIC, minimum inhibitory concentration; 
MD, menadione; TBHP, tert-butyl hydroperoxide; NGEN, naringenin; HCP, hexachlorophene; BAC, 
benzalkonium chloride; TRI, triclosan.
Figure 5. Biofilm formation and swimming motility of S. maltophilia strains. (A) The biofilm formation assay 
was carried out by measuring the absorbance at 570 nm of crystal violet after 48 h incubation. Error bars show 
standard deviations from eight replicate samples. ****Indicates P < 0.001 calculated by one-way ANOVA test. 
(B) The swimming motility assay was performed by measuring the growth area after 48 h incubation on LB 
semisolid agar (0.3%) plates. Error bars show standard deviations from three independent experiments.
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antibiotic resistance54, the evolutionary trajectories followed by S. maltophilia parallel cultures submitted to anti-
biotic selective pressure, shared some common elements, namely mutations in the efflux pump transporter gene 
smeH (present in the four evolved populations) and in the two-component sensor histidine kinase phoQ (three 
out of the four evolved populations), indicating that, as stated in54,55, evolution towards antibiotic resistance might 
present some degree of predictability. Some genes that present mutations in the evolved bacterial populations 
have been previously described to have a role in antimicrobial resistance in other microorganisms. This is the 
case of ftsI, a gene encoding a peptidoglycan transpeptidase56, whose mutation has been reported to be involved 
in resistance to beta-lactam drugs55,57,58, or phoQ, which is involved in polymyxin and antimicrobial peptides 
resistance59,60, although its potential role in beta-lactams resistance has not been studied in detail. The other 
genes presenting mutations involved in the acquisition of ceftazidime resistance in S. maltophilia have not been 
described previously to be involved in antibiotic resistance. Namely, mutations in genes encoding the auxiliary 
Figure 6. Mapping of SmeH-amino acid residues on the 3D structure of AcrB. (A) Surface representation of the 
predicted deep binding pocket (violet) on the AcrB tight monomer (PDB code 4DX7.B). P326 is represented by 
red spheres. (B) Surface representation of the predicted access pocket (green) on the AcrB loose monomer (PDB 
code 4DX7.A). V672, the Q663-corresponding residue in AcrB, is represented by red spheres.
Figure 7. Effect of P326Q substitution on the residue orientation in the SmeH deep binding pocket. Surface 
representation of the deep binding pocket on the AcrB tight monomer (PDB code 4DX7.B) with the wild-type 
residue P326 (A) and the mutant allele Q326 (B). Both residues are represented by red sticks and doxorubicin is 
represented in orange.
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(yrbC) and the permease components (yrbE) of an uncharacterized ABC transporter, or the RND transporter 
smeH, as well as four hypothetical proteins were selected upon antibiotic selective pressure. Temporal analysis of 
the dynamics of evolution showed that several of the mutations emerged from day 20 of evolution; however, for 
all the populations, the first step leading to acquisition of resistance to ceftazidime was the P326Q substitution in 
SmeH, being the first and only mutation detected at day 5 of evolution. A second substitution in SmeH, Q663R, 
emerged in two of the treated populations days later after P326Q.
Considering the important role that the SmeGH efflux pump seems to have in the acquisition of ceftazidime 
resistance, we focused on these amino acid substitutions to get more insights into their contribution to resist-
ance. Data showed that strains PBT101 (P326Q) and PBT103 (P326Q; Q663R) exhibited an increase of 5- and 
10-fold in the ceftazidime MIC, respectively, while PBT102 (Q663R) remained at the same level of the wild-type 
strain, indicating this mutation to be neutral concerning ceftazidime resistance in the wild-type genomic back-
ground. Meanwhile, the presence of both mutations in the smeH gene has a positive effect regarding ceftazidime 
resistance, having the second mutation an impact just in combination with the first one. In agreement with data 
derived from the study of the evolution of extended spectrum beta-lactamases61, this result supports the notion 
that epistatic interactions (including neutral mutations) modulate the evolution towards resistance and, conse-
quently, the order of acquisition of mutations is highly relevant for the final phenotypic outcome.
Several RND efflux pumps extrude a broad range of unrelated compounds from the bacterial cell62. With the 
aim of determining whether the P326Q and Q663R changes are specific for ceftazidime resistance or they change 
S. maltophilia susceptibility to other antibiotics, MICs of other drugs were measured. Our results showed that 
PBT101 exhibited increased resistance to the beta-lactams aztreonam and cefazolin, and PBT103, besides these 
ones, presented also increased resistance to cefotaxime and the quinolone norfloxacin. Besides, growth-based 
experiments allowed us to detect an increased resistance against cefotaxime in the PBT101 strain, and against 
cefoxitin in both PBT101 and PBT103 strains. These data indicate that P326Q and the combination of both 
P326Q/Q663R in SmeH do not confer specific resistance to ceftazidime, but also to other antibiotics, mostly 
beta-lactams. Conversely, PBT102 did not show any change in the susceptibility to beta-lactams but it did for tet-
racycline, suggesting that, while the Q663R substitution does not play any role in beta-lactams resistance by itself, 
it could lead to tetracycline resistance, a feature that may allow to select this mutation in a wild-type background, 
independently of the P326Q mutation, under tetracycline challenge.
Finally, the hyper-susceptibility of the smeH-defective mutant PBT104 to some beta-lactam drugs, as well as 
to quinolones, polymyxin B and tetracycline, suggests that SmeGH is an intrinsic resistant determinant for these 
antibiotics. In addition, the fact that this mutant presents changes in the susceptibility to the same beta-lactams as 
PBT101 and PBT103 does indicate that the mutations selected in smeH along experimental evolution likely alter 
the efficiency of extrusion of these substrates.
According to our results, SmeGH might not only be involved in resistance to antibiotics, but also to other 
toxic compounds belonging to different families, as the oxidative stress agents menadione and tert-butyl hydrop-
eroxide, the plant-derived compound naringenin, and the biocide benzalkonium chloride. Other S. maltophilia 
RND efflux pumps have been previously reported to be involved in the extrusion of toxic molecules. For instance, 
SmeDEF, besides antibiotics, is able to extrude triclosan63 and the plant exudate phloretin64. Since RND efflux 
pumps are important bacteria detoxification elements65, it is possible that some of these compounds are substrates 
of SmeGH, which would participate in their detoxification. Further, as happened with beta-lactams, PBT101, 
PBT102 and PBT103 strains also showed changes in their MICs to some of these toxic compounds, indicating 
that the amino acid substitutions present in SmeH in these mutants and selected in presence of ceftazidime could 
interfere in the capability of this efflux pump for extruding these molecules.
In order to get more insights into the physiological roles that the SmeGH efflux pump could have, biofilm 
formation and swimming motility assays were assessed in all the strains. While the swimming ability was neither 
compromised nor increased in any of the S. maltophilia strains, deletion of the transporter component SmeH led 
to an enhanced biofilm production in the PBT104 strain. Although the molecular mechanisms regarding this 
phenotype remain to be clarified, it is possible that the SmeGH efflux pump contributes negatively to biofilm 
formation by the regulation of biofilm-related genes, as happens with the ABC transporter lm.G_1771 in Listeria 
monocytogenes66, or by the accumulation of toxic molecules that could trigger the expression of genes involved 
in biofilm formation through a general stress response, as proposed by Bazzini et al. in the case of Burkholderia 
cenocepacia67.
It has been generally assumed that, in the absence of selection, the acquisition of antibiotic resistance will 
impose a burden to the resistant organism, which would be outcompeted by the susceptible ones68–70. For 
instance, mutations leading to the overproduction of MDR efflux pumps can lead to the extrusion of beneficial 
compounds outside the cell, as well as a non-physiological expense of energy, having an impact on the bacterial 
fitness unless compensation mechanisms are triggered71 or secondary compensatory mutations are selected72. 
With the aim of determining the effect on the S. maltophilia fitness of each of the smeH mutations alone and 
in combination, all the strains were grown in absence of antibiotics and their growth was recorded. The only 
strain impaired in growth was the smeH-deficient PBT104, while none of the resistant mutants showed any defi-
ciency regarding bacterial growth, indicating that: I) the removal/inhibition of intrinsic resistance determinants 
may impair bacterial fitness. In other words, intrinsic resistance determinants might be under positive selection 
pressure; II) the presence of the analyzed antibiotic resistance mutations, separate or together, does not lead to 
a decrease on the S. maltophilia fitness in an antibiotic-free environment; and III) the second mutation in smeH 
does not seem to have been selected for compensating the potential fitness cost of the first mutation, at least in 
the recreated strains background. Previous studies have shown that some resistant mutations are cost-free73–75, 
or even confer an enhanced fitness and virulence in infected hosts76,77. This fact makes that bacteria harbouring 
no-cost resistance mutations, as those described in the current article, to be more likely to persist in the absence 
of antibiotics78.
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Acquisition of resistance in S. maltophilia regarding RND efflux pumps, is usually associated with mutations 
in their regulatory genes28–30. Nevertheless, this is the first report of mutations occurring in an efflux pump trans-
porter protein that lead to a change in the susceptibility to several antibiotics belonging to different categories in 
this bacterium. Previous studies have shown that amino acid substitutions in the transporter proteins of RND 
efflux pumps belonging to other bacterial species can change the susceptibility to some antibiotics35–40. In these 
reports, authors highlight the importance of those substitutions located inside or near the transporter binding 
pocket, where they are of relevance for the recognition and/or accommodation of certain substrates. To better 
understand how the amino acid substitutions in SmeH impact in the observed acquisition of resistance in S. 
maltophilia, we mapped both residues P326 and Q663 using the AcrB structure from E. coli as a model, since 
no crystal structures for SmeH or other S. maltophilia transporters are available. The location of both residues 
suggests that they could be involved in the entrance and/or recognition of the SmeH substrates, which would 
have an effect in the resistance levels to these compounds. Since the P326 residue is conserved in both pro-
teins, we performed an in silico mutagenesis on the AcrB structure in its doxorubicin-bound form in order to 
determine whether the mutation P326Q had an impact in the deep binding pocket conformation. According 
to our prediction, this amino acid change made the Q326 residue to be pointing to the base of the deep binding 
pocket. In addition to AcrB, P326 is also found to be conserved in the AcrB-homolog MexB from P. aeruginosa 
(Supplementary Fig. S1), as well as in another RND transporter protein from the same bacterium, MexD, cor-
responding in this case with the P328 moiety. Mao et al.79 reported that, together with other amino acid substi-
tutions, P328L in MexD increased resistance in P. aeruginosa against aztreonam and carbenicillin. This residue 
was mapped to the large periplasmic loop (LPL) of the RND efflux pump, which can potentially surround the 
drug-binding pocket. In agreement with this, LPLs have also been reported to play an important role in substrate 
recognition in AcrB and AcrD from E. coli80. Although it is unclear how this mutation affects the efflux pump 
function, the change in the residue orientation might cause interactions with other neighboring residues that are 
part of the cavity and influence somehow the recognition of the efflux pumps substrates, as beta-lactams, leading 
to the observed resistance phenotype.
But, why does Q663R only confer changes in beta-lactams susceptibility in combination with P326Q, and not 
by itself? It has been recently reported that V672, the Q663-equivalent residue in AcrB, might form part of the 
meropenem binding site of this protein81. Besides, our mapping prediction showed that this residue was located 
at the bottom of the AcrB access pocket. We postulate that changes just in the access cavity could not be enough 
to have a direct effect on substrate extrusion; however, when P326Q is present and, presumably, binding is ame-
liorated, the existence of Q663R suppose a beneficial outcome, since both access and recognition of the antibiotic 
would be improved. Further studies on the structures of RND efflux pump transporters might shed light on this 
issue.
Concluding Remarks
Experimental evolution and whole-genome sequencing after ceftazidime exposure, have revealed new mecha-
nisms of acquired resistance in the opportunistic pathogen S. maltophilia. Among them, we highlight the selec-
tion, in all the ceftazidime-challenged strains, of mutations in the RND efflux pump transporter smeH for the first 
time. Some few publications have reported that mutations in efflux transporters may decrease the susceptibility 
to antibiotics of bacterial pathogens35–40. However, this is the first formal demonstration showing that this type 
of mutations can be selected as a first response to the presence of antibiotics. Besides contributing to ceftazidime 
resistance, the presence of P326Q and P326Q/Q663R also confers resistance to other beta-lactam drugs and do 
not suppose a fitness cost in an antibiotic-free environment. The SmeH-homolog from E. coli AcrB has been 
a suitable model for predicting the positions of both amino acid residues, showing that P326 is located in the 
proximities of the deep binding pocket of the efflux pump, while V672, the corresponding Q663 in AcrB, was 
mapped at the bottom of the access pocket. Taken together, these results suggest that changes in both access and 
binding pockets might be required for the incremented observed resistance. Whether or not in vitro experimental 
evolution assays are of relevance for understanding evolution during infection in the treated patient is a topic that 
requires further studies. Nevertheless, a recent analysis of the evolution of carbapenem resistance in Acinetobacter 
baumannii during a prolonged infection in a burn patient shows that a first event in the evolution was the selec-
tion of a mutation in a gene encoding a structural component of an efflux pump (adeB), followed by the mutation 
of ftsI82. This evolution trajectory resembles the one we have observed and supports that the application of experi-
mental evolution and whole-genome sequencing approaches can help to understand and identify the mechanisms 
of acquired resistance to ceftazidime and other antibiotics by bacterial pathogens.
Materials and Methods
Bacterial strains and growth conditions. All the plasmids and strains used in this work are listed in 
Table 3. The wild-type strain S. maltophilia D457 was used as the parental strain for the evolution experiments. 
Ceftazidime (GlaxoSmithKline) was used at different concentrations during the evolution assay. Cultures were 
grown using LB medium at 37 °C. Antibiotics were added when required: ampicillin (Ap; 100 µg/ml) for E. coli 
containing the pGEM-T Easy and pGEM-T derived plasmids. Medium was supplemented with 0.5 mM iso-
propyl-β-D-thiogalactopyranoside (IPTG) and 80 µg/ml 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside 
(X-Gal) in order to induce and detect beta-galactosidase production.
Experimental evolution. Experimental evolution was performed with the wild-type strain D457 grow-
ing in the presence of increasing concentrations of ceftazidime. Cultures were initially grown at the maximum 
ceftazidime concentration that allowed growth (1 μg/ml) in liquid LB medium. One microliter of a bacterial 
overnight culture was inoculated in four independent test tubes containing 2 ml of LB medium with ceftazidime 
Serial passages were performed inoculating 1 μl of bacterial cell cultures in fresh medium containing the same 
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antibiotic concentration every 24 h for 4 days. At day 5, ceftazidime concentration was doubled. This procedure 
was repeated for 30 days (around 300 generations), until the ceftazidime concentration was 32 μg/ml (32-fold 
increase). Four independent replicates were also cultured in the same conditions, but in the absence of antibiotic 
as controls. Every 5 days, and after the passage, the minimum inhibitory concentration (MIC) for ceftazidime 
was determined for all the evolving populations and samples were taken and kept at −80 °C for further analysis.
DNA extraction, WGS and identification of mutations. After the 30-days experimental evolution, the 
total genomic DNAs from the evolved populations and the original wild-type D457 strain were extracted using a 
Gnome® DNA kit following the manufacturer’s protocol (MP Biomedicals). Quality and quantity of the extracted 
DNA was assessed by agarose gel electrophoresis and using a NanoDrop Spectrophotometer (Thermo Fischer), 
respectively. DNA samples were sent to the CRG (Center for Genomic Regulation, Barcelona) and sequenced 
using the HiSeq2,000 Sequencing System (Illumina) generating 125-bp paired-end reads. The number of reads 
per sample was 2,093,625 on average, representing a sequencing depth of 100x approximately. Data analysis was 
accomplished with CLC Genomics Workbench software (Qiagen) and the resulting reads were mapped to the S. 
maltophilia D457 reference genome (NC_017671.1) using default parameters. Single nucleotide polymorphisms 
(SNPs) detection was performed using the Fixed Ploidy Variant Detection tool (ploidy = 1, required variant prob-
ability = 90%, minimum coverage = 8, minimum frequency = 15%) and the given variants were filtered against 
those obtained for the wild-type D457 strain. Insertions, deletions, inversions, tandem duplications and translo-
cations were detected using the InDel and Structural Variants tool (P-value threshold = 0.0001). The identified 
mutations were verified by PCR and Sanger-sequencing. Unless otherwise stated, the thermocycler was pro-
grammed for 56 °C of annealing. Primers are listed in Supplementary Table S2.
Recreation of the smeH mutations. The amino acid substitutions P326Q and Q663R were introduced 
alone and in combination in S. maltophilia D457. Two 1,000-bp regions of the smeH gene, containing each one 
SNP, were amplified from the ceftazidime evolved population B using primers SmeH_snp1_F and SmeH_snp1_R 
for Q326 amplification, and SmeH_snp2_F and SmeH_snp2_R for R663 amplification. Both 1,000-bp fragments 
were cloned into pGEM-T Easy (Promega) following the manufacturer’s instructions obtaining respectively 
pPBT21 and pPBT22 plasmids, which were introduced by transformation into E. coli OmniMAX (Invitrogen). 
Constructions were verified by DNA sequencing. Both plasmids were extracted with the Qiaprep ® Spin Miniprep 
Kit 250 (Qiagen) following the manufacturer’s protocol, and digested with EcoRI (New England BioLabs). The 
obtained products containing either Q326 or R663 were purified and cloned into the suicide vector pEx18Tc83, 
giving rise to pPBT101 and pPBT102, respectively. Both plasmids were then introduced by transformation into 
CC118λpir and selection was performed using tetracycline (4 μg/ml). Then, by tripartite matting, pPBT101 or 
pPBT102 were introduced into S. maltophilia D45784 and selection was carried out on LB agar plates containing 
tetracycline (12 μg/ml) and imipenem (20 µg/ml). TetR colonies were then streaked onto LB agar plates with 
10% sucrose and 12 μg/ml tetracycline. TetR and SacS colonies were selected and streaked onto LB plates with 
10% sucrose. From these sucrose plates, SacS colonies were streaked onto LB plates containing sucrose 10% and 
12 μg/ml tetracycline with the aim of obtaining the mutants with the amino acid changes. The presence of the 
Strain or plasmid Description Source or reference
Bacterial strains
E. coli
   OmniMAX
Strain used in transformation. F’ mcrA ∆(mrr-hsdRMS-mcrBC) 
Φ80(lacZ)∆M15 ∆(lacZYA-argF) U169 endA1 supE44 thi−1 gyrA96 
relA1 deoR tonA panD
Invitrogen, Life Technologies
   CC118λpir
Donor cell in conjugation. Strain CC118 lisogenized with λ pir phage 
(Tc’) Δ(ara-leu), araD, ΔlacX74, galE, galK, phoA20, thi-1, rpsE, 
rpoB, argE (Am), recA1
84
   1047 (pRK2013) Helper cell in conjugation harbouring pRK2013 (KanR) plasmid 87
S. maltophilia
   D457 Clinical strain 88
   PBT101 D457 carrying the smeH P326Q substitution This work
   PBT102 D457 carrying the smeH Q663R substitution This work
   PBT103 D457 carrying the smeH P326Q and Q663R substitutions This work
   PBT104 D457 ΔsmeH This work
Plasmids
   pGEM®-T Easy Vector Cloning vector, AmpR Promega
   pPBT21 pGEM-T-derived plasmid carrying the fragment SmeH:P326R This work
   pPBT22 pGEM-T-derived plasmid carrying the fragment SmeH:Q663R This work
   pEX18Tc Gene replacement vector; sacB, TetR 83
   pPBT101 pEX18Tc-derived plasmid carrying the fragment SmeH:P326Q This work
   pPBT102 pEX18Tc-derived plasmid carrying the fragment SmeH:Q663R This work
   pHAB5 pEX18Tc-derived plasmid containing the 5′ and 3′ regions of smeH This work
Table 3. Bacterial strains and plasmids.
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mutations was confirmed by SNP-specific PCR; the P326Q change was identified in the PBT101 strain using 
primers Comp_snp1_F and Comp_snp1_R; the Q663R modification was confirmed in the PBT102 strain using 
primers Comp_snp2_F and Comp_snp2_R (65 °C annealing temperature). DNA sequencing was performed with 
primers SmeH_snp1_F and SmeH_snp1_R, and SmeH_snp2_F and SmeH_snp2_R to further confirm the pres-
ence of the mutations. Plasmid pPBT102 was introduced as described above in the PBT101 strain in order to 
obtain a mutant with both amino acid substitutions. Confirmation was carried out in the PBT103 strain with the 
above-mentioned primers and DNA sequencing. Primers are listed in Supplementary Table S2.
Generation of a smeH deletion mutant. A derivative S. maltophilia mutant with a partial deletion in 
the smeH gene was generated through homologous recombination. Using primers HAF and HAR (Table S1), a 
494-bp fragment (HA) corresponding to the 5′-end of smeH was amplified; primers HBF and HBR were used to 
amplify a 514-bp fragment (HB) of the smeH 3′-end. The thermocycler was programmed for 10 cycles of 52 °C 
of annealing, followed by 20 cycles of 56 °C. Using HA and HB fragments as templates, an overlapping PCR was 
carried out using primers HAF and HBR, yielding a 1,000-bp fragment (HAB). The obtained product was cloned 
into pGEM-T Easy (Promega) and introduced by transformation into E. coli CC118λpir. DNA sequencing was 
performed for sequence verification. The plasmid was then digested with EcoRI and the HAB fragment was 
cloned into pEx18Tc. The resulting plasmid pHAB5 was introduced by transformation into E. coli CC118λpir 
and then, by tripartite matting, into S. maltophilia D457. The smeH-defective mutant was selected following the 
above-described process and confirmation of the deletion in the PBT104 strain was performed using the primers 
Ext_smeH_L and Ext_smeH_R, as well as Int_smeH_L and Int_smeH_R. Primers are listed in Supplementary 
Table S2.
Antimicrobials susceptibility assay. MICs for the antibiotics cefotaxime, cefoxitin and cefazolin, as well 
as for menadione, tert-butyl hydroperoxide, hexachlorophene, benzalkonium chloride, triclosan and naringenin, 
were determined by microbroth double dilution in 96-well microtiter plates (NUNCLONTM Delta Surface) con-
taining LB medium with two-fold dilutions of each antibiotic. Two replicates of each strain were inoculated to a 
final OD600 of 0.01 and plates were incubated for 20 h at 37 °C without shaking. MICs for ceftazidime, aztreonam, 
ofloxacin, norfloxacin, nalidixic acid, chloramphenicol, tetracycline, tigecycline and polymyxin B were deter-
mined using MIC test strips (Liofilchem), which were placed on LB agar plate seeded with an overnight 1:1,000 
dilution of each bacterial population. Plates were incubated at 37 °C and results were analyzed after 20 h. The MIC 
was defined at the lowest concentration at which no bacterial growth was observed.
Growth curves in the presence of β-lactams. The S. maltophilia wild-type strain D457 and the derived 
mutants PBT101 (SmeH:P326Q), PBT102 (SmeH:Q663R), PBT103 (SmeH:P326Q;Q663R), and PBT104 
(ΔsmeH) were grown in the presence or in the absence of ceftazidime (4 µg/ml), cefoxitin (256 µg/ml) or cefo-
taxime (128 µg/ml). The assay was carried out in 96-well plates (NUNCLONTM Δ Surface) where 10 µl of an 
overnight bacterial culture were added to 140 µl of LB medium, with or without the antibiotics, to a final OD600 of 
0.01. Plates were then incubated at 37 °C for 20 h, and growth (OD600) was measured every 10 min using the plate 
reader Tecan Spark 10 M (Tecan). Shaking for 5 s was performed every 10 min before each measurement.
Biofilm formation assay. An overnight culture from each tested strain was diluted 1:100 and 100 µl of bac-
terial suspension were inoculated per well in a 96-well plate (Costar SeroclusterTM, Corning Incorporated). After 
48 h incubation at 37 °C without agitation, biofilms were stained by adding 25 µl of crystal violet 0.1% for 5 min. 
The stained biofilms were rinsed three times using 100 µl of Milli-Q water and then 150 µl of 0.25% Triton X-100 
were added in order to dissociate biofilms. Hundred microliters were transfer to a clean 96-well plate (NunclonTM 
Delta Surface) and biofilm formation was assessed through the quantification of crystal violet staining by meas-
uring absorbance at 570 nm. The assay was performed in octuplicate.
Swimming assay. The swimming motility of all the tested strains was determined on LB agar (0.3%) plates. 
An overnight culture from each strain was diluted to a final OD600 of 2 and 5 µl were spotted on the surface of 
the swimming plates. After 48 h incubation at 30 °C, the growth zone was measured in milliliters. The assay was 
performed in triplicate.
Prediction of the amino acid substitutions location. Structural alignment of SmeH and AcrB amino 
acid sequences was performed using I-Tasser85. the positions of the SmeH amino acid substitutions were repre-
sented using the AcrB crystal structures of E. coli as a reference (PDB ID codes 4DX7.A and 4DX7.B37). Prediction 
of both access and deep binding pocket cavities in AcrB was performed with CASTp86. Figures were generated 
using PyMol (The PyMOL Molecular Graphics System, Schrödinger, LLC).
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Table S1. MICs of several antibiotics for S. maltophilia strains 
 MIC (µg/ml) 
Strain CAZ CTX FOX CFZ ATM OFX NOR NAL CHL TET TGC PMB 
D457 0.75 128 256 4,096 4 1 8 6 6 1.5 0.5 8 
PBT101 
(P326Q) 4 192 384 8,192 8 1 8 6 8 1.5 0.75 8 
PBT102 
(Q663R) 0.75 96 256 3,072 6 1 8 6 6 6 0.75 12 
PBT103 
(P326Q; 
Q663R) 
8 256 384 8,192 24 1 24 6 4 2 0.5 8 
PBT104 
(DsmeH) 0.38 96 256 3,072 2 0.5 6 4 6 1 0.5 3 
 
MIC, minimum inhibitory concentration; CAZ, ceftazidime; CTX, cefotaxime; FOX, cefoxitin; 
CFZ, cefazolin; ATM, aztreonam; OFX, ofloxacin; NOR, norfloxacin; NAL, nalidixic acid; CHL, 
chloramphenicol; TET, tetracycline; TGC, tigecycline; PMB, polymyxin B. 
  
Table S2. Primers used in this study 
 
Name Sequence (5’-3’) Utilization 
SmeH_snp1_F GAATTCAGTACGCCATGAACATCTGG Amplification of the 
1000-bp fragment 
containing P326Q in 
smeH 
SmeH_snp1_R GAATTCACTTGTTGAAGGTGCGGTAG 
SmeH_snp2_F GAATTCCCGGTGAGATCTACAAGCAG Amplification of the 
1000-bp fragment 
containing Q663R in 
smeH 
SmeH_snp2_R GAATTCGACTTGACCACCGTGTTGAG 
Comp_snp1_F GTGACCTGGTTCTCGCA 
Verification of Q326  
Comp_snp1_R GAACAGGGTCAGCTGGTT 
Comp_snp2_F ACCTGCCCACCGTGCG 
Verification of R663 
Comp_snp2_R CGGCCTTCGTAGAAGAAGTCGTT 
HAF 
GAATTCCGAACATCCAGTCTTCGCCTG
GGTGGTTGCGATCCTG 
Amplification of the 
489-bp fragment 
corresponding to the 5’-
end of smeH HAR 
AGCTTTCATACAGGGCGGCCGGGGAT
ACGCGAGACCTGGT 
HBF 
ACCAGGTCTCGCGTATCCCCGGCCGCC
CTGTATGAAAGCT 
Amplification of the 
489-bp fragment 
corresponding to the 3’-
end of smeH 
HBR 
GAATTCTCAACGATCCGGGCGGTGTG
CAGCATCCGC 
Ext_smeH_L GATTCGAACAAGCAGTAAG Amplification of the 
3404-bp fragment 
including the complete 
smeH gene Ext_smeH_R ATTGGTAATCGTGGCAGTGT 
Int_smeH_L ACAACTACGGCTTCGACAC Amplification of a 211-
bp fragment inside 
smeH gene Int_smeH_R GTCTTGACCACTTCCTGGAT 
acrD1_L GTCGGCCAGCCAGGTACT Verification of P326Q 
in smeH acrD1_R ATCTGGGTCATCGCCTTCT 
acrD2_L ATGATCCTGTTCGTGGTGCT Verification of Q663R 
in smeH acrD2_R GAAGCTCTTCAGCGACTCCT 
phoQ_cef_L ACCCTGGCGATAACACGAT Verification of I76N 
and P81L in phoQ phoQ_cef_R ACCTTGGTCAACTCGGTGAT 
phoQ_tig3_L CGAATTCCCGTACACCATCT Verification of S307L 
and P324L in phoQ phoQ_tig3_R CACTTGAAGGCGTTCTCCAG 
mrkC_L GCTGGCACCTACCGTGTC Verification of 
G187_F188del in mrkC mrkC_R AGATCAGCTGCTGGTTCTGG 
ftsI4_L CAGATCATCGACGAGAACG Verification of A592D 
in ftsI ftsI4_R AACATCGAAGGACTCATTGC 
yrbE_L GTTCTCGCTGACCGTGCT Verification of I49fs in 
yrbE yrbE_R GTGAACAACATTGCCGACAG 
yrbC_L GTCGGCAAGTACATGTTCAG Verification of Q126* 
in yrbC yrbC_R AAGTGCGTTACTTGCCATTG 
yciM_L ATCGAAGATGGATTTCGTCA Verification of A206fs 
in yciM yciM_R AGGTCAGCAACGCACTGA 
SMD_0534_L TGCGGAATTTTTCGAGTATC Verification of V398fs 
in smd_0534 SMD_0534_tig_R AGGTTGGAGATGGACTGTGG 
SMD_1278_L CCCAACCACTCTTCTGTGG Verification of 
F91_G92insDF in 
smd_1278 SMD_1278_R CGTTCCTGGTACTCCTTGAC 
SMD_0260_L GATTGGAACCTGGTCGAG Verification of K88R in 
smd_0260 
SMD_0260_R TCTTCGACCAGAAGGATACG 
SMD_2719_L GCAACGGGATCTGGGT Verification of V232G 
in smd_2719 SMD_2719_R ACCACGAACGGCAGCTTG 
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
  
 
 
Figure S1. Alignment of the S. maltophilia SmeH amino acid sequence with its homologues 
AcrB from E. coli, and MexB from P. aeruginosa. The conserved P326 residue is marked with 
a red square in the amino acid sequences of the three species. Color scheme is based on amino 
acid identity. 
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 Despite the fact that trimethoprim/sulfamethoxazole (SXT) is the first-line agent for the 
treatment of S. maltophilia infections, the increased acquisition of resistance to this antibiotic 
by this bacterial species has complicated its use. In addition to the beta-lactam ceftazidime, the 
glycylcyclines-group antibiotic tigecycline, has shown a good activity against SXT-resistant 
S. maltophilia isolates. Some of the molecular mechanism involved in the acquisition of 
tigecycline resistance have been studied in other bacterial species. However, concerning 
S. maltophilia, little is known about the mechanisms involved in the acquisition of mutation-
driven resistance to this antibiotic. 
 
 In the present work, we challenged S. maltophilia with increasing concentrations of 
tigecycline and then analysed the mutations by whole-genome sequencing that were potentially 
involved in the acquisition of resistance to this drug. Besides acquiring high-level resistance at 
the end of the experimental evolutions, all the replicates acquired mutations in the gene 
encoding the transcriptional regulator of the SmeDEF RND efflux pump, SmeT, being the first 
event towards tigecycline resistance. In addition, mutations affecting the ribosome biogenesis 
and the lipopolysaccharide biosynthesis pathway, were also detected. The effect of these 
mutations on the susceptibilities against other antibiotics were also assessed, showing that the 
tigecycline-evolved populations display cross-resistance to several antibiotics, notably 
quinolones, tetracycline, chloramphenicol or aztreonam, but are hypersusceptible to 
fosfomycin. Finally, all the evolved populations, as well as single isolated clones, present a 
significant fitness cost when they grow in the absence of antibiotic. This effect could 
compromise the maintenance of these mutants in the population when the selection pressure is 
absent.   
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Synopsis: The full understanding of the mechanisms leading to the acquisition of antibiotic resistance by 
bacterial pathogens requires the identification of the mutational pathways that make bacteria become resistant 
to antibiotics. In the present work, we use adaptive laboratory evolution and whole-genome sequencing with 
the aim of exploring the genetic mechanism involved in the acquisition of tigecycline resistance by the 
multidrug-resistant opportunistic pathogen Stenotrophomonas maltophilia. Our study shows that all the 
evolved populations are able to reach high-level resistance against tigecycline following different mutational 
trajectories, yet with some common elements. Among the mechanism involved in the low susceptibility to 
tigecycline, mutations in the SmeDEF efflux pump negative regulator smeT, changes in proteins involved in 
the biogenesis of the ribosome, and modifications in the lipopolysaccharide biosynthesis pathway, seem to 
play a major role. Besides tigecycline resistance, the evolved populations present cross-resistance to other 
antibiotics, as aztreonam and quinolones, and they are hypersusceptible to fosfomycin. Whether or not the 
use of fosfomycin sequentially or in combination with tygecycline would be useful for reducing the 
emergence of S. maltophilia antibiotic resistant mutants is a feature that remains to be established. However, 
it is clear that sequential use of tygecycline and quinolones should be disregarded. Further, we found that the 
selected resistance mechanisms impose a relevant fitness cost when bacteria grow in the absence of antibiotic, 
suggesting that mutational resistance to tigecycline should be easily selected along treatment, but will not be 
stably maintained in S. maltophilia populations. 
Introduction 
Stenotrophomonas maltophilia is an opportunistic nosocomial pathogen causing different infections, mainly 
in immunocompromised patients and in those with underlying pathologies. 1,2 Further, this microorganism is 
one of the most common pathogens causing chronic lung infections in cystic fibrosis patients. 3,4 
S. maltophilia exhibits a characteristic phenotype of low susceptibility to antibiotics, being considered as a 
model of intrinsically resistant pathogen. 5 Besides presenting a low membrane permeability, S. maltophilia 
possesses a set of intrinsic resistance determinants, including antibiotic-modifying enzymes and multidrug 
resistance (MDR) efflux pumps. 6-9 Further, acquisition of antibiotic resistance by mutation is particularly 
relevant when this bacterium produces a chronic infection. 10 
 
 
II 
The antimicrobial options for the treatment of S. maltophilia infections are limited, being 
trimethoprim/sulfamethoxazole (SXT) the most effective drug of choice. 11 However, different mechanisms 
of resistance, such as the presence of sul1, sul2 and dfrA genes, and the increased expression of MDR efflux 
pumps, limits its use. 12-15 Tigecycline, which presents good in vitro activity against SXT-resistant strains 
isolates, 16-18 is a promising alternative for treating S. maltophilia infections. Tigecycline belongs to a new 
group of tetracyclines called glycylcyclines, whose target is the ribosomal A site of the 30S subunit, leading 
to translation interference. 19,20 The main mechanism of tigecycline resistance in pathogens as Klebsiella 
pneumoniae, Bacteroides fragilis, Acinetobacter baumannii, Enterobacter spp or Salmonella enterica is the 
overexpression of MDR efflux pumps. 21 The presence of the flavin-dependent monooxygenase TetX, which 
modifies first- and second-generation tetracyclines, has also been described as a tigecycline resistance 
mechanism in Bacteroides strains. 22  In Escherichia coli, besides overexpression of the AcrAB efflux pump, 
tigecycline resistance has also been associated with mutations affecting the lipopolysaccharide (LPS) 
biosynthesis pathway. 23 Regarding S. maltophilia, the tigecycline resistance mechanisms are not well 
established. A recent study has proposed that the observed non-susceptibility to tigecycline of a set of 
S. maltophilia clinical isolates might be due to the overexpression of the resistance nodulation division 
(RND) SmeDEF efflux pump. 24 However, this statement is based in correlations and a formal demonstration 
of the molecular basis of the acquisition of tigecycline resistance by S. maltophilia is still needed. 
To this end, experimental evolution studies in the presence of increasing concentrations of tigecycline were 
performed in S. maltophilia. This approach, followed by whole-genome sequencing (WGS), has allowed to 
determine the genetic changes underlying antibiotic resistance, as well as the evolutionary trajectories 
towards that resistance in different organisms.  25,26 Besides providing a predictive analysis of the potential 
genetic determinants involved in tigecycline resistance, the cross-resistance and collateral sensitivity against 
other antibiotics, as well as the resistance-associated fitness costs, were also assessed. 
Materials and Methods 
Growth conditions and antibiotic susceptibility assays 
Bacteria were grown using liquid Lysogeny Broth, Lennox (LB) at 37 °C with agitation at 250 rpm. Evolution 
experiments were performed with S. maltophilia D457. Tigecycline (Pfizer) was used at different 
concentrations during the evolution period. The minimum inhibitory concentrations (MICs) for tigecycline, 
ciprofloxacin, ofloxacin and erythromycin were determined by double dilution in 96-well microtiter plates 
(NUNCLONTM Delta Surface) in LB at 37 °C. MICs of ceftazidime, aztreonam, 
trimethoprim/sulfamethoxazole, chloramphenicol, fosfomycin, nalidixic acid, streptomycin, gentamicin and 
tetracycline were determined using MIC test strips (Liofilchem) in LB-Agar plates at 37 °C. 
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Experimental evolution 
Eight independent experimental evolutions (four in the presence of tigecycline and four controls without 
antibiotic) were performed during 30 days. Tigecycline-challenged S. maltophilia D457 populations were 
initially grown at the maximum concentration that allowed bacterial growth in these conditions (1 mg/L) and 
serial passages were performed as described in Blanco et al. 27 until a final concentration of 32 mg/L was 
reached at day 30. Samples were preserved at -80 °C every 5 days for further analysis.  
Whole-genome sequencing (WGS)  
Genomic DNA was extracted from the evolved populations at day 30 of evolution, as well as from the D457 
parental strain, using a Gnome® DNA kit (MP Biomedicals). The quality and quantity of the DNA was 
determined by agarose gel electrophoresis and by using a NanoDrop spectrophotometer, respectively. WGS 
was performed at the Center for Genomic Regulation (CRG, Barcelona) using a HiSeq 2,000 Sequencing 
System (Illumina), which generated 125-bp paired-end reads. On average, the number of reads per sample 
was 2,399,250, which represents a sequencing coverage of 100x approximately.  
Data analysis and verification of genetic changes 
The S. maltophilia D457 reference genome (NC_017671.1) was used to align the WGS-obtained reads. 
Mutations were identified using the CLC Genomics Workbench software (Qiagen). Single nucleotide 
polymorphisms (SNPs) were analyzed using the Fixed Ploidy Variant Detection tool and the resulting 
variants were filtered against those obtained for the parental D457 strain. Other deviations from the reference 
genomes, such as inversions, insertions, deletions or duplications were identified using the InDel and 
Structural Variants tools. PCR amplification of the regions containing the mutations and Sanger-sequencing 
were performed to verify the WGS-detected mutations. The primers used are shown in Supplementary 
Table S1.  
Fitness cost determination 
Bacterial samples from the four tigecycline-evolved populations, as well as single clones isolated from each 
population at different time points of the evolution, were used for the assay. Ten µl of each culture were 
inoculated in 140 µl of LB medium to a final OD600 of 0.01 using 96-well plates (NUNCLONTM Δ Surface). 
Growth (OD600) from three independent replicates was monitored every 10 min using the plate reader Spark 
10M (Tecan) during 20 h at 37 ºC. Shaking for 5 s was performed before each measurement. OD600 values 
at exponential growth phase were used to calculate the maximum growth rates. Relative growth rates were 
calculated by dividing the values of each population, or individual clone, to those obtained for the parental 
strain D457 from the same experiment.  
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Results 
Step-wise evolution of S. maltophilia towards tigecycline resistance 
Four independent S. maltophilia D457 lineages were serially passaged for 30 days in the presence of 
increasing concentrations of tigecycline until reaching 32 mg/L. In parallel, four independent replicates were 
also passaged at the same conditions in the absence of antibiotic as control. At the end of the experiment, the 
antibiotic-evolved cultures were submitted to three daily passages in LB medium in order to discard any 
potential induction of resistance triggered by tigecycline exposure. Afterwards, MICs for the four tigecycline-
evolved populations were determined. As shown in Figure 1, all the populations exhibit high-level resistance 
against tigecycline, ranging from 96 to 192 mg/L.  
  
Mutations and adaptive trajectories to tigecycline resistance in S. maltophilia 
Whole genomic DNA of all the evolved populations, as well as that of the parental strain D457, were 
sequenced in order to determine the genetic changes potentially responsible for the tigecycline decreased 
susceptibility. Those mutations selected under tigecycline pressure, but absent in the control populations 
evolved in the absence of antibiotic, were taken into consideration and are listed in Table 1. Altogether, 
genetic modifications were found in 19 different genes, being SNPs causing amino acid substitutions the 
most common changes. The four antibiotic-evolved populations shared some genetic changes on common 
elements. A mutation in smeT, which in S. maltophilia encodes the repressor of the RND efflux pump 
SmeDEF, 28 was found in all the populations. In addition, the four populations present mutations in the 
ribosome recycling protein frr. SNPs in other ribosome-related genes, such as in rpsU and rpsJ in populations 
A and B, respectively, and a single-base insertion in rpsA in population C, were also detected. Genes 
encoding different enzymes were also found mutated, including those involved in the LPS biosynthesis, such 
as the phosphoethanolamine transferase SMD_RS16325 in population A, the lipid A biosynthesis lauroyl 
acyltransferase htrB in population B, and the UDP-glucose dehydrogenase ugd in population D; or involved 
in the phosphatidic acid biosynthetic process, as dgkA in population D. In addition to SNPs, insertions or 
deletions leading to frame shifts in the protein-coding sequences were also detected. For instance, a 30-bp 
Figure 1. MICs of tigecycline of the four 
S. maltophilia evolved populations. Tigecycline 
susceptibility was determined in populations A, B, 
C and D after 30 days of experimental evolution in 
the presence of increasing concentrations of 
tigecycline. The wild-type strain D457 was used as 
a reference. MIC, minimum inhibitory 
concentration. 
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insertion was found in the rpoD gene in population C, and a 101-bp deletion was identified in the TIGR02099 
family protein coding gene (SMD_RS15850) in population D. Two different inverted duplications were also 
detected. The first one was found in population C and comprised 262 genes (~ 300 kbp), while the second 
one was found in population D and included 53 genes (~ 60 kbp), which are common to those of the 
duplicated-inverted sequence in population C (Figure 2; Supplementary Table S2). 
Table 1. WGS-identified mutations in the tigecycline-evolved lineages 
P Gene Product Localization Type 
Nucleotide 
change 
Amino 
acid 
change 
(%) 
Detected 
day of 
emergence 
A smeT 
TetR-family 
transcriptional 
regulator 
4099641 SNV T à A L166Q 100 5 
 frr 
Ribosome recycling 
protein 
1493591 SNV T à G T50P 94.9 10 
 
SMD_RS
16325 
Phosphoethanolamine 
transferase 
3492054 SNV C à T S284L 99.2 15 
 rpsU 
30S ribosomal protein 
S21 
434736 SNV C à T E24K 78.7 30 
 
SMD_RS
15850 
TIGR02099 family 
protein 
3391847 Ins 
Ins-
GCCGCCA 
V239fs 54.5 ND 
B smeT 
TetR-family 
transcriptional 
regulator 
4099641 SNV T à A L166Q 100 5 
 frr 
Ribosome recycling 
protein 
1493470 SNV G à T P90Q 100 15 
 rpsJ 
30S ribosomal protein 
S10 
900713 SNV T à G V73G 100 15 
 speD 
S-adenosylmethionine 
decarboxylase 
proenzyme 
4369955 SNV A à G V117A 100 15 
 htrB 
Lipid A biosynthesis 
lauroyl acyltransferase 
3952269 SNV  A à G H290R 100 30 
 
SMD_RS
02920 
Hypothetical protein 613184 SNV C à T Q364* 100 30 
C smeT 
TetR-family 
transcriptional 
regulator 
4099733 SNV A à C T197P 99.1 5 
 frr 
Ribosome recycling 
protein 
1493591 SNV T à G T50P 98.5 15 
 
 
VI 
 phoQ 
Two-component sensor 
histidine kinase 
315823 SNV G à T V277L 98.4 15 
 hutI Imidazolonepropionase 2992107 SNV G à A G283D 99.2 15 
 InvDup - 1331537 - - - ND 20 
 dsbB 
Periplasmic 
thiol:disulfide 
oxidoreductase 
915108 SNV C à T A20V 70.2 25 
 ompR 
Two-component 
system regulatory 
protein 
3753106 Ins Ins-T L54fs 32.3 30 
 rpsA 
30S ribosomal protein 
S1 
2033510 Ins Ins-C N463fs 49.6 30 
 dedD 
Cell division protein 
950264 SNV C à G A249G 26.4  ND 
 dedD 950269 SNV A à T S251C 25.2 ND 
 rpoD 
RNA polymerase 
sigma factor 
4232255 Ins Ins-30 bp 
A176_D17
7insEVIV
GFNDLA 
ND ND 
D smeT 
TetR-family 
transcriptional 
regulator 
4099641 SNV T à A L166Q 100 5 
 cheY Chemotaxis protein 3488433 SNV C à T E21K 100 10 
 frr 
Ribosome recycling 
protein 
1493591 SNV T à G T50P 98.9 15 
 ugd 
UDP-glucose 
dehydrogenase 
3075488 SNV A à G F66S 100 20 
 dgkA Diacylglycerol kinase 796027 Ins 
Ins-
TGCTGG 
L71_A72i
nsVL 
48.4 30 
 
SMD_RS
15850 
TIGR02099 family 
protein 
3391974 Del Del-101 bp V163fs ND ND 
 InvDup - 1425560 - - - ND ND 
P: Population; SNV: single nucleotide variant; Ins: insertion; Del: deletion; fs: frame shift; InvDup: inverted 
duplication; (%): Frequency, percentage of reads that contain the variation within a heterogeneous population; 
ND: non-determined (CLC Genomics Software do not determine the frequency of big insertion/deletions; ND in 
the mutation day of emergence was due to low frequency of the mutation in the population or impairment of 
sequence amplification. 
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Figure 2. Inverted duplications detected in the tigecycline-evolved populations C and D. Two different 
inverted duplicated sequences were detected after 30 days of tigecycline evolution in populations C (~300 kbp) 
and D (~60 kbp), containing 262 and 53 genes, respectively. 
In order to confirm the presence of the WGS-identified genetic changes and to determine the evolutionary 
trajectories, the sequences containing the different mutations were amplified and Sanger-sequenced from 
stored samples of the four populations at days 5, 10, 15, 20, 25 and 30 (Table 1). Tigecycline susceptibility 
was also evaluated at these time points. Figure 3 shows the order of appearance of the genetic changes, as 
well as the increase in the tigecycline MICs, along the 30-days evolutions. Although every population has 
reached resistance to tigecycline through the accumulation of different mutations, some common aspects can 
be found. The first mutation selected in all the populations is located in the SmeDEF regulator smeT, leading 
to a L166Q substitution in populations A, B and D, and a T197P change in population C. Together with 
previously published epidemiological work, this result suggests that smeDEF overexpression should 
contribute to the acquisition of resistance by S. maltophilia. 24 To analyze this possibility, the tigecycline 
susceptibility of the wild-type D457 strain, and that of the SmeDEF overproducer strain D57R, 29 was 
analyzed. Tigecycline MIC raised from 1 mg/L in the wild-type strain to 3 mg/L in D457R, indicating that 
smeDEF overexpression contributes to S. maltophilia tigecycline resistance.  
Mutations in frr were detected in the four populations between days 10 and 15 of evolution, while the 300-
kbp duplication-inversion of population C was detected at day 20 of evolution. In other cases, such as 
SMD_RS15850 or dedD, the low frequency of the mutations did not allow to detect the genetic change within 
the whole population (Table 1). 
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Figure 3. Mutational trajectories and tigecycline resistance during the 30-days tigecycline experimental 
evolution. The MICs of tigecycline and the order of appearance of the genetic changes was determined in 
populations A (A), B (B), C (C) and D (D) from samples stored during the evolution period every 5 days by PCR 
amplification and sequencing. Those dots without any gene name indicate that no new mutations were detected in 
the corresponding day. MIC, minimum inhibitory concentration; InvDup, inverted duplication.  
Antibiotic susceptibility profile of the tigecycline-evolved populations 
To analyze the influence of the mutations selected under tigecycline pressure on the susceptibility to other 
antimicrobials, the MICs of antibiotics belonging to different families were determined at the end of evolution 
(Supplementary Table S3). All the evolved populations present a decreased susceptibility to quinolones, 
chloramphenicol, streptomycin and tetracycline (Figure 4), suggesting that not all the selected mutations are 
tigecycline-specific. A low susceptibility for aztreonam, erythromycin and gentamicin is also observed for 
some of the populations. Regarding collateral sensitivity, the four evolved populations are more susceptible 
to fosfomycin. In addition, population C presents collateral susceptibility to SXT. All populations present 
mutations in the smeDEF repressor smeT. Since smeDEF overexpression is associated with a reduced 
susceptibility to SXT in S. maltophilia, 14 it might be possible that the collateral susceptibility of population 
C to SXT could be due to mutations selected after the first selection of the smeT mutation. To address this 
possibility, the susceptibility to SXT was measured in all the populations at day 5 of evolution. In all cases, 
the populations present a decreased susceptibility to SXT, consistent with the presence of smeT mutants in 
these populations (not shown). Finally, population D shows collateral sensitivity to aztreonam, despite the 
low susceptibility observed to this antibiotic in the other populations.  
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Figure 4. Susceptibility of the S. maltophilia evolved populations to antibiotics from different families. MICs 
were determined in the four tigecycline-evolved populations from the stored samples of day 30 of evolution. MICs 
changes were determined using the MIC values of the wild-type strain D457 as reference (dashed line). MIC, 
minimum inhibitory concentration; CAZ, ceftazidime; ATM, aztreonam; SXT, trimethoprim/sulfamethoxazole; 
E, erythromycin; C, chloramphenicol; FOS, fosfomycin; CIP, ciprofloxacin; OFX, ofloxacin; NA, nalidixic acid; 
S, streptomycin; CN, gentamicin; TE, tetracycline.  
Fitness cost associated with tigecycline resistance during experimental evolution 
 
 
Figure 5. Fitness costs of the tigecycline-evolved S. maltophilia populations. Growth experiments were 
performed in the four evolved populations from samples stored during the evolution period every 5 days. Growth 
rates were calculated from OD600 values corresponding to exponential growth. Relative growth rates were 
calculated using the wild-type D457 value as a reference (1). Error bars represent the standard deviation from three 
independent replicates.  
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The relative fitness costs of the four tigecycline-evolved populations were assessed at days 5, 10, 15, 20, 25 
and 30 of evolution by measuring their growth rates and comparing with that of the parental strain D457.  All 
the populations show around a 20 % deficiency in their growth rate at day 5 of evolution (Figure 5). During 
the following days, while tigecycline concentration increases, mutations accumulate in the bacteria and 
fitness costs becomes notably higher, ranging from 35 % to 45 % at the end of the experiment. Interestingly, 
in some cases the fitness cost seems to be recovered at different days. For instance, in population A, the 
relative fitness cost is 27 % at day 10; however, at day 15, it is reduced to 21 %, suggesting that compensatory 
mutations are selected.  
 
Figure 6. Fitness costs of isolated clones from the tigecycline-evolved S. maltophilia populations. Growth 
experiments were performed in five single clones isolated from the four evolved populations from samples stored 
during the evolution period every 5 days. Growth rates were calculated from OD600 values corresponding to 
exponential growth. Relative growth rates were calculated using the wild-type D457 value as a reference (1). Error 
bars represent the standard deviation from three independent replicates. 
With the aim of determining whether the tigecycline resistance-associated fitness costs of the evolved 
populations were also observed in individual clones, five single colonies from each population and time 
points (5, 10, 15, 20, 25 and 30) were isolated on LB agar plates and the relative fitness of each clone was 
assessed. As shown in Figure 6, all the isolated colonies present a defect in growth in comparison with the 
wild-type strain from day 5 of evolution, although, in some cases, these costs are not as accused as the ones 
observed in the population setting. In the case of the colonies isolated from days 25 from the populations B 
and D, some of them present a better growth rate in comparison with the previous time point, indicating 
possible compensatory events during the evolution. 
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Discussion 
Using in vitro experimental evolution, we have determined the adaptive changes and the phenotypical 
consequences driven by the exposure of S. maltophilia to increasing concentrations of tigecycline. The 
tigecycline-evolved populations reached high-level resistance to this antibiotic in a step-wise manner through 
the accumulation of sequential mutations in different genetic elements. The evolutionary trajectories 
followed by the four parallel cultures show that the first event in the evolution leading to tigecycline 
resistance is a mutation in smeT. Mutations in this regulator have been previously associated with antibiotic 
resistance in S. maltophilia clinical isolates. Indeed, both L166Q and T197P amino acid substitutions have 
been already found in S. maltophilia clinical isolates that overexpress smeDEF. 29,30 Further, L166Q in SmeT 
has been detected more recently in a clinical isolate from a patient with bacteremia treated with the quinolone 
levofloxacin. 31 These findings support that the results derived from our in vitro analysis can be translated to 
the clinical settings. With the exception of smeT mutations, which have been already detected in 
S. maltophilia clinical isolates, none of the other mutations were found in the available genomes of 
S. maltophilia strains after an in silico analysis in GenBank, but some of them have been associated with 
resistance, or have been found in clinical isolates, in other bacterial pathogens (see below).  
The second common aspect among the four evolutions is the selection of two different SNPs in the ribosome 
recycling factor frr. A different mutation that those obtained in this work has been previously found in frr 
after a similar 35-days experimental evolution in the presence of tigecycline in Pseudomonas aeruginosa, 32 
confirming that modifications in the ribosome result in tigecycline resistance. Other ribosome-related genes 
selected in this study have been previously reported to cause antibiotic resistance in other bacterial species. 
For instance, rpsJ, which encodes for the 30S ribosomal protein S10, has been described as a general marker 
of adaptation and reduced susceptibility to tigecycline, 33 since mutations in this gene have been detected 
after experimental evolutions in the presence of this antibiotic in different bacterial pathogens, 32-34 as well 
as in tigecycline-resistant K. pneumoniae clinical isolates. 35 Furthermore, an V57L amino acid substitution 
in RpsJ has been recently detected in a K. pneumoniae clinical isolate from a patient undergoing tigecycline 
therapy, indicating that tigecycline resistance can occur in vivo through the selection of mutations in the 
ribosomal S10-coding gene. 36 Mutations in the genes encoding the 30S ribosomal proteins S21 (rpsU) and 
S1 (rpsA) have also been detected. In contrast to frr and rpsJ, this is the first time that rpsU and rpsA are 
identified to have a role in tigecycline resistance.   
Tigecycline exposure has also driven to the selection of mutations in different S. maltophilia genes involved 
in the LPS biosynthesis and membrane homeostasis. LPS is a major component of the outer membrane in 
Gram-negatives, being involved in pathogen-host interactions during infections, antimicrobials resistance 
and virulence. 37-39 In our study, amino acid substitutions were found in the lipid A biosynthetic enzymes 
lauroyl acyltransferase (htrB) and phosphoethanolamine transferase (SMD_RS16325). HtrB performs one of 
the last modifications that lipid A suffers before being transported to the outer membrane. 40 Regarding 
antibiotic resistance, we found two amino acid changes (V236I and D246N) in the HtrB protein of a 
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tigecycline-resistant K. pneumoniae clinical isolate from a patient with bacteraemia through a search in the 
Pathosystems Resource Integration Center (PATRIC) database. 41 Nevertheless, the particular contribution 
of these mutations to the tigecycline resistance phenotype is unknown. Besides, mutants of P. aeruginosa 
lacking two htrB homologs display a phenotype of increased susceptibility to antimicrobial peptides and cell 
wall inhibitor antibiotics. 42 SMD_RS16325, a homolog of the E. coli phosphoethanolamine transferase 
EptA, modifies the 1 and 4’ headgroups of the lipid A with phosphoethanolamine. 43 Mutants of Neisseria 
gonorrhoeae lacking its EptA homolog (LptA) show an increased susceptibility to antimicrobial peptides 
and an attenuated colonization of mice genital tract and human urethra. 44 Other LPS-related genes that were 
found mutated after the tigecycline challenge were ugd, encoding an UDP-glucose dehydrogenase that 
converts UDP-glucose into the UDP-glucuronic acid necessary for the synthesis of extracellular 
polysaccharides and LPS in many pathogenic bacteria; 45,46 and the two-component sensor histidine kinase 
phoQ, reported to be involved in polymyxin resistance through lipid A modification in P. aeruginosa isolates 
from cystic fibrosis patients. 47 A 6-bp insertion was also detected in the diacylglycerol kinase-coding gene 
(dgkA), which is involved in the synthesis of phosphatidic acid, the universal precursor of phospholipids. 48 
Although the mechanism of tigecycline uptake by the cell is not known, it is generally assumed that it follows 
the same pathway as tetracycline, either by diffusing through the outer membrane lipid barrier or via porins. 
49,50 It is possible that mutations occurring in LPS-related genes lead to modifications of the bacterial outer 
membrane, preventing the uptake of tigecycline, assuming that it diffuses through the membrane, and 
explaining the observed increment of resistance against this antibiotic. 23 
Genetic modifications were also found in other S. maltophilia enzymes. For instance, a V117A change was 
detected in speD, which encodes a S-adenosylmethionine decarboxylase involved in the synthesis of 
polyamines. 51 Polyamines are polycationic compounds that modulate gene expression leading to optimal 
cell growth and defense against adverse conditions. 52,53 Mutations in speD have been linked to high-level 
resistance against the aminoglycoside kasugamycin in Bacillus subtilis. 54 Also, a A20V change was detected 
in the dsbB gene. The DsbA/DsbB system mediates the disulfide bonds formation, required for protein 
stability, activity and folding of a wide range of proteins, including those involved in virulence. 55 dsbB 
mutants present an attenuated virulence and an increase sensitivity to a variety of antibiotics in other bacterial 
species. 56,57 Although the molecular mechanisms by which these mutations lead to tigecycline resistance in 
S. maltophilia remain to be clarified, our data highlight the variety of resources that this bacterium has to 
overcome tigecycline exposure.  
A fact to be highlighted from this work is the presence of two inverted duplications comprising 262 and 53 
genes, respectively (Supplementary Table S2). A wide variety of genes, including transporters, two-
component systems, transcriptional regulators and enzymes, are included in these regions and might 
potentially contribute to tigecycline resistance. Genome rearrangements, such as deletions, duplications or 
large chromosomal inversions, as the ones present in our study, are responsible of chromosomal stability and 
variation, which can be relevant for niche occupation and/or adaptation in pathogenic and non-pathogenic 
bacteria. 58,59 Besides, gene inversion can lead to an increased bacterial virulence and drug resistance, 
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promoting as well bacterial evolvability. 60 Notwithstanding the fact that these chromosomal rearrangements 
arise frequently, they are usually lost due to its instability. 61 However, in our experiment, the 300-kbp 
duplication-inversion is first detected at day 20 and maintained until the end of the evolution, suggesting that 
it confers a selective advantage to bacteria growing in the presence of tigecycline. Further, the 53 genes from 
the 60-kpb duplicated-inverted region in population D are also included in the 300-kbp sequence from 
population C, suggesting that in this region there might be genes whose duplication and/or inversion causes 
an increment in tigecycline resistance or a fitness cost compensation. 
The acquisition of mutations in relevant resistance determinants may imply that the susceptibility to other 
antibiotics might be affected as well. To test this possibility, the susceptibility to other antibiotics belonging 
to different families was assessed in all the tigecycline-evolved populations. The observed cross-resistance 
to quinolones, chloramphenicol, erythromycin and tetracycline in all the populations is consistent with the 
fact that these antimicrobials are substrates of SmeDEF, which would be overexpressed because of smeT 
mutation. 62 Acquisition of tetracycline resistance can also be explained by the selected mutations in some 
ribosome-related genes, which might be also a target of this antibiotic, 63 as well as of streptomycin. 64 
Remarkably, all the evolved populations show an increased susceptibility to fosfomycin in comparison with 
the parental strain. This is in agreement with the study of Sanz-García et al., 32 where exposure to tigecycline 
renders high susceptibility to fosfomycin in P. aeruginosa. Besides these common features, we also found 
some differences in the susceptibilities to other antibiotics. For instance, populations C and D displayed a 
higher susceptibility to SXT and aztreonam, respectively, despite the fact that populations A, B and C showed 
an increased resistance to the last one. These results suggest that the different mutational trajectories render 
different outcomes regarding susceptibility to other antibiotics, not used in selection.  
One of the key factors that influences the emergence and persistence of antibiotic resistant bacteria is the 
resistance-associated fitness cost. The acquisition of resistance entails a fitness advantage in the presence of 
antibiotics in comparison with its susceptible counterpart. Nevertheless, in the absence of selective pressure, 
antibiotic resistance may lead to a fitness burden, thus resistant bacteria would be outcompeted by the 
susceptible ones. 65,66 Our data show that, in the absence of tigecycline, the four evolved populations, as well 
as the single isolated clones, present a considerable fitness cost. Although we have highlighted the role of 
several of these mutations in antimicrobial resistance, it is possible that some of them were selected in order 
to compensate these costs. These results suggest that, in the absence of antibiotics, it could be difficult for 
these mutants to be maintained in the overall susceptible population. Nevertheless, they will re-emerge when 
S. maltophilia is confronted to antibiotic selective pressure, being an example of short-sighted evolution. 67 
The use of tigecycline in combination with quinolones have been proposed for treating S. maltophilia 
infections. 68 Our findings that all evolved populations present increased quinolones MICs introduces some 
concerns on this possibility. However, tigecycline/fosfomycin combinations might be taken into 
consideration since all tigecycline-resistant populations present fosfomycin collateral susceptibility. Finally, 
the fact that smeDEF overexpression stands as a major element in quinolones, SXT and tigecycline 
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resistance, which are the most useful antibiotics against S. maltophilia, is of special concern since, once a 
smeDEF-overexpressing mutant is selected by the treatment with any of these antibiotics, it will be resistant 
to all of them. 
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Name Sequence (5’-3’) Utilization 
smeT_L GAGGGAGCTGATATCGATGG Verification of L166Q 
and T197P in smeT smeT_R GATGGGAGCAGCCTCGTT 
frr_L CGTCCCGTATTCGCCTATAA Verification of T50P 
and P90Q in frr frr_R GAAGGCATCGACTTCAGACC 
smd_3146_L CTACATGAGCCGCTACCACA Verification of S284L 
in SMD_RS16325 smd_3146_R CAGGATCTCGTCCATGCAG 
rpsU_L TCGCATGCCTGCTATTATGA Verification of E24L in 
rpsU rpsU_R GAACCTCGTGGTGGTAGGTG 
rpsJ_L AGGTCCATGGAGTGACCTTG Verification of V73G in 
rpsJ 
rpsJ_R GGCCATCTTCGGTGAACA 
htrB_L GTAGAATGGCCCCATGTCAG Verification of H290R 
in htrB htrB_R CACCGCATCCGATTATTTGT 
speD_L GCCAGAACTCTTGCGTCTTC Verification of V117A 
in speD speD_R GGCTTACTCGGACAGGTTCC 
smd_0534_L TTTTGGCACGTTGGTGAGTA Verification of Gln364* 
in SMD_RS02920 smd_0534_R AGGTTGGAGATGGACTGTGG 
hutI_L GAGGAATGCCGGGTCAAC Verification of G283D 
in hutI  hutI_R TGGAGCAACACATGAGCAA 
	phoQ_tig3_L CGAATTCCCGTACACCATCT Verification of V279L 
in phoQ phoQ_tig3_R CACTTGAAGGCGTTCTCCAG 
dsbB_2_L GCTCTCGGTTACGCTTGG Verification of A20V in 
dsbB dsbB_2_R GACCCCATCCTGCTTCA 
smd_3368_L CCTGTATCGTTCAGCAGGTA Verification of L54fs in 
ompR smd_3368_R ATCAGCGGCACTTCAAAC 
rpsA_L GTTCTCGCTGACCGTGCT Verification of N463fs 
in rpsA rpsA_R GTGAACAACATTGCCGACAG 
cheY_L TGGTACGAACTTCCGTGGAT Verification of E21K in 
cheY cheY_R CGACACTGAATACTGCAATCG 
smd_2759_L CCTGCCGTAAGCGACCAC Verification of F66S in 
ugd smd_2759_R ATCTTGGTCGCCAGCATC 
dgkA_L AAGGGGAGCTCCATCATAG Verification of 
L71_A72insVL in dgkA dgkA_R ATGGAAATGAACACCAGGTT 
TigC_1_L GGTGGTCCTTCCTGCTTG Verification of the 
inverted duplication in 
lineage C TigC_2_L CCAGGAGCAGATCGAGATT 
	 	
	Ta
bl
e 
S2
. G
en
es
 in
cl
ud
ed
 in
 th
e 
in
ve
rt
ed
 d
up
lic
at
io
ns
 o
f t
he
 e
vo
lv
ed
 p
op
ul
at
io
ns
 C
 a
nd
 D
 
	
C
hr
om
os
om
e 
re
gi
on
 
G
en
e 
L
oc
us
 ta
g 
Pr
ot
ei
n 
na
m
e 
Po
pu
la
tio
n 
13
30
80
9 
13
33
60
7 
- 
SM
D
_R
S0
63
00
 T
on
B
-d
ep
en
de
nt
 re
ce
pt
or
 
C
 
13
33
62
2 
13
34
59
0 
- 
SM
D
_R
S0
63
05
 D
U
F4
88
0 
do
m
ai
n-
co
nt
ai
ni
ng
 p
ro
te
in
 
C
 
13
34
58
7 
13
35
12
0 
- 
SM
D
_R
S0
63
10
 s
ig
m
a-
70
 fa
m
ily
 R
N
A
 p
ol
ym
er
as
e 
si
gm
a 
fa
ct
or
 
C
 
13
35
35
3 
13
38
22
6 
- 
SM
D
_R
S0
63
15
 a
ut
ot
ra
ns
po
rte
r d
om
ai
n-
co
nt
ai
ni
ng
 p
ro
te
in
 
C
 
13
38
32
4 
13
39
32
5 
- 
SM
D
_R
S0
63
20
 2
-h
yd
ro
xy
ac
id
 d
eh
yd
ro
ge
na
se
 
C
 
13
39
54
7 
13
44
93
4 
- 
SM
D
_R
S2
20
10
 R
H
S 
re
pe
at
 p
ro
te
in
 
C
 
13
44
90
3 
13
45
87
1 
- 
SM
D
_R
S2
22
60
 h
yp
ot
he
tic
al
 p
ro
te
in
 
C
 
13
45
87
5 
13
46
48
9 
- 
SM
D
_R
S2
22
65
 D
U
F4
16
 fa
m
ily
 p
ro
te
in
 
C
 
13
46
56
8 
13
46
97
8 
- 
SM
D
_R
S2
27
75
 h
yp
ot
he
tic
al
 p
ro
te
in
 
C
 
13
46
98
9 
13
47
95
7 
- 
SM
D
_R
S2
22
70
 h
yp
ot
he
tic
al
 p
ro
te
in
 
C
 
13
47
95
4 
13
48
28
0 
- 
SM
D
_R
S0
63
35
 h
yp
ot
he
tic
al
 p
ro
te
in
 
C
 
13
48
53
5 
13
48
87
0 
- 
SM
D
_R
S0
63
45
 h
yp
ot
he
tic
al
 p
ro
te
in
 
C
 
13
48
88
4 
13
49
51
9 
- 
SM
D
_R
S0
63
50
 h
yp
ot
he
tic
al
 p
ro
te
in
 
C
 
13
49
87
5 
13
50
91
5 
cy
oA
 
SM
D
_R
S0
63
55
 M
U
LT
IS
PE
C
IE
S:
 u
bi
qu
in
ol
 o
xi
da
se
 su
bu
ni
t I
I 
C
 
13
50
91
8 
13
52
91
5 
cy
oB
 
SM
D
_R
S0
63
60
 c
yt
oc
hr
om
e 
o 
ub
iq
ui
no
l o
xi
da
se
 su
bu
ni
t I
 
C
 
13
52
91
2 
13
53
55
0 
cy
oC
 
SM
D
_R
S0
63
65
 c
yt
oc
hr
om
e 
o 
ub
iq
ui
no
l o
xi
da
se
 su
bu
ni
t I
II
 
C
 
13
53
55
0 
13
53
89
1 
cy
oD
 
SM
D
_R
S0
63
70
 M
U
LT
IS
PE
C
IE
S:
 c
yt
oc
hr
om
e 
o 
ub
iq
ui
no
l o
xi
da
se
 su
bu
ni
t I
V
 
C
 
13
54
24
9 
13
56
30
6 
- 
SM
D
_R
S0
63
75
 b
ifu
nc
tio
na
l d
ig
ua
ny
la
te
 c
yc
la
se
/p
ho
sp
ho
di
es
te
ra
se
 
C
 
13
56
45
6 
13
57
83
2 
- 
SM
D
_R
S0
63
80
 M
U
LT
IS
PE
C
IE
S:
 D
N
A
 re
pa
ir 
pr
ot
ei
n 
R
ad
A
 
C
 
13
57
96
8 
13
59
82
7 
- 
SM
D
_R
S0
63
85
 h
is
tid
in
e 
ki
na
se
 
C
 
13
59
87
6 
13
62
18
2 
- 
SM
D
_R
S0
63
90
 h
yp
ot
he
tic
al
 p
ro
te
in
 
C
 
13
62
29
0 
13
62
75
4 
- 
SM
D
_R
S0
63
95
 h
yp
ot
he
tic
al
 p
ro
te
in
 
C
 
13
62
85
4 
13
63
64
8 
- 
SM
D
_R
S0
64
00
 m
em
br
an
e 
pr
ot
ei
n 
C
 
	1
36
37
71
 
13
65
14
7 
- 
SM
D
_R
S0
64
05
 M
U
LT
IS
PE
C
IE
S:
 si
gn
al
 re
co
gn
iti
on
 p
ar
tic
le
 p
ro
te
in
 
C
 
13
65
29
6 
13
66
37
2 
- 
SM
D
_R
S0
64
10
 n
itr
on
at
e 
m
on
oo
xy
ge
na
se
 
C
 
13
66
36
9 
13
67
18
1 
- 
SM
D
_R
S0
64
15
 a
m
in
ot
ra
ns
fe
ra
se
 
C
 
13
67
29
3 
13
67
55
3 
- 
SM
D
_R
S0
64
20
 M
U
LT
IS
PE
C
IE
S:
 3
0S
 ri
bo
so
m
al
 p
ro
te
in
 S
16
 
C
 
13
67
59
8 
13
68
11
0 
- 
SM
D
_R
S0
64
25
 M
U
LT
IS
PE
C
IE
S:
 ri
bo
so
m
e 
m
at
ur
at
io
n 
fa
ct
or
 R
im
M
 
C
 
13
68
11
9 
13
68
87
7 
- 
SM
D
_R
S0
64
30
 t
R
N
A
 (g
ua
no
si
ne
(3
7)
-N
1)
-m
et
hy
ltr
an
sf
er
as
e 
Tr
m
D
 
C
 
13
69
03
2 
13
69
43
3 
- 
SM
D
_R
S0
64
35
 M
U
LT
IS
PE
C
IE
S:
 5
0S
 ri
bo
so
m
al
 p
ro
te
in
 L
19
 
C
 
13
69
51
6 
13
69
89
6 
- 
SM
D
_R
S0
64
40
 h
yp
ot
he
tic
al
 p
ro
te
in
 
C
 
13
69
97
6 
13
70
41
0 
- 
SM
D
_R
S0
64
45
 D
U
F1
80
1 
do
m
ai
n-
co
nt
ai
ni
ng
 p
ro
te
in
 
C
 
13
70
44
9 
13
70
85
6 
- 
SM
D
_R
S0
64
50
 D
U
F1
80
1 
do
m
ai
n-
co
nt
ai
ni
ng
 p
ro
te
in
 
C
 
13
70
97
4 
13
72
43
4 
- 
SM
D
_R
S0
64
55
 M
A
TE
 fa
m
ily
 e
ff
lu
x 
tra
ns
po
rte
r 
C
 
13
72
49
7 
13
72
73
6 
- 
SM
D
_R
S0
64
60
 h
yp
ot
he
tic
al
 p
ro
te
in
 
C
 
13
72
74
6 
13
73
15
3 
- 
SM
D
_R
S0
64
65
 R
N
A
-b
in
di
ng
 S
4 
do
m
ai
n-
co
nt
ai
ni
ng
 p
ro
te
in
 
C
 
13
73
19
2 
13
73
79
4 
- 
SM
D
_R
S0
64
70
 D
U
F9
37
 d
om
ai
n-
co
nt
ai
ni
ng
 p
ro
te
in
 
C
 
13
73
90
3 
13
75
54
6 
- 
SM
D
_R
S0
64
75
 c
at
al
as
e 
C
 
13
75
73
6 
13
78
32
7 
m
ut
S 
SM
D
_R
S0
64
80
 D
N
A
 m
is
m
at
ch
 re
pa
ir 
pr
ot
ei
n 
M
ut
S 
C
 
13
78
46
3 
13
78
85
5 
- 
SM
D
_R
S0
64
85
 h
yp
ot
he
tic
al
 p
ro
te
in
 
C
 
13
79
18
5 
13
79
37
6 
- 
SM
D
_R
S0
64
90
 h
yp
ot
he
tic
al
 p
ro
te
in
 
C
 
13
79
65
9 
13
79
85
0 
- 
SM
D
_R
S0
64
95
 h
yp
ot
he
tic
al
 p
ro
te
in
 
C
 
13
79
84
9 
13
80
28
6 
- 
SM
D
_R
S0
65
00
 h
yp
ot
he
tic
al
 p
ro
te
in
 
C
 
13
80
48
2 
13
80
80
2 
- 
SM
D
_R
S0
65
05
 h
yp
ot
he
tic
al
 p
ro
te
in
 
C
 
13
80
80
3 
13
80
98
5 
- 
SM
D
_R
S2
22
75
 D
U
F5
96
 d
om
ai
n-
co
nt
ai
ni
ng
 p
ro
te
in
 
C
 
13
81
27
6 
13
83
49
8 
- 
SM
D
_R
S0
65
10
 m
et
hy
l-a
cc
ep
tin
g 
ch
em
ot
ax
is
 p
ro
te
in
 
C
 
13
83
66
5 
13
84
03
3 
- 
SM
D
_R
S0
65
15
 M
U
LT
IS
PE
C
IE
S:
 g
ly
ci
ne
 z
ip
pe
r 2
TM
 d
om
ai
n-
co
nt
ai
ni
ng
 p
ro
te
in
 
C
 
13
84
16
2 
13
85
28
9 
- 
SM
D
_R
S0
65
20
 A
B
C
 tr
an
sp
or
te
r p
er
m
ea
se
 
C
 
13
85
28
6 
13
86
47
3 
- 
SM
D
_R
S0
65
25
 A
B
C
 tr
an
sp
or
te
r p
er
m
ea
se
 
C
 
	1
38
64
58
 
13
87
47
1 
- 
SM
D
_R
S0
65
30
 H
ly
D
 fa
m
ily
 e
ff
lu
x 
tra
ns
po
rte
r p
er
ip
la
sm
ic
 a
da
pt
or
 su
bu
ni
t 
C
 
13
87
46
4 
13
88
86
4 
- 
SM
D
_R
S0
65
35
 T
ol
C
 fa
m
ily
 p
ro
te
in
 
C
 
13
88
94
3 
13
89
83
6 
- 
SM
D
_R
S0
65
40
 L
ys
R
 fa
m
ily
 tr
an
sc
rip
tio
na
l r
eg
ul
at
or
 A
rg
P 
C
 
13
89
94
3 
13
90
55
7 
- 
SM
D
_R
S0
65
45
 a
m
in
o 
ac
id
 tr
an
sp
or
te
r 
C
 
13
90
55
4 
13
91
34
2 
m
ap
 
SM
D
_R
S0
65
50
 t
yp
e 
I m
et
hi
on
yl
 a
m
in
op
ep
tid
as
e 
C
 
13
91
34
4 
13
91
55
6 
- 
SM
D
_R
S0
65
55
 h
yp
ot
he
tic
al
 p
ro
te
in
 
C
 
13
91
62
5 
13
91
98
4 
- 
SM
D
_R
S0
65
60
 V
O
C
 fa
m
ily
 p
ro
te
in
 
C
 
13
92
12
4 
13
93
00
8 
- 
SM
D
_R
S0
65
65
 h
yp
ot
he
tic
al
 p
ro
te
in
 
C
 
13
93
01
2 
13
94
07
6 
- 
SM
D
_R
S0
65
70
 G
N
A
T 
fa
m
ily
 N
-a
ce
ty
ltr
an
sf
er
as
e 
C
 
13
94
10
5 
13
95
50
5 
- 
SM
D
_R
S0
65
75
 a
m
in
ot
ra
ns
fe
ra
se
 c
la
ss
 II
I-
fo
ld
 p
yr
id
ox
al
 p
ho
sp
ha
te
-d
ep
en
de
nt
 e
nz
ym
e 
C
 
13
95
57
0 
13
96
28
6 
- 
SM
D
_R
S0
65
80
 p
ho
sp
ha
ta
se
 
C
 
13
96
45
5 
13
97
66
3 
- 
SM
D
_R
S0
65
85
 n
uc
le
ot
id
e 
su
ga
r a
m
in
ot
ra
ns
fe
ra
se
 
C
 
13
97
67
4 
13
98
07
2 
- 
SM
D
_R
S0
65
90
 E
am
A
 fa
m
ily
 tr
an
sp
or
te
r 
C
 
13
98
06
9 
13
98
42
8 
- 
SM
D
_R
S0
65
95
 M
U
LT
IS
PE
C
IE
S:
 m
em
br
an
e 
pr
ot
ei
n 
C
 
13
98
43
0 
13
99
26
6 
- 
SM
D
_R
S0
66
00
 a
lp
ha
/b
et
a 
fo
ld
 h
yd
ro
la
se
 
C
 
13
99
34
7 
14
00
72
6 
- 
SM
D
_R
S0
66
05
 s
en
so
r h
is
tid
in
e 
ki
na
se
 
C
 
14
00
72
3 
14
01
40
6 
- 
SM
D
_R
S0
66
10
 r
es
po
ns
e 
re
gu
la
to
r 
C
 
14
01
54
0 
14
02
66
7 
- 
SM
D
_R
S0
66
15
 m
et
al
lo
ph
os
ph
oe
st
er
as
e 
C
 
14
02
74
1 
14
03
19
0 
- 
SM
D
_R
S0
66
20
 t
ra
ns
cr
ip
tio
na
l r
eg
ul
at
or
 
C
 
14
03
20
5 
14
04
46
7 
- 
SM
D
_R
S0
66
25
 M
FS
 tr
an
sp
or
te
r 
C
 
14
04
56
3 
14
05
97
8 
- 
SM
D
_R
S0
66
30
 d
ig
ua
ny
la
te
 c
yc
la
se
 
C
 
14
06
26
5 
14
08
51
4 
- 
SM
D
_R
S0
66
35
 T
on
B
-d
ep
en
de
nt
 si
de
ro
ph
or
e 
re
ce
pt
or
 
C
 
14
08
69
8 
14
09
67
8 
- 
SM
D
_R
S0
66
40
 c
at
io
n 
tra
ns
po
rte
r 
C
 
14
09
71
7 
14
10
39
1 
- 
SM
D
_R
S0
66
45
 d
eo
xy
rib
on
uc
le
as
e 
V
 
C
 
14
10
48
5 
14
11
23
4 
gp
m
A 
SM
D
_R
S0
66
50
 M
U
LT
IS
PE
C
IE
S:
 2
,3
-d
ip
ho
sp
ho
gl
yc
er
at
e-
de
pe
nd
en
t p
ho
sp
ho
gl
yc
er
at
e 
m
ut
as
e 
C
 
	1
41
13
45
 
14
11
81
2 
- 
SM
D
_R
S0
66
55
 h
yp
ot
he
tic
al
 p
ro
te
in
 
C
 
14
11
94
4 
14
14
03
7 
- 
SM
D
_R
S0
66
60
 M
13
 fa
m
ily
 p
ep
tid
as
e 
C
 
14
14
23
8 
14
14
85
5 
- 
SM
D
_R
S0
66
65
 H
D
 d
om
ai
n-
co
nt
ai
ni
ng
 p
ro
te
in
 
C
 
14
14
90
1 
14
18
36
5 
- 
SM
D
_R
S0
66
70
 t
ra
ns
cr
ip
tio
n-
re
pa
ir 
co
up
lin
g 
fa
ct
or
 
C
 
14
18
51
5 
14
19
06
0 
- 
SM
D
_R
S0
66
75
 M
U
LT
IS
PE
C
IE
S:
 G
N
A
T 
fa
m
ily
 N
-a
ce
ty
ltr
an
sf
er
as
e 
C
 
14
19
15
6 
14
20
01
3 
- 
SM
D
_R
S0
66
80
 2
3S
 rR
N
A
 (a
de
ni
ne
(2
03
0)
-N
(6
))
-m
et
hy
ltr
an
sf
er
as
e 
R
lm
J 
C
 
14
20
04
9 
14
20
77
4 
- 
SM
D
_R
S0
66
85
 t
w
o-
co
m
po
ne
nt
 sy
st
em
 re
sp
on
se
 re
gu
la
to
r C
re
B
 
C
 
14
20
77
8 
14
22
23
8 
- 
SM
D
_R
S0
66
90
 t
w
o-
co
m
po
ne
nt
 sy
st
em
 se
ns
or
 h
is
tid
in
e 
ki
na
se
 C
re
C
 
C
 
14
22
32
0 
14
23
63
9 
- 
SM
D
_R
S0
66
95
 c
el
l e
nv
el
op
e 
in
te
gr
ity
 p
ro
te
in
 C
re
D
 
C
 
14
23
65
0 
14
24
06
0 
- 
SM
D
_R
S0
67
00
 h
yp
ot
he
tic
al
 p
ro
te
in
 
C
 
14
24
21
6 
14
25
80
8 
- 
SM
D
_R
S0
67
05
 M
20
/M
25
/M
40
 fa
m
ily
 m
et
al
lo
-h
yd
ro
la
se
 
C
 a
nd
 D
 
14
25
96
3 
14
27
36
6 
- 
SM
D
_R
S0
67
10
 g
lu
ta
m
at
e-
-tR
N
A
 li
ga
se
 
C
 a
nd
 D
 
14
27
40
1 
14
27
89
2 
- 
SM
D
_R
S0
67
15
 M
U
LT
IS
PE
C
IE
S:
 F
ur
 fa
m
ily
 tr
an
sc
rip
tio
na
l r
eg
ul
at
or
 
C
 a
nd
 D
 
14
28
00
4 
14
29
15
8 
- 
SM
D
_R
S0
67
20
 H
ly
D
 fa
m
ily
 se
cr
et
io
n 
pr
ot
ei
n 
C
 a
nd
 D
 
14
29
16
7 
14
30
84
0 
- 
SM
D
_R
S0
67
25
 M
FS
 tr
an
sp
or
te
r 
C
 a
nd
 D
 
14
30
84
0 
14
31
40
6 
- 
SM
D
_R
S0
67
30
 T
et
R
/A
cr
R
 fa
m
ily
 tr
an
sc
rip
tio
na
l r
eg
ul
at
or
 
C
 a
nd
 D
 
14
31
60
6 
14
33
81
6 
- 
SM
D
_R
S0
67
35
 T
on
B
-d
ep
en
de
nt
 re
ce
pt
or
 
C
 a
nd
 D
 
14
33
95
3 
14
34
36
6 
- 
SM
D
_R
S0
67
40
 M
U
LT
IS
PE
C
IE
S:
 M
er
C
 d
om
ai
n-
co
nt
ai
ni
ng
 p
ro
te
in
 
C
 a
nd
 D
 
14
34
47
7 
14
34
65
6 
- 
SM
D
_R
S0
67
45
 M
U
LT
IS
PE
C
IE
S:
 3
0S
 ri
bo
so
m
al
 p
ro
te
in
 T
H
X
 
C
 a
nd
 D
 
14
34
78
7 
14
36
03
7 
- 
SM
D
_R
S0
67
50
 a
lk
al
in
e 
ph
os
ph
at
as
e 
fa
m
ily
 p
ro
te
in
 
C
 a
nd
 D
 
14
36
14
2 
14
36
63
3 
- 
SM
D
_R
S0
67
55
 m
et
hy
la
te
d-
D
N
A
- 
C
 a
nd
 D
 
14
36
63
0 
14
38
10
8 
- 
SM
D
_R
S0
67
60
 D
N
A
-3
-m
et
hy
la
de
ni
ne
 g
ly
co
sy
la
se
 2
 fa
m
ily
 p
ro
te
in
 
C
 a
nd
 D
 
14
38
57
9 
14
39
74
2 
- 
SM
D
_R
S0
67
65
 h
yp
ot
he
tic
al
 p
ro
te
in
 
C
 a
nd
 D
 
14
39
80
1 
14
40
34
6 
- 
SM
D
_R
S0
67
70
 D
U
F4
01
9 
do
m
ai
n-
co
nt
ai
ni
ng
 p
ro
te
in
 
C
 a
nd
 D
 
14
40
35
8 
14
40
74
7 
- 
SM
D
_R
S0
67
75
 m
em
br
an
e 
pr
ot
ei
n 
C
 a
nd
 D
 
14
40
82
7 
14
42
00
5 
- 
SM
D
_R
S0
67
80
 F
A
D
-d
ep
en
de
nt
 h
yd
ro
xy
la
se
 
C
 a
nd
 D
 
	1
44
20
17
 
14
42
23
8 
- 
SM
D
_R
S0
67
85
 M
U
LT
IS
PE
C
IE
S:
 R
N
A
-b
in
di
ng
 S
4 
do
m
ai
n-
co
nt
ai
ni
ng
 p
ro
te
in
 
C
 a
nd
 D
 
14
42
50
5 
14
44
44
2 
- 
SM
D
_R
S0
67
90
 D
EA
D
/D
EA
H
 b
ox
 h
el
ic
as
e 
C
 a
nd
 D
 
14
44
66
1 
14
47
08
4 
- 
SM
D
_R
S0
67
95
 E
A
L 
do
m
ai
n-
co
nt
ai
ni
ng
 p
ro
te
in
 
C
 a
nd
 D
 
14
47
19
4 
14
48
85
8 
- 
SM
D
_R
S0
68
00
 d
ig
ua
ny
la
te
 c
yc
la
se
 
C
 a
nd
 D
 
14
48
89
3 
14
49
61
5 
- 
SM
D
_R
S0
68
05
 p
se
ud
ou
rid
in
e 
sy
nt
ha
se
 
C
 a
nd
 D
 
14
49
73
3 
14
50
80
3 
- 
SM
D
_R
S0
68
10
 s
en
so
r d
om
ai
n-
co
nt
ai
ni
ng
 d
ig
ua
ny
la
te
 c
yc
la
se
 
C
 a
nd
 D
 
14
50
94
6 
14
52
10
6 
- 
SM
D
_R
S0
68
15
 A
TP
-b
in
di
ng
 p
ro
te
in
 
C
 a
nd
 D
 
14
52
13
7 
14
53
08
4 
- 
SM
D
_R
S0
68
20
 D
M
T 
fa
m
ily
 tr
an
sp
or
te
r 
C
 a
nd
 D
 
14
53
16
4 
14
53
77
8 
- 
SM
D
_R
S0
68
25
 h
yp
ot
he
tic
al
 p
ro
te
in
 
C
 a
nd
 D
 
14
53
69
9 
14
54
57
4 
- 
SM
D
_R
S0
68
30
 D
U
F7
2 
do
m
ai
n-
co
nt
ai
ni
ng
 p
ro
te
in
 
C
 a
nd
 D
 
14
54
57
1 
14
55
01
4 
- 
SM
D
_R
S0
68
35
 g
ly
ox
al
as
e 
C
 a
nd
 D
 
14
55
12
5 
14
56
68
7 
- 
SM
D
_R
S0
68
40
 s
er
in
e 
hy
dr
ol
as
e 
C
 a
nd
 D
 
14
56
84
4 
14
58
67
6 
- 
SM
D
_R
S0
68
45
 m
ul
tid
ru
g 
ef
flu
x 
A
B
C
 tr
an
sp
or
te
r S
m
rA
 
C
 a
nd
 D
 
14
58
73
5 
14
59
85
9 
- 
SM
D
_R
S0
68
50
 h
yp
ot
he
tic
al
 p
ro
te
in
 
C
 a
nd
 D
 
14
59
79
3 
14
60
77
0 
- 
SM
D
_R
S0
68
55
 h
yp
ot
he
tic
al
 p
ro
te
in
 
C
 a
nd
 D
 
14
62
06
3 
14
63
33
1 
- 
SM
D
_R
S0
68
60
 b
ifu
nc
tio
na
l g
lu
co
se
-1
-p
ho
sp
ha
ta
se
/in
os
ito
l p
ho
sp
ha
ta
se
 
C
 a
nd
 D
 
14
63
34
1 
14
64
33
9 
- 
SM
D
_R
S0
68
65
 p
ol
ys
ac
ch
ar
id
e 
ly
as
e 
C
 a
nd
 D
 
14
64
55
1 
14
64
78
7 
- 
SM
D
_R
S0
68
70
 h
yp
ot
he
tic
al
 p
ro
te
in
 
C
 a
nd
 D
 
14
64
87
7 
14
66
68
5 
- 
SM
D
_R
S0
68
75
 D
U
F8
85
 d
om
ai
n-
co
nt
ai
ni
ng
 p
ro
te
in
 
C
 a
nd
 D
 
14
66
79
8 
14
67
15
4 
- 
SM
D
_R
S0
68
80
 G
FA
 fa
m
ily
 p
ro
te
in
 
C
 a
nd
 D
 
14
67
15
1 
14
67
96
6 
- 
SM
D
_R
S0
68
85
 D
U
F4
34
9 
do
m
ai
n-
co
nt
ai
ni
ng
 p
ro
te
in
 
C
 a
nd
 D
 
14
67
99
8 
14
68
27
6 
- 
SM
D
_R
S0
68
90
 h
yp
ot
he
tic
al
 p
ro
te
in
 
C
 a
nd
 D
 
14
68
36
0 
14
69
30
4 
- 
SM
D
_R
S0
68
95
 L
ys
R
 fa
m
ily
 tr
an
sc
rip
tio
na
l r
eg
ul
at
or
 
C
 a
nd
 D
 
14
69
42
0 
14
70
29
2 
- 
SM
D
_R
S0
69
00
 D
M
T 
fa
m
ily
 tr
an
sp
or
te
r 
C
 a
nd
 D
 
14
70
88
1 
14
71
78
3 
- 
SM
D
_R
S0
69
05
 p
ep
tid
yl
pr
ol
yl
 is
om
er
as
e 
C
 a
nd
 D
 
14
71
92
0 
14
72
28
5 
- 
SM
D
_R
S0
69
10
 M
U
LT
IS
PE
C
IE
S:
 P
ad
R
 fa
m
ily
 tr
an
sc
rip
tio
na
l r
eg
ul
at
or
 
C
 a
nd
 D
 
	1
47
22
82
 
14
73
27
1 
- 
SM
D
_R
S0
69
15
 m
em
br
an
e 
pr
ot
ei
n 
C
 a
nd
 D
 
14
73
38
2 
14
74
68
9 
- 
SM
D
_R
S0
69
20
 p
ol
yh
yd
ro
xy
al
ka
no
at
e 
de
po
ly
m
er
as
e 
C
 a
nd
 D
 
14
74
78
3 
14
75
37
3 
- 
SM
D
_R
S0
69
25
 c
la
ss
 I 
SA
M
-d
ep
en
de
nt
 m
et
hy
ltr
an
sf
er
as
e 
C
 a
nd
 D
 
14
75
52
3 
14
75
97
8 
- 
SM
D
_R
S0
69
30
 m
em
br
an
e 
pr
ot
ei
n 
C
 a
nd
 D
 
14
76
11
8 
14
77
07
7 
- 
SM
D
_R
S0
69
35
 a
ce
ty
l-C
oA
 c
ar
bo
xy
la
se
 c
ar
bo
xy
l t
ra
ns
fe
ra
se
 su
bu
ni
t a
lp
ha
 
C
 a
nd
 D
 
14
77
19
1 
14
78
06
0 
- 
SM
D
_R
S0
69
40
 h
yp
ot
he
tic
al
 p
ro
te
in
 
C
 a
nd
 D
 
14
78
12
5 
14
81
71
5 
- 
SM
D
_R
S0
69
45
 D
N
A
 p
ol
ym
er
as
e 
II
I s
ub
un
it 
al
ph
a 
C
 a
nd
 D
 
14
81
95
3 
14
82
61
2 
- 
SM
D
_R
S0
69
50
 r
ib
on
uc
le
as
e 
H
II
 
C
 a
nd
 D
 
14
82
60
9 
14
83
86
8 
- 
SM
D
_R
S0
69
55
 M
U
LT
IS
PE
C
IE
S:
 li
pi
d-
A
-d
is
ac
ch
ar
id
e 
sy
nt
ha
se
 
C
 a
nd
 D
 
14
83
86
5 
14
84
65
6 
- 
SM
D
_R
S0
69
60
 a
cy
l-A
C
P-
-U
D
P-
N
-a
ce
ty
lg
lu
co
sa
m
in
e 
O
-a
cy
ltr
an
sf
er
as
e 
C
 a
nd
 D
 
14
84
67
3 
14
85
13
1 
fa
bZ
 
SM
D
_R
S0
69
65
 M
U
LT
IS
PE
C
IE
S:
 3
-h
yd
ro
xy
ac
yl
-A
C
P 
de
hy
dr
at
as
e 
Fa
bZ
 
C
 a
nd
 D
 
14
85
12
8 
14
86
15
0 
lp
xD
 
SM
D
_R
S0
69
70
 U
D
P-
3-
O
-(
3-
hy
dr
ox
ym
yr
is
to
yl
) g
lu
co
sa
m
in
e 
N
-a
cy
ltr
an
sf
er
as
e 
C
 
14
86
53
3 
14
88
89
6 
ba
m
A 
SM
D
_R
S0
69
75
 o
ut
er
 m
em
br
an
e 
pr
ot
ei
n 
as
se
m
bl
y 
fa
ct
or
 B
am
A
 
C
 
14
88
97
1 
14
90
32
9 
rs
eP
 
SM
D
_R
S0
69
80
 R
IP
 m
et
al
lo
pr
ot
ea
se
 R
se
P 
C
 
14
90
38
5 
14
91
57
5 
- 
SM
D
_R
S0
69
85
 1
-d
eo
xy
-D
-x
yl
ul
os
e-
5-
ph
os
ph
at
e 
re
du
ct
oi
so
m
er
as
e 
C
 
14
91
57
8 
14
92
41
4 
- 
SM
D
_R
S0
69
90
 h
yp
ot
he
tic
al
 p
ro
te
in
 
C
 
14
92
41
1 
14
93
17
8 
up
pS
 
SM
D
_R
S0
69
95
 M
U
LT
IS
PE
C
IE
S:
 d
i-t
ra
ns
,p
ol
y-
ci
s-
de
ca
pr
en
yl
ci
st
ra
ns
fe
ra
se
 
C
 
14
93
18
4 
14
93
73
8 
- 
SM
D
_R
S0
70
00
 M
U
LT
IS
PE
C
IE
S:
 ri
bo
so
m
e 
re
cy
cl
in
g 
fa
ct
or
 
C
 
14
93
83
5 
14
94
56
3 
- 
SM
D
_R
S0
70
05
 M
U
LT
IS
PE
C
IE
S:
 U
M
P 
ki
na
se
 
C
 
14
94
68
5 
14
96
22
3 
- 
SM
D
_R
S0
70
10
 G
G
D
EF
 d
om
ai
n-
co
nt
ai
ni
ng
 p
ro
te
in
 
C
 
14
96
48
1 
14
97
35
6 
ts
f 
SM
D
_R
S0
70
15
 e
lo
ng
at
io
n 
fa
ct
or
 T
s 
C
 
14
97
48
2 
14
98
28
8 
rp
sB
 
SM
D
_R
S0
70
20
 M
U
LT
IS
PE
C
IE
S:
 3
0S
 ri
bo
so
m
al
 p
ro
te
in
 S
2 
C
 
14
98
50
9 
14
99
20
7 
- 
SM
D
_R
S0
70
25
 p
ilu
s a
ss
em
bl
y 
pr
ot
ei
n 
C
 
14
99
20
7 
14
99
42
2 
- 
SM
D
_R
S0
70
30
 h
yp
ot
he
tic
al
 p
ro
te
in
 
C
 
14
99
57
5 
15
00
61
2 
- 
SM
D
_R
S0
70
35
 s
po
re
 c
oa
t U
 d
om
ai
n-
co
nt
ai
ni
ng
 p
ro
te
in
 
C
 
15
00
60
9 
15
02
97
8 
- 
SM
D
_R
S0
70
40
 f
im
br
ia
l b
io
ge
ne
si
s o
ut
er
 m
em
br
an
e 
us
he
r p
ro
te
in
 
C
 
	1
50
29
86
 
15
03
73
5 
- 
SM
D
_R
S0
70
45
 m
ol
ec
ul
ar
 c
ha
pe
ro
ne
 
C
 
15
03
73
5 
15
04
26
5 
- 
SM
D
_R
S0
70
50
 S
C
PU
 d
om
ai
n-
co
nt
ai
ni
ng
 p
ro
te
in
 
C
 
15
04
43
9 
15
05
28
1 
m
ap
 
SM
D
_R
S0
70
55
 t
yp
e 
I m
et
hi
on
yl
 a
m
in
op
ep
tid
as
e 
C
 
15
05
28
4 
15
07
91
1 
gl
nD
 
SM
D
_R
S0
70
60
 [
pr
ot
ei
n-
PI
I]
 u
rid
yl
yl
tra
ns
fe
ra
se
 [S
te
no
tro
ph
om
on
as
 m
al
to
ph
ili
a]
 
C
 
15
07
91
1 
15
08
99
0 
da
pD
 
SM
D
_R
S0
70
65
 2
,3
,4
,5
-te
tra
hy
dr
op
yr
id
in
e-
2,
6-
di
ca
rb
ox
yl
at
e 
N
-s
uc
ci
ny
ltr
an
sf
er
as
e 
C
 
15
08
99
3 
15
09
85
9 
- 
SM
D
_R
S0
70
70
 h
yp
ot
he
tic
al
 p
ro
te
in
 
C
 
15
09
89
7 
15
10
26
2 
- 
SM
D
_R
S0
70
75
 a
rs
en
at
e 
re
du
ct
as
e 
C
 
15
10
25
9 
15
11
38
6 
da
pE
 
SM
D
_R
S0
70
80
 s
uc
ci
ny
l-d
ia
m
in
op
im
el
at
e 
de
su
cc
in
yl
as
e 
C
 
15
11
50
7 
15
12
38
5 
- 
SM
D
_R
S0
70
85
 s
el
1 
re
pe
at
 fa
m
ily
 p
ro
te
in
 
C
 
15
12
72
4 
15
14
41
5 
as
nB
 
SM
D
_R
S0
70
90
 a
sp
ar
ag
in
e 
sy
nt
ha
se
 B
 
C
 
15
14
51
7 
15
15
90
5 
- 
SM
D
_R
S0
70
95
 s
od
iu
m
:p
ro
to
n 
sy
m
po
rte
r 
C
 
15
15
98
8 
15
18
31
5 
- 
SM
D
_R
S0
71
00
 p
en
ic
ill
in
 a
cy
la
se
 fa
m
ily
 p
ro
te
in
 
C
 
15
18
43
9 
15
18
92
7 
bf
r 
SM
D
_R
S0
71
05
 M
U
LT
IS
PE
C
IE
S:
 b
ac
te
rio
fe
rr
iti
n 
C
 
15
19
32
0 
15
21
56
3 
pa
rC
 
SM
D
_R
S0
71
10
 D
N
A
 to
po
is
om
er
as
e 
IV
 su
bu
ni
t A
 
C
 
15
21
62
4 
15
22
53
2 
- 
SM
D
_R
S0
71
15
 A
ra
C
 fa
m
ily
 tr
an
sc
rip
tio
na
l r
eg
ul
at
or
 
C
 
15
22
67
8 
15
23
12
1 
- 
SM
D
_R
S0
71
20
 M
U
LT
IS
PE
C
IE
S:
 m
ul
tid
ru
g 
ef
flu
x 
sy
st
em
 tr
an
sc
rip
tio
na
l r
eg
ul
at
or
 E
m
rR
 
C
 
15
23
11
8 
15
24
61
1 
- 
SM
D
_R
S0
71
25
 m
ul
tid
ru
g 
ef
flu
x 
tra
ns
po
rte
r o
ut
er
 m
em
br
an
e 
su
bu
ni
t E
m
rC
 
C
 
15
24
62
3 
15
25
80
4 
- 
SM
D
_R
S0
71
30
 m
ul
tid
ru
g 
ef
flu
x 
M
FS
 tr
an
sp
or
te
r p
er
ip
la
sm
ic
 a
da
pt
or
 su
bu
ni
t E
m
rA
 
C
 
15
25
81
2 
15
27
39
8 
em
rB
 
SM
D
_R
S0
71
35
 M
U
LT
IS
PE
C
IE
S:
 m
ul
tid
ru
g 
ef
flu
x 
M
FS
 tr
an
sp
or
te
r p
er
m
ea
se
 su
bu
ni
t E
m
rB
 
C
 
15
27
68
7 
15
28
58
6 
- 
SM
D
_R
S0
71
45
 L
ys
R
 fa
m
ily
 tr
an
sc
rip
tio
na
l r
eg
ul
at
or
 
C
 
15
28
68
5 
15
29
43
1 
- 
SM
D
_R
S0
71
50
 s
ul
fit
e 
ex
po
rte
r T
au
E/
Sa
fE
 fa
m
ily
 p
ro
te
in
 
C
 
15
29
99
3 
15
32
45
2 
rn
r 
SM
D
_R
S0
71
65
 r
ib
on
uc
le
as
e 
R
 
C
 
15
32
53
7 
15
33
01
9 
- 
SM
D
_R
S0
71
70
 G
FA
 fa
m
ily
 p
ro
te
in
 
C
 
15
33
18
1 
15
33
92
4 
- 
SM
D
_R
S0
71
75
 M
U
LT
IS
PE
C
IE
S:
 2
3S
 rR
N
A
 (g
ua
no
si
ne
(2
25
1)
-2
\'-
O
)-
m
et
hy
ltr
an
sf
er
as
e 
R
lm
B
 
C
 
15
34
00
2 
15
35
44
1 
- 
SM
D
_R
S0
71
80
 T
ol
C
 fa
m
ily
 p
ro
te
in
 
C
 
	1
53
54
38
 
15
37
39
6 
- 
SM
D
_R
S0
71
85
 M
ac
B
 fa
m
ily
 e
ff
lu
x 
pu
m
p 
su
bu
ni
t 
C
 
15
37
39
3 
15
38
63
4 
- 
SM
D
_R
S0
71
90
 e
ff
lu
x 
R
N
D
 tr
an
sp
or
te
r p
er
ip
la
sm
ic
 a
da
pt
or
 su
bu
ni
t 
C
 
15
38
83
9 
15
39
56
7 
- 
SM
D
_R
S0
71
95
 r
es
po
ns
e 
re
gu
la
to
r 
C
 
15
41
16
1 
15
44
18
7 
- 
SM
D
_R
S0
72
00
 d
ig
ua
ny
la
te
 c
yc
la
se
 
C
 
15
44
35
0 
15
45
00
0 
rn
t 
SM
D
_R
S0
72
05
 r
ib
on
uc
le
as
e 
T 
C
 
15
45
13
2 
15
45
65
3 
- 
SM
D
_R
S0
72
10
 D
ox
X
 fa
m
ily
 p
ro
te
in
 
C
 
15
45
67
8 
15
46
43
3 
- 
SM
D
_R
S0
72
15
 h
yp
ot
he
tic
al
 p
ro
te
in
 
C
 
15
46
42
6 
15
47
30
1 
- 
SM
D
_R
S0
72
20
 D
U
F6
92
 d
om
ai
n-
co
nt
ai
ni
ng
 p
ro
te
in
 
C
 
15
47
28
8 
15
47
64
1 
- 
SM
D
_R
S0
72
25
 h
yp
ot
he
tic
al
 p
ro
te
in
 
C
 
15
47
87
8 
15
48
58
5 
ph
oU
 
SM
D
_R
S0
72
30
 M
U
LT
IS
PE
C
IE
S:
 p
ho
sp
ha
te
 si
gn
al
in
g 
co
m
pl
ex
 p
ro
te
in
 P
ho
U
 
C
 
15
48
66
2 
15
49
49
2 
- 
SM
D
_R
S0
72
35
 M
U
LT
IS
PE
C
IE
S:
 p
ho
sp
ha
te
 A
B
C
 tr
an
sp
or
te
r A
TP
-b
in
di
ng
 p
ro
te
in
 P
st
B
 
C
 
15
49
51
2 
15
50
37
5 
ps
tA
 
SM
D
_R
S0
72
40
 p
ho
sp
ha
te
 A
B
C
 tr
an
sp
or
te
r p
er
m
ea
se
 P
st
A
 
C
 
15
50
37
5 
15
51
34
3 
ps
tC
 
SM
D
_R
S0
72
45
 M
U
LT
IS
PE
C
IE
S:
 p
ho
sp
ha
te
 A
B
C
 tr
an
sp
or
te
r p
er
m
ea
se
 su
bu
ni
t P
st
C
 
C
 
15
51
42
3 
15
52
51
1 
ps
tS
 
SM
D
_R
S0
72
50
 p
ho
sp
ha
te
 A
B
C
 tr
an
sp
or
te
r s
ub
st
ra
te
-b
in
di
ng
 p
ro
te
in
 P
st
S 
C
 
15
52
92
8 
15
53
94
4 
ps
tS
 
SM
D
_R
S0
72
55
 M
U
LT
IS
PE
C
IE
S:
 p
ho
sp
ha
te
 A
B
C
 tr
an
sp
or
te
r s
ub
st
ra
te
-b
in
di
ng
 p
ro
te
in
 P
st
S 
C
 
15
54
49
9 
15
55
73
1 
- 
SM
D
_R
S0
72
60
 p
or
in
 
C
 
15
55
81
3 
15
56
50
5 
nt
h 
SM
D
_R
S0
72
65
 e
nd
on
uc
le
as
e 
II
I 
C
 
15
56
50
5 
15
56
85
8 
- 
SM
D
_R
S0
72
70
 h
yp
ot
he
tic
al
 p
ro
te
in
 
C
 
15
56
86
3 
15
57
64
5 
- 
SM
D
_R
S0
72
75
 e
no
yl
-C
oA
 h
yd
ra
ta
se
 
C
 
15
57
81
3 
15
58
51
4 
- 
SM
D
_R
S0
72
80
 F
K
B
P-
ty
pe
 p
ep
tid
yl
-p
ro
ly
l c
is
-tr
an
s i
so
m
er
as
e 
C
 
15
58
68
1 
15
59
48
4 
- 
SM
D
_R
S0
72
85
 C
oA
 p
yr
op
ho
sp
ha
ta
se
 
C
 
15
59
48
1 
15
60
38
3 
- 
SM
D
_R
S0
72
90
 s
ul
fu
rtr
an
sf
er
as
e 
C
 
15
60
64
6 
15
61
21
2 
- 
SM
D
_R
S0
72
95
 N
-a
ce
ty
lm
ur
am
oy
l-L
-a
la
ni
ne
 a
m
id
as
e 
C
 
15
61
28
5 
15
61
81
2 
- 
SM
D
_R
S0
73
00
 a
lp
ha
/b
et
a 
hy
dr
ol
as
e 
C
 
15
61
95
8 
15
64
09
6 
- 
SM
D
_R
S0
73
05
 b
ifu
nc
tio
na
l 2
3S
 rR
N
A
 (g
ua
ni
ne
(2
06
9)
-N
(7
))
-m
et
hy
ltr
an
sf
er
as
e 
R
lm
K
/2
3S
 
rR
N
A
 (g
ua
ni
ne
(2
44
5)
-N
(2
))
-m
et
hy
ltr
an
sf
er
as
e 
R
lm
L 
C
 
	1
56
42
17
 
15
64
54
6 
- 
SM
D
_R
S0
73
10
 D
U
F3
32
5 
do
m
ai
n-
co
nt
ai
ni
ng
 p
ro
te
in
 
C
 
15
64
54
3 
15
66
18
0 
- 
SM
D
_R
S0
73
15
 P
ep
SY
 d
om
ai
n-
co
nt
ai
ni
ng
 p
ro
te
in
 
C
 
15
66
17
7 
15
66
49
1 
- 
SM
D
_R
S0
73
20
 D
U
F3
64
9 
do
m
ai
n-
co
nt
ai
ni
ng
 p
ro
te
in
 
C
 
15
66
73
7 
15
68
02
3 
- 
SM
D
_R
S0
73
25
 D
U
F4
45
 fa
m
ily
 p
ro
te
in
 
C
 
15
68
14
8 
15
69
02
6 
- 
SM
D
_R
S0
73
30
 h
yp
ot
he
tic
al
 p
ro
te
in
 
C
 
15
69
09
0 
15
70
44
2 
- 
SM
D
_R
S0
73
35
 a
sp
ar
ta
te
 a
m
in
ot
ra
ns
fe
ra
se
 fa
m
ily
 p
ro
te
in
 
C
 
15
70
54
6 
15
72
04
2 
- 
SM
D
_R
S0
73
40
 a
ld
eh
yd
e 
de
hy
dr
og
en
as
e 
C
 
15
72
24
3 
15
73
54
4 
- 
SM
D
_R
S0
73
45
 M
FS
 tr
an
sp
or
te
r 
C
 
15
73
52
5 
15
73
98
6 
- 
SM
D
_R
S0
73
50
 M
U
LT
IS
PE
C
IE
S:
 h
em
er
yt
hr
in
 
C
 
15
74
07
2 
15
75
41
5 
- 
SM
D
_R
S0
73
55
 d
ig
ua
ny
la
te
 c
yc
la
se
 
C
 
15
75
51
2 
15
77
07
4 
- 
SM
D
_R
S0
73
60
 m
em
br
an
e 
pr
ot
ei
n 
C
 
15
77
53
4 
15
78
02
2 
- 
SM
D
_R
S0
73
65
 h
yp
ot
he
tic
al
 p
ro
te
in
 
C
 
15
78
18
1 
15
79
77
3 
- 
SM
D
_R
S0
73
70
 m
em
br
an
e 
pr
ot
ei
n 
C
 
15
79
99
9 
15
81
27
6 
- 
SM
D
_R
S0
73
75
 F
A
D
-b
in
di
ng
 o
xi
do
re
du
ct
as
e 
C
 
15
81
43
8 
15
82
19
9 
- 
SM
D
_R
S0
73
80
 g
am
m
a-
gl
ut
am
yl
-g
am
m
a-
am
in
ob
ut
yr
at
e 
hy
dr
ol
as
e 
C
 
15
82
19
6 
15
83
59
3 
- 
SM
D
_R
S0
73
85
 g
lu
ta
m
in
e 
sy
nt
he
ta
se
 
C
 
15
83
68
6 
15
84
79
5 
- 
SM
D
_R
S0
73
90
 p
ol
ya
m
in
e 
A
B
C
 tr
an
sp
or
te
r s
ub
st
ra
te
-b
in
di
ng
 p
ro
te
in
 
C
 
15
84
98
5 
15
86
12
1 
po
tG
 
SM
D
_R
S0
73
95
 p
ol
ya
m
in
e 
A
B
C
 tr
an
sp
or
te
r A
TP
-b
in
di
ng
 p
ro
te
in
 
C
 
15
86
11
8 
15
87
05
0 
- 
SM
D
_R
S0
74
00
 p
ut
re
sc
in
e 
A
B
C
 tr
an
sp
or
te
r p
er
m
ea
se
 
C
 
15
87
04
7 
15
87
88
9 
- 
SM
D
_R
S0
74
05
 M
U
LT
IS
PE
C
IE
S:
 p
ut
re
sc
in
e 
A
B
C
 tr
an
sp
or
te
r p
er
m
ea
se
 P
ot
I 
C
 
15
87
97
3 
15
89
33
7 
- 
SM
D
_R
S0
74
10
 N
A
D
-d
ep
en
de
nt
 su
cc
in
at
e-
se
m
ia
ld
eh
yd
e 
de
hy
dr
og
en
as
e 
C
 
15
89
50
4 
15
90
52
6 
- 
SM
D
_R
S0
74
15
 m
ag
ne
si
um
 a
nd
 c
ob
al
t t
ra
ns
po
rt 
pr
ot
ei
n 
C
or
A
 
C
 
15
90
53
3 
15
91
79
2 
- 
SM
D
_R
S0
74
20
 D
U
F4
10
5 
do
m
ai
n-
co
nt
ai
ni
ng
 p
ro
te
in
 
C
 
15
91
78
9 
15
92
67
0 
- 
SM
D
_R
S0
74
25
 M
U
LT
IS
PE
C
IE
S:
 C
B
S 
do
m
ai
n-
co
nt
ai
ni
ng
 p
ro
te
in
 
C
 
15
92
73
5 
15
93
30
1 
- 
SM
D
_R
S0
74
30
 h
yp
ot
he
tic
al
 p
ro
te
in
 
C
 
15
93
37
9 
15
93
98
4 
- 
SM
D
_R
S0
74
35
 h
yp
ot
he
tic
al
 p
ro
te
in
 
C
 
	1
59
40
32
 
15
94
51
7 
- 
SM
D
_R
S0
74
40
 M
U
LT
IS
PE
C
IE
S:
 e
nd
or
ib
on
uc
le
as
e 
Y
be
Y
 
C
 
15
94
51
4 
15
95
50
0 
- 
SM
D
_R
S0
74
45
 P
ho
H
 fa
m
ily
 p
ro
te
in
 
C
 
15
96
02
4 
15
96
98
0 
- 
SM
D
_R
S0
74
50
 H
ly
D
 fa
m
ily
 e
ff
lu
x 
tra
ns
po
rte
r p
er
ip
la
sm
ic
 a
da
pt
or
 su
bu
ni
t 
C
 
15
97
00
1 
15
97
92
4 
- 
SM
D
_R
S0
74
55
 A
B
C
 tr
an
sp
or
te
r A
TP
-b
in
di
ng
 p
ro
te
in
 
C
 
15
97
92
1 
15
99
03
3 
- 
SM
D
_R
S0
74
60
 A
B
C
 tr
an
sp
or
te
r p
er
m
ea
se
 
C
 
15
99
12
2 
16
00
54
0 
- 
SM
D
_R
S0
74
65
 t
R
N
A
 (N
6-
is
op
en
te
ny
l a
de
no
si
ne
(3
7)
-C
2)
-m
et
hy
lth
io
tra
ns
fe
ra
se
 M
ia
B
 
C
 
16
00
72
8 
16
01
34
5 
- 
SM
D
_R
S0
74
70
 g
lu
ta
th
io
ne
 S
-tr
an
sf
er
as
e 
fa
m
ily
 p
ro
te
in
 
C
 
16
01
42
6 
16
02
39
4 
- 
SM
D
_R
S0
74
75
 W
Y
L 
do
m
ai
n-
co
nt
ai
ni
ng
 tr
an
sc
rip
tio
na
l r
eg
ul
at
or
 
C
 
16
02
44
1 
16
03
34
6 
- 
SM
D
_R
S0
74
80
 l
yt
ic
 tr
an
sg
ly
co
sy
la
se
 d
om
ai
n-
co
nt
ai
ni
ng
 p
ro
te
in
 
C
 
16
03
54
6 
16
04
16
6 
pe
tA
 
SM
D
_R
S0
74
85
 M
U
LT
IS
PE
C
IE
S:
 u
bi
qu
in
ol
-c
yt
oc
hr
om
e 
c 
re
du
ct
as
e 
iro
n-
su
lfu
r s
ub
un
it 
C
 
16
04
16
6 
16
05
42
5 
- 
SM
D
_R
S0
74
90
 c
yt
oc
hr
om
e 
b 
C
 
16
05
41
8 
16
06
16
7 
- 
SM
D
_R
S0
74
95
 M
U
LT
IS
PE
C
IE
S:
 c
yt
oc
hr
om
e 
c1
 
C
 
16
06
30
2 
16
06
93
7 
- 
SM
D
_R
S0
75
00
 M
U
LT
IS
PE
C
IE
S:
 st
rin
ge
nt
 st
ar
va
tio
n 
pr
ot
ei
n 
A
 
C
 
16
07
02
2 
16
07
47
4 
- 
SM
D
_R
S0
75
05
 M
U
LT
IS
PE
C
IE
S:
 C
lp
X
P 
pr
ot
ea
se
 sp
ec
ifi
ci
ty
-e
nh
an
ci
ng
 fa
ct
or
 
C
 
16
07
57
9 
16
07
92
9 
- 
SM
D
_R
S0
75
10
 M
U
LT
IS
PE
C
IE
S:
 D
U
F3
30
1 
do
m
ai
n-
co
nt
ai
ni
ng
 p
ro
te
in
 
C
 
16
07
99
7 
16
08
99
8 
- 
SM
D
_R
S0
75
15
 D
U
F2
27
2 
do
m
ai
n-
co
nt
ai
ni
ng
 p
ro
te
in
 
C
 
16
09
17
9 
16
10
03
0 
na
dC
 
SM
D
_R
S0
75
20
 c
ar
bo
xy
la
tin
g 
ni
co
tin
at
e-
nu
cl
eo
tid
e 
di
ph
os
ph
or
yl
as
e 
C
 
16
10
02
7 
16
10
29
6 
- 
SM
D
_R
S0
75
25
 M
U
LT
IS
PE
C
IE
S:
 h
yp
ot
he
tic
al
 p
ro
te
in
 
C
 
16
10
35
5 
16
10
85
8 
pu
rE
 
SM
D
_R
S0
75
30
 M
U
LT
IS
PE
C
IE
S:
 5
-(
ca
rb
ox
ya
m
in
o)
im
id
az
ol
e 
rib
on
uc
le
ot
id
e 
m
ut
as
e 
C
 
16
10
85
5 
16
12
00
3 
- 
SM
D
_R
S0
75
35
 5
-(
ca
rb
ox
ya
m
in
o)
im
id
az
ol
e 
rib
on
uc
le
ot
id
e 
sy
nt
ha
se
 
C
 
16
12
11
6 
16
12
45
7 
- 
SM
D
_R
S0
75
40
 M
U
LT
IS
PE
C
IE
S:
 c
ar
bo
xy
m
uc
on
ol
ac
to
ne
 d
ec
ar
bo
xy
la
se
 fa
m
ily
 p
ro
te
in
 
C
 
16
12
53
3 
16
13
11
1 
- 
SM
D
_R
S0
75
45
 s
up
er
ox
id
e 
di
sm
ut
as
e 
C
 
16
13
23
2 
16
13
55
2 
gr
xD
 
SM
D
_R
S0
75
50
 M
U
LT
IS
PE
C
IE
S:
 G
rx
4 
fa
m
ily
 m
on
ot
hi
ol
 g
lu
ta
re
do
xi
n 
C
 
16
13
54
9 
16
14
32
5 
- 
SM
D
_R
S0
75
55
 S
D
R
 fa
m
ily
 N
A
D
(P
)-
de
pe
nd
en
t o
xi
do
re
du
ct
as
e 
C
 
16
14
57
7 
16
17
77
7 
- 
SM
D
_R
S0
75
60
 T
on
B
-d
ep
en
de
nt
 re
ce
pt
or
 
C
 
16
18
03
1 
16
19
41
9 
- 
SM
D
_R
S0
75
65
 M
U
LT
IS
PE
C
IE
S:
 L
O
G
 fa
m
ily
 p
ro
te
in
 
C
 
	1
61
95
81
 
16
20
09
6 
- 
SM
D
_R
S0
75
70
 p
re
pi
lin
-ty
pe
 N
-te
rm
in
al
 c
le
av
ag
e/
m
et
hy
la
tio
n 
do
m
ai
n-
co
nt
ai
ni
ng
 p
ro
te
in
 
C
 
16
20
09
3 
16
20
59
0 
pi
lV
 
SM
D
_R
S0
75
75
 M
U
LT
IS
PE
C
IE
S:
 ty
pe
 IV
 p
ilu
s m
od
ifi
ca
tio
n 
pr
ot
ei
n 
Pi
lV
 
C
 
16
20
59
9 
16
21
75
6 
- 
SM
D
_R
S0
75
80
 p
re
pi
lin
-ty
pe
 N
-te
rm
in
al
 c
le
av
ag
e/
m
et
hy
la
tio
n 
do
m
ai
n-
co
nt
ai
ni
ng
 p
ro
te
in
 
C
 
16
21
76
2 
16
22
28
3 
- 
SM
D
_R
S0
75
85
 p
ilu
s a
ss
em
bl
y 
pr
ot
ei
n 
C
 
16
22
29
7 
16
26
04
9 
- 
SM
D
_R
S0
75
90
 h
yp
ot
he
tic
al
 p
ro
te
in
 
C
 
16
26
07
3 
16
26
48
0 
- 
SM
D
_R
S0
75
95
 t
yp
e 
IV
 p
ili
n 
pr
ot
ei
n 
C
 
16
26
65
7 
16
27
20
2 
- 
SM
D
_R
S0
76
05
 p
re
pi
lin
-ty
pe
 N
-te
rm
in
al
 c
le
av
ag
e/
m
et
hy
la
tio
n 
do
m
ai
n-
co
nt
ai
ni
ng
 p
ro
te
in
 
C
 
16
27
33
1 
16
29
35
5 
- 
SM
D
_R
S0
76
10
 e
xc
in
uc
le
as
e 
A
B
C
 su
bu
ni
t U
vr
B
 
C
 
	Table S3. MICs of several antibiotics for S. maltophilia tigecycline-evolved populations 
 
MIC, minimum inhibitory concentration; TIG, tigecycline; CAZ, ceftazidime; ATM, aztreonam; 
SXT, trimethoprim/sulfamethoxazole; E, erythromycin; C, chloramphenicol; FOS, fosfomycin; 
CIP, ciprofloxacin; OFX, ofloxacin; NAL, nalidixic acid; S, streptomycin; CN, gentamicin; TE, 
tetracycline. 
 
 
 
 MIC (mg/L)  
Strain TGC CAZ ATM SXT E C FOS CIP OFX NA S CN TE 
D457 1 0.75 6 0.094 1024 8 192 4 4 4 16 1.5 2 
Population 
A 128 0.75 96 0.125 2048 64 64 128 128 64 96 1.5 32 
Population 
B 192 1 256 0.094 4096 128 128 128 128 96 192 2 64 
Population 
C 96 1.5 96 0.032 4096 96 96 512 256 24 192 3 32 
Population 
D 128 0.75 3 0.19 4096 64 64 512 256 16 64 3 48 
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4. Discussion 
 
The evolution and spread of multidrug resistant bacteria has become a major threat to 
modern medicine, being the infections caused by these microorganisms a significant economic 
and health burden 169. To efficiently tackle this problem, it is necessary to better understand the 
factors and mechanisms that can potentially have an effect on the evolution, emergence and 
spread of antibiotic resistance. 
 
MDR is particularly common in Gram-negative bacteria, having important clinical 
consequences concerning their spread and treatment options 170. Among MDR Gram-negative 
bacteria, S. maltophilia, an important nosocomial pathogen in clinical environments, exhibits 
an intrinsic low susceptibility to a wide range of antimicrobial agents due to the presence of 
several resistance mechanisms encoded in its genome 129,135. Besides the presence of intrinsic 
resistance determinants, S. maltophilia can also acquire resistance as a result of genetic changes 
that allow this bacterium to overcome the toxic effects of an antibiotic, or transiently expressing 
certain genes that would permit this opportunistic pathogen to resist, in a temporal and 
reversible way, the effect of an antimicrobial drug 171. In all cases, MDR efflux pumps, 
particularly those from the RND family, are key players in the low susceptibility that 
S. maltophilia displays against a great part of the available antibiotics 172. 
 
During the course of this PhD thesis, we have aimed our research at the study of the 
S. maltophilia inducible and acquired resistance to antibiotics, specially focusing on the role 
that RND efflux pumps play in both types of resistance.  
 
4.1. S. maltophilia transient resistance to antibiotics 
 
RND efflux pumps are complex biological machineries that, connecting the inner and 
outer membranes through the periplasm of the bacterial cell, are able to extrude a wide variety 
of compounds, including antibiotics 35. The regulation of the expression of these systems is 
usually mediated by the action of positive and/or negative transcription factors, which are 
normally encoded upstream the operon coding for the efflux pump 82. Although some RND 
efflux systems present low levels of basal expression, high-level expression can be achieved 
through the presence of an effector or a specific environmental condition that trigger the 
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expression of the efflux pump. This induction can be achieved directly through the binding of 
the specific effector molecule to the corresponding transcriptional regulator, or indirectly by 
the action of the inducer-derived molecules or the generated stress response 173,174. In spite of 
the wide variety of compounds that are known to be substrates of RND efflux pumps, the 
number of effectors or cues known to trigger their expression, and potentially contribute to 
transient resistance, is lower in comparison 175.  
 
Regarding S. maltophilia, the contribution of the RND efflux pumps to transient 
resistance to antibiotics has not been fully explored and only few studies regarding this topic 
have been carried out. For instance, it is known that the expression of smeDEF can be triggered 
by the presence of the biocides triclosan and benzalkonium chloride 69,176, as well as by some 
plant-derived flavonoids 68, that bind to the transcriptional repressor SmeT and subsequently 
change the bacterial susceptibility to quinolones. The study of the situations or signals that 
induce transient antibiotic resistance is valuable since bacteria can encounter these conditions 
during the course of an infection. However, the detection of this kind of resistance is usually 
complicated when classical susceptibility methodologies are used 177.  
 
The use of fluorescence-based reporters has been widely employed for several purposes, 
from environmental applications, as detection of toxic pollutants 178, to monitoring gene 
expression, for instance, in response to the host environment 179. In this thesis, we have 
developed YFP-based reporters of the expression of two RND efflux pumps, SmeVWX and 
SmeYZ, with the purpose of finding conditions and/or molecules that trigger the expression of 
these S. maltophilia efflux systems. To this end, two screenings of potential effector compounds 
of the expression of either smeVWX or smeYZ were performed.  
 
4.1.1. RND efflux pumps as stress-induced determinants 
 
The first screening was carried out by measuring the fluorescence levels produced by 
the smeVWX reporter strain during the exposure to 29 compounds from different categories 
(antibiotics, biocides, heavy metals, etc.) at several concentrations. A S. maltophilia strain 
harbouring the smeVWX reporter was grown in the presence of the selected compounds in a 
microtiter plate, and fluorescence and growth were recorded over time. This methodology 
allowed us to identify vitamin K3 as a potential inducer of the smeVWX expression, which was 
confirmed by real-time PCR. Moreover, two structural analogues of vitamin K3, vitamin K2 and 
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plumbagin, which belong to the naphthoquinones family as well 180, were also found to increase 
smeVWX expression in a concentration-dependent way.  
 
In the second screening, we improved the previous approach in order to analyse a much 
wider range of compounds: the Biolog phenotype microarrays. These microarrays are 96-well 
microtiter plates, each one containing 24 toxic compounds at 4 different concentrations. The 
Biolog plates have been developed for performing a metabolic fingerprinting of bacterial 
strains, testing the effect of genetic changes, particularly knock-outs, under nearly 2,000 
chemical and nutrient conditions 181. In our case, we combined this high-throughput technology 
together with the smeYZ sensor, as well as with the previously tested sensor corresponding to 
smeVWX, to analyse 144 different compounds as potential inducers of these systems. A 
S. maltophilia strain harbouring a reporter plasmid that constitutively produces YFP was used 
as a reference to decipher the induction situations of smeVWX and smeYZ. Among all the tested 
compounds, iodoacetate, clioquinol and sodium selenite were identified as smeVWX inducers, 
while in the case of smeYZ, boric acid and the antibiotics erythromycin, chloramphenicol, and 
lincomycin, were recognized as potential inducers. Induction was confirmed by performing 
flow cytometry and real-time PCR. 
 
RND-type efflux systems have been mainly studied in Gram-negative bacteria as 
antibiotic resistance determinants 182,183. However, they are involved in other physiological 
processes that are important for the bacterial cell, such as detoxification of secondary 
metabolites or toxic molecules, survival in the host environment, biofilm formation, or cell-to-
cell communication 184. In addition, a substantial number of efflux pumps are stress-inducible, 
being able to respond to a plethora of stress conditions (ribosome disruption, the presence of 
reactive oxygen species, membrane-damaging agents, nutrient limitation, etc.). This fact 
indicates that at least some of these efflux systems have evolved to respond to environmental 
stresses, thus working as components of the organism’s stress response 185. For instance, the 
expression of a number of efflux pumps and/or their regulatory elements, is modulated by 
oxidative stress agents. Thus, these efflux systems could be involved in the amelioration of the 
detrimental conditions generated by these products 186-188. We propose that if RND efflux 
pumps participate as stress determinants in S. maltophilia, a common inducer mechanism could 
be identified by analysing the effector compounds that trigger their expression.  
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About SmeVWX, the identification of vitamin K3 and its analogues as inducers, which 
are known to generate oxidative stress, led us to the idea that oxidative stress might be the signal 
triggering the expression of smeVWX. However, the generator of oxidative stress tert-butyl 
hydroperoxide did not lead to an increment of the efflux pump expression, hence suggesting 
that just oxidative stress could not be the inducer signal of smeVWX. The results from the second 
screening, which included many more compounds, shed some light on the possible smeVWX 
inducer cue, since the new identified compounds, iodoacetate, clioquinol and sodium selenite, 
as well as vitamin K3, are thiol-reactive compounds, that is, they are able to interact with thiol 
groups on proteins causing different effects 180,189-191. Although the molecular mechanism by 
which smeVWX expression is triggered is not fully understood, our data suggest that the 
induction of this efflux pump is associated with the thiol reactivity of the identified molecules. 
 
Regarding SmeYZ, boric acid and a set of antibiotics including erythromycin, 
chloramphenicol, and lincomycin, were identified as inducers. The three inducer antibiotics are 
known to inhibit the protein synthesis through different mechanisms involving the 50S subunit 
of the ribosome 192-194. Although boric acid is not an antibiotic, is has been reported that it 
impairs the tRNAs acylation, inhibiting protein synthesis 195. Other compounds identified from 
the Biolog microarrays that led to an overexpression of smeYZ (e.g. fusidic acid, tylosin, 
spiramycin, oleandomycin, etc.), are also known inhibitors of the protein synthesis. All the 
reported findings suggest that the mechanism underlying smeYZ induction is associated with 
protein synthesis inhibition. Indeed, it has been previously reported that ribosome-targeting 
antibiotics are able to trigger the expression of the P. aeruginosa MexXY efflux pump 196. In 
S. maltophilia, it is possible that SmeYZ plays a role in exporting anomalous peptides or 
processed by-products, thus alleviating the ribosome-stalling stress. However, the molecular 
basis behind this mechanism is still unknown. 
 
4.1.2. Inducers are not necessarily substrates of RND efflux pumps  
 
A common feature of some RND efflux pumps is the ability to extrude some of the 
inducer molecules that trigger their expression as a mechanism of protection against the toxicity 
of such molecules. For instance, bile salts are both inducers and substrates of the AcrAB efflux 
pump of Salmonella 197; and triclosan induces and is extruded by the S. maltophilia SmeDEF 
efflux pump 69. Concerning our recently identified compounds, we showed that only vitamin 
K3 acts as a possible substrate of SmeVWX, since bacterial growth in the presence of this 
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inducer is impaired in the absence of the efflux protein SmeW. Vitamin K3, a compound that 
has been isolated from phanerogams and fungi 198, has been reported to have a role in the 
defence against plant-pathogens 199,200. Since S. maltophilia is able to colonize plant roots, 
SmeVWX efflux pump could be involved in the detoxification of noxious plant-derived 
compounds, as menadione, which would be produced by plants during pathogenesis and would 
act as a stress inducer factor.  
 
None of the other inducers of smeVWX or smeYZ seems to be substrate of their 
respective efflux pumps, due to the fact that the strains lacking either SmeW or SmeZ do not 
show differences in growth during exposure to the toxic inducer molecules. As a consequence, 
here we propose that not all the RND efflux pump inducers are necessarily their substrates as 
well. This can be explained through the fact that bacteria might employ other detoxifying 
determinants in order to counteract the toxicity generated by the inducers. We also hypothesize 
that inducer compounds might not always be efflux pump substrates due to the cell 
compartmentalization. That is, the induction processes occur in the cytoplasm, while RND 
efflux pumps principally extrude the molecules from the inner membrane or from the periplasm 
of the cell 201. Thus, if the inducer molecule is degraded or extruded by other determinants, or 
if it remains in the cytoplasm, it can justify why these inducers are not being extruded by the 
efflux systems whose expression they trigger. 
 
4.1.3. Inducer-triggered transient resistance to antibiotics  
 
The study of RND efflux pumps inducers in S. maltophilia is also relevant from a 
clinical point of view, since overexpression of these resistance determinants during exposure to 
their respective inducers could lead to a transient situation of antibiotic resistance. Our results 
show that sodium selenite is able to promote transient resistance against the antibiotic ofloxacin, 
a substrate of SmeVWX; and vitamin K3, besides leading to transient resistance towards 
ofloxacin, it also does against chloramphenicol. Besides, transient resistance is also achieved 
for amikacin (a SmeYZ substrate) when S. maltophilia is exposed to the smeYZ inducer 
lincomycin, being an example of an antibiotic triggering resistance against a different antibiotic. 
In the case that bacteria are exposed to these external compounds in a treated patient, it could 
potentially increase the resistance levels, thus challenging therapy. For instance, vitamin K3 and 
sodium selenite, due to their cytotoxic effects, show good antitumor activity against various 
human cancer cells 202,203. Because of this, vitamin K3, as well as some of its analogues, have 
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been used alone or in combination with other chemotherapeutic drugs in several in vitro and in 
vivo studies for the treatment of different types of cancer 204-208. Likewise, sodium selenite has 
also been administered to terminal cancer patients during a phase I clinical trial 209. Since 
S. maltophilia usually causes infections in immunocompromised patients, as those affected 
with cancer, the presence of these compounds during an infection could lead to efflux pump 
overexpression and transient antibiotic resistance, which may complicate the treatment course. 
 
4.2. S. maltophilia acquired resistance to antibiotics 
 
During the last decades, we have witnessed one of the most fast and dramatic events of 
biological evolution of anthropogenic origin: the adaptation of bacteria to antibiotics. This 
adaptation can be the result of acquisition of new exogenous genetic material, as well as 
mutations or genome rearrangements that occur in the bacterial chromosome and modify the 
pre-existing genes 210.  Understanding the dynamics through which bacteria develop resistance 
to antibiotics, as well as knowing the parameters that determine the persistence and spread of 
acquired resistance, is essential for making an effective use of antibiotics.  
 
A methodology that enables the study of adaptation under controlled laboratory settings 
is the performance of experimental evolution assays 211. The longest bacterial evolution 
experiment was initiated by Lenski in 1988 212, in which more than 60,000 generations were 
reached in the last analysis 213. In this study, which is currently in progress, the genetic dynamics 
and fitness of several daily-passaged E. coli populations are determined to study long-term 
adaptation to a constant environment 213. Regarding antibiotic resistance, exposure to 
antimicrobial drugs implies an environmental change that influences the evolutionary dynamics 
of bacterial populations 54,214. In this respect, experimental evolution in the presence of 
antibiotics is used as a practical application for predicting the evolution towards resistance to 
antibiotics that are currently used at clinics, as well as to new antimicrobial drugs that are under 
development 54,215-217.   
 
S. maltophilia is known to acquire multidrug resistance rapidly after exposure to 
different antimicrobials 218. However, most of the studies concerning acquisition of resistance 
in this bacterium are performed using resistant clinical isolates or through the isolation of 
colonies from plates with high antibiotic concentration 152,219. Consequently, little information 
is available about the genetic dynamics and phenotypic effects derived from the acquisition of 
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antibiotic resistance in S. maltophilia populations challenged with variable antibiotic 
concentrations overtime. During the course of this thesis, we have performed experimental 
evolution experiments exposing S. maltophilia to increasing concentrations of the antibiotics 
ceftazidime or tigecycline, both appropriate alternatives for the treatment of S. maltophilia 
infections, with the aim of revealing new potential genetic mechanisms underlying the 
acquisition of resistance to these antibiotics, as well as the evolutionary trajectories involved. 
The results derived from both experimental evolutions have led to the discovery of different 
mechanisms potentially involved in the resistance phenotype observed in this opportunistic 
pathogen after such evolutions.   
 
4.2.1. Adaptation to ceftazidime and the role of SmeGH efflux pump in resistance and 
bacterial physiology 
 
In the case of ceftazidime evolution, acquisition of resistance against this beta-lactam 
by S. maltophilia seems to be mainly associated with the extrusion of the antibiotic through 
efflux systems. Particularly, the four evolved populations present two different mutations in the 
gene coding for the transporter protein of the SmeGH efflux pump, smeH, and two of them 
have mutations in genes encoding the auxiliary (yrbC) and the permease components (yrbE), 
respectively, of an uncharacterized ABC transporter. In addition to these efflux-associated 
genes, three of the populations show different mutations in the gene coding for the two-
component sensor histidine kinase phoQ, whose role in beta-lactams resistance has not been 
studied deeply, but is known to be involved in polymyxin and antimicrobial peptides resistance 
in other bacterial species 220,221. Ceftazidime exposure also led to the acquisition of genetic 
changes in the genes encoding four hypothetical proteins, as well as in the peptidoglycan 
transpeptidase-coding gene, ftsI, which has been previously associated with resistance against 
beta-lactam drugs 52,222.  
 
Among all the identified S. maltophilia RND efflux pumps, some of them have been 
well characterized and their role in resistance and/or virulence have been described 144,146-149,155. 
Regarding SmeGH, a recent work has reported that the overexpression of this efflux pump 
contributes to the acquisition of resistance towards fluoroquinolones. However, the mutation(s) 
leading to the observed phenotype are not elucidated 151. Concerning our study, the fact that 
both mutations have been selected in the efflux transporter protein, but not in a regulatory 
element, which is the most common event when associating acquired resistance and RND efflux 
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pumps, makes the study of this efflux system very interesting. Hence, we constructed strains 
carrying both ceftazidime-selected amino acid substitutions (P326Q and Q663R), 
independently and in combination, to study their particular contribution to ceftazidime 
resistance. Our results show that the presence of both mutations in smeH confers higher levels 
of resistance to ceftazidime in comparison with the unique presence of P326Q. Surprisingly, 
when present alone, the second amino acid substitution Q663R does not confer any change in 
ceftazidime susceptibility, that is, this mutation is neutral in the wild-type background, 
regarding ceftazidime susceptibility. This result, together with the fact that Q663R only 
emerges in the evolution when P326Q is already present, can be interpreted as a possible 
epistasis event, in which the effect of Q663R on ceftazidime resistance is dependent on the 
genetic background. This kind of epistasis (sign epistasis) can limit the evolutionary paths 
available to a population, having profound effects on the evolution trajectory 96.  
 
S. maltophilia RND efflux pumps can be involved in the three types of resistance that 
have been previously described. Our results performed with a smeH-deficient mutant show that 
this efflux pump seems to be an important intrinsic resistance determinant for several 
antibiotics, including not only beta-lactams, but also quinolones, polymyxin B and tetracycline. 
Besides antibiotics, SmeGH efflux pump could be a detoxification element for other toxic 
compounds, due to the hypersusceptibility phenotype that this mutant displays against the 
previously described vitamin K3, the oxidative stress agent tert-butyl hydroperoxide, the 
biocide benzalkonium chloride, and the plant-derived compound naringenin. Besides, the 
smeH-deficient strain shows an enhanced capacity of biofilm formation, suggesting that 
SmeGH negatively contributes to the formation of biofilm in S. maltophilia. It is possible that 
this RND efflux pump regulates somehow biofilm-related genes, as in the case of the Listeria 
monocytogenes ABC transporter lm.G_1771, which negatively regulates the expression of cell 
surface proteins involved in biofilm formation 223. Another explanation is that SmeH deletion 
could lead to the accumulation of toxic compounds, or metabolic by-products, that could trigger 
a stress response and the enhancement of the expression of the biofilm-related genes, as happens 
in Burkholderia cenocepacia 224. Overall, these data indicate that S. maltophilia SmeGH efflux 
pump plays a wider role than just in antibiotic resistance, influencing additional features, such 
as biofilm formation, that are fundamental for bacterial pathogenesis.     
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4.2.2. Adaptation to tigecycline: from SmeDEF efflux pump to several genetic determinants 
 
Concerning tigecycline evolution, acquisition of resistance seems to be a more complex 
process since it involves the participation of several genes: mutations in antibiotic extrusion-
associated genes, ribosome-related genes, genes involved in the LPS biosynthesis and 
membrane homeostasis, and even large chromosomal rearrangements. In this case, the efflux 
pump-associated mutation selected in the four evolved populations is present in smeT, which 
encodes the negative transcriptional regulator of the SmeDEF efflux pump. This result suggests 
that smeDEF overexpression leads to the increased extrusion of tigecycline outside the bacterial 
cell, rendering bacteria less susceptible to this antibiotic. It is important to highlight the fact 
that both amino acid substitutions selected in SmeT after tigecycline exposure (L166Q and 
T197P) have been previously associated with antibiotic resistance due to smeDEF 
overexpression in clinical isolates, supporting the notion that experimental evolution results can 
be extrapolated to the clinical settings 225-228.  
 
Several mutations were also detected in some ribosome-related genes, such as the 
ribosome recycling factor (frr), and the 30S ribosomal proteins S10 (rpsJ), S21 (rpsU) and S1 
(rpsA). Since tigecycline, as other tetracyclines, binds to the bacterial 30S ribosome subunit, 
blocking the entry of transfer RNA and preventing protein synthesis, mutations in the target-
related genes are expected as a protective mechanism 229. Mutations in frr have been previously 
found in a similar experimental evolution performed in P. aeruginosa in the presence of 
tigecycline 51; and rpsJ has been designated as a relevant marker for detecting tigecycline 
resistance due to the fact that mutations in this gene have been identified  in other pathogenic 
bacteria after tigecycline experimental evolutions, as well as in non-susceptible tigecycline 
clinical isolates 230-232. Furthermore, a mutation in rpsJ has been recently found in a tigecycline-
resistant Klebsiella pneumoniae clinical isolate from a patient undergoing tigecycline therapy, 
pointing that rpsJ mutations can be selected in vivo during tigecycline exposure 233. Regarding 
rpsU and rpsA, this is the first report where these genes are potentially related to tigecycline 
resistance. 
 
A third set of genes related to the LPS biosynthesis and membrane homeostasis were 
found mutated after tigecycline challenge. These genes code for the lipid A biosynthesis 
enzymes lauroyl acyltransferase HtrB and the phosphoethanolamine transferase 
SMD_RS16325, the UDP-glucose dehydrogenase Ugd, the two-component sensor histidine 
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quinase PhoQ, and the diacylglycerol kinase DgkA. Except for ugd and dgkA, whose role in 
resistance has not been reported yet, the other LPS-related genes have been previously 
identified as contributors to antibiotic and/or antimicrobial peptides resistance in other bacterial 
pathogens, as in P. aeruginosa 220,234 and N. gonorrhoeae 235. Mutations in genes from the LPS 
biosynthesis pathway, but different than the ones found in our study, have also been identified 
in spontaneous E. coli mutants with low susceptibility to tigecycline 236. Although the 
relationship between LPS modification and acquisition of tigecycline resistance is unclear, we 
propose that the observed phenotype could be due to an impairment of tigecycline to diffuse 
through the membrane inside the cell (assuming that tigecycline follows the same entrance 
mechanism as tetracycline 236,237) as a result of the outer membrane modification. Mutations in 
enzymes related to other important bacterial processes, and previously described to have a role 
in resistance and/or virulence in other species were also detected, as in the S-
adenosylmethionine decarboxylase (SpeD) 238, or in the dsbB gene, an element of the 
DsbA/DsbB system 239. Nevertheless, the mechanism through which they contribute to 
tigecycline resistance needs further study.   
 
Besides SNPs and small insertions/deletions, two inverted duplications of 300- and 60-
kbp were detected in two of the tigecycline-evolved populations, respectively. Both regions, 
which share 63 common genes, contain a great variety of genetic determinants with diverse 
functions, as transcriptional regulators, transporters or enzymes. Since both inverted-and-
duplicated sequences are located within the same region of the S. maltophilia chromosome and 
share 63 genes, we suggest that these chromosomal rearrangements provide an advantage to the 
bacterium, either by contributing to tigecycline resistance, or by providing a fitness cost 
compensation. 
 
4.2.3. Evolutionary trajectories and the importance of RND efflux pumps towards ceftazidime 
and tigecycline resistance 
 
Reconstruction of the evolutionary dynamics of all the evolved lineages allowed us to 
highlight the striking similarities they share: the first step towards ceftazidime resistance in the 
four evolved populations is the P326Q amino acid substitution in SmeH, while the first genetic 
change identified in the tigecycline-evolved populations are two different amino acid 
substitutions in the SmeDEF regulator SmeT. For all the ceftazidime-evolved populations, the 
following mutations towards resistance occur from the 20th day of evolution; while for those 
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populations undergoing tigecycline exposure, mutations emerged along the whole evolution 
period, being frr the next in appearing mutated for most cases after smeT.  
 
These results highlight the importance that RND efflux pumps have in the adaptation 
towards antibiotics in S. maltophilia. This RND efflux pump-mediated acquired resistance is 
achieved through different mechanisms depending on the location of the mutations. Concerning 
the SmeGH efflux pump, the in silico analysis of its structure allowed us to localize the P326 
residue in the vicinity of the deep binding pocket of the SmeH-homolog AcrB from E. coli, 
which was used as a model for mapping the S. maltophilia SmeH residues. In addition, the in 
silico mutagenesis performed on this protein structure for predicting the impact that the P326Q 
change could have in the binding pocket conformation, shows that the Q326 residue is pointing 
towards the base of the binding cavity. Although the change in the residue orientation does not 
seem to directly affect the interaction between the SmeH binding pocket and the antibiotic 
substrate, we propose that it could interact with other residues that constitute the binding pocket 
and affect the recognition of the substrates, thus ameliorating their extrusion. Furthermore, the 
second mutated residue in SmeH, Q663, which corresponds to the V672 in AcrB, is located at 
the bottom of the predicted access pocket, which would be involved in the initial stage of drug 
binding 240. All these data suggest that ceftazidime resistance is in part achieved as a result of a 
change in the recognition and/or accommodation of the substrate, in this case ceftazidime, 
inside the transporter protein. This fact would also explain the reason why the Q663R 
substitution only confers ceftazidime resistance when P326Q is present. We suggest that 
modifications just in the access cavity, where Q663R is predicted to be located, could not be 
sufficient to cause an effect in the extrusion of the substrates. Nevertheless, when P326Q is 
present, and antibiotic binding supposedly ameliorated, both access and recognition of the 
antibiotic would be enhanced, resulting in an improved substrate extrusion. Conversely, in the 
case of SmeDEF, as mutations arose in the negative transcriptional regulator-coding gene smeT, 
we propose that the first step towards tigecycline resistance acquisition in S. maltophilia is the 
result of smeDEF overexpression, leading to an increased efflux of tigecycline outside the cell. 
Hyperproduction of RND efflux pumps, including SmeDEF, as a consequence of mutations in 
the regulatory elements, has been previously reported to contribute to the acquisition of 
resistance in S. maltophilia 47,146,150,154,225,226. However, the presence of amino acid substitutions 
in SmeH, allows us to report, for the first time, on the selection of mutations occurring in an 
efflux pump transporter protein after antibiotic exposure in S. maltophilia. 
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Although high-level resistance to both antibiotics has been acquired through the 
accumulation of mutations in different genetic elements, the fact that some of the evolved 
lineages share common aspects indicates that evolution towards either ceftazidime or 
tigecycline resistance is, to a certain degree, a deterministic process driven by the selective 
pressure and suggests that evolution can be more predictable than expected.  
 
4.2.4. Cross-resistance and collateral sensitivity as a consequence of acquisition of 
ceftazidime or tigecycline resistance 
 
Acquisition of resistance against one antibiotic can imply a variation in the susceptibility 
towards other antibiotics (cross-resistance or collateral sensitivity), from the same and/or 
different family. This possibility was examined for the reconstructed mutants carrying the 
SmeH substitutions, either alone or in combination, showing that, besides contributing to 
ceftazidime resistance, the presence of P326Q and the combination of P326Q/Q663R, also 
decrease the susceptibility to other antibiotics, particularly beta-lactams. However, the presence 
of just Q663R, does not change neither the susceptibility to ceftazidime nor to other beta-
lactams, but it does for tetracycline, suggesting that such mutation could be selected under 
tetracycline exposure without the presence of P326Q. The location of both P326Q and Q663R 
amino acid substitutions in the proximities of the predicted binding and access pockets of the 
efflux pump transporter, respectively, could lead to cross-resistance not only to ceftazidime, 
but also to other antimicrobials that are substrates of the efflux pump due to an amelioration of 
their extrusion. This picture is supported by the fact that the susceptibility to the other tested 
toxic compounds also changes in these strains.  
 
Regarding tigecycline evolution, cross-resistance and collateral susceptibility to other 
antibiotics was assessed in the four last-step tigecycline-evolved populations. The fact that 
smeDEF is overexpressed due to smeT mutations can explain the observed cross-resistance 
displayed by all the populations against quinolones, chloramphenicol, erythromycin and 
tetracycline, since they are SmeDEF substrates 147. Mutations in some ribosome-related genes, 
which are also tetracycline targets, may also explain the observed cross-resistance to this 
antibiotic. Besides these similarities, the different mutational trajectories followed by each 
independent line have also led to some differences, such as the higher susceptibility observed 
for trimethoprim/sulfamethoxazole in two of the populations. It is also important to highlight 
the observed collateral sensitivity to fosfomycin for all the tigecycline-evolved populations. 
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Although the mechanism by which this phenotype occurs remains unclear, it is relevant to 
consider a combination of fosfomycin as an antimicrobial agent for the treatment of tigecycline-
resistant S. maltophilia strains. Conversely, combination treatments including tigecycline and 
one of the antibiotics to which cross-resistance is observed, as quinolones, should be 
disregarded. 
 
4.2.5. Fitness costs associated to the acquisition of ceftazidime or tigecycline resistance 
 
The fate of a resistance mutation in a bacterial population is in part determined by the 
changes in the fitness associated to its presence. While mutations that impose little or no fitness 
cost are more probably to persist in the population in the absence of antibiotic, those resistance 
mechanisms that impose a fitness burden, typically observed as a reduction of bacterial growth 
rate, drive resistant bacteria to be outcompeted by their susceptible counterpart in an antibiotic-
free medium 87,92. Thus, fitness cost is a key parameter that influences the evolution and spread 
of antibiotic resistance 86.  
 
The fitness analysis for the S. maltophilia SmeH mutants, measured as growth in the 
absence of antibiotic, shows that the presence of smeH mutations, alone or in combination, does 
not lead to a cost in fitness. However, the absence of the efflux pump transporter implies a more 
deficient growth, which suggests that this intrinsic resistance determinant may be under positive 
selection pressure. The fact that the second amino acid substitution in SmeH emerged days after 
the first one, and did not cause ceftazidime resistance by itself, led us to think that this mutation 
could be a compensatory mutation selected to counteract a potential cost of the first one. 
However, this idea is discarded since the presence of P326Q does not suppose an impairment 
in growth, at least in the laboratory tested conditions. It has been reported that no-cost (or low-
cost) mutations are usually selected in clinical isolates 241-243. This fact makes that, in the 
absence of antibiotic treatment, bacteria harbouring these no-cost mutations are more likely to 
be maintained in the population.   
 
Regarding acquisition of tigecycline resistance, fitness was measured at different time 
points in the four evolved populations. In this case, as mutations accumulate and susceptibility 
against tigecycline decreases, bacterial fitness gets more compromised in the absence of 
antibiotic in comparison with the wild-type strain during the evolution process. Although less 
drastic than in the populations, the individual clones isolated from each evolved lineage at 
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different time points also exhibit a fitness burden along time. Although the majority of the 
selected mutations might have a potential role in tigecycline resistance, we postulate that some 
of these genetic changes, including both inverted duplications, may have been selected in order 
to compensate the costs derived from other mutations, since, in some cases, the fitness cost 
seems to be recovered between two continuous time points in both the populations and the 
single clones. These results point that, in the absence of selective pressure, tigecycline-resistant 
strains containing these mutations in their genome are less probable to be maintained in the 
whole population. 
 
The fact that SmeH substitutions drive to no fitness cost while the tigecycline-evolved 
populations and clones present an impairment in growth, demonstrates that the cost of 
resistance can be highly variable and highlights that fitness effects are strongly dependent on 
the genetic background 244. While in the first case fitness is measured in the context of the 
recreated strains, in the second situation, growth rate is determined in the whole population 
setting, as well as in single clones isolated from that populations, which may have different 
non-detected mutations that can influence the measurement of this parameter. Thus, the cross-
talk between the resistance mutation and the genetic background, including other resistance or 
compensatory mutations, can remarkably modulate the resistance-derived costs. 
 
4.2.6. Concluding remarks 
 
The results derived from this thesis provide important information concerning the 
prediction of the acquisition of antibiotic resistance by S. maltophilia, both through the transient 
expression of RND efflux pumps and via the selection of antibiotic resistance mutations. We 
have found numerous inducer compounds of the expression of two of these efflux systems by 
the use of fluorescent-based strains. This methodology can be applied to monitoring the 
expression of other types of efflux pumps of this bacterium and other bacterial species, being 
an interesting topic for future work. In addition, we have elucidated the main S. maltophilia 
mechanisms of tigecycline and ceftazidime resistance acquisition by experimental evolution 
studies, showing that RND efflux pumps play a decisive role. The clinical implications of the 
appearance of these resistance mutations under antibiotic treatment in vivo is a question for 
future research. However, the presence of some of these mutations in bacterial clinical isolates 
highlights the relevance of experimental evolution studies to understand the potential 
mechanisms involved in the acquisition of antibiotic resistance by bacterial pathogens.  
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5. Conclusions 
 
I. The use of the YFP-based S. maltophilia reporter strains allows the quantification 
and analysis of the expression driven by the promoters of SmeVWX and SmeYZ 
RND efflux pumps.  
 
II. The Biolog phenotype microarray technology can be used as a high-throughput tool 
for the identification of MDR efflux pump inducers. 
 
III. Vitamin K3, and its analogues vitamin K2 and plumbagin, as well as iodoacetate, 
clioquinol and sodium selenite are smeVWX inducers, suggesting that thiol 
reactivity is the signal that triggers smeVWX expression. 
 
IV. Boric acid, erythromycin, chloramphenicol and lincomycin are smeYZ inducer 
compounds, pointing that protein synthesis inhibition is the signal underlying the 
induction of smeYZ. 
 
V. Excepting vitamin K3, which seems to be a substrate of SmeVWX, the remaining 
identified inducer compounds of both SmeVWX and SmeYZ do not seem to be 
extruded by the efflux pump they induce, indicating that not all MDR efflux pumps 
inducers are substrates of these systems. 
 
VI. The overexpression of smeVWX and smeYZ triggered by their inducer molecules 
leads to transient resistance to antibiotics that are known substrates of one or 
another efflux system.  
 
VII. The first step leading to the acquisition of resistance to ceftazidime is achieved by 
two amino acid substitutions in the SmeGH efflux pump transporter protein, SmeH, 
possibly due to modifications in the antibiotic recognition and binding cavities. 
 
VIII.  The genetic background is of relevance regarding the contribution of each SmeH 
amino acid substitutions to ceftazidime resistance, since Q663R only changes 
ceftazidime susceptibility when P326Q is already present. 
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IX. SmeGH RND efflux pump is a relevant intrinsic resistance determinant of 
S. maltophilia for several antibiotics, including beta-lactams, quinolones, 
polymyxin B and tetracycline, as well as for other toxic compounds. SmeGH could 
also negatively regulate biofilm formation. 
 
X. The first step towards acquisition of tigecycline resistance is smeDEF 
overexpression due to mutations in the negative regulator SmeT. Ribosome-, LPS 
biosynthesis- and membrane homeostasis-related genes are also involved in the 
tigecycline acquired resistance. 
 
XI. Experimental evolution in the presence of either ceftazidime or tigecycline implies 
variation in the susceptibilities to other antibiotics, from the same and different 
families, indicating that the selected resistance mechanisms are not specific of the 
antibiotic which the evolution has been performed with. 
 
XII. Whereas ceftazidime-resistance SmeH amino acid substitutions do not lead to a 
fitness burden in S. maltophilia, the populations challenged with tigecycline present 
a more compromised fitness in the absence of antibiotic. 
 
XIII. The similarities present in the evolutionary trajectories of all the lineages in each 
of both experimental evolutions highlight the importance of RND efflux pumps in 
the acquisition of antibiotic resistance in S. maltophilia and suggest that mutation-
driven evolution towards ceftazidime and tigecycline resistance evolution can be 
largely predictable.  
 
 
  
Conclusiones 
 161 
6. Conclusiones 
 
I. El uso de cepas reporteras de S. maltophilia basadas en la proteína fluorescente 
amarilla (YFP) permite la cuantificación y el análisis de la expresión debida a los 
promotores de las bombas de expulsión RND SmeVWX y SmeYZ. 
 
II. La tecnología Biolog phenotype microarray puede usarse como una herramienta de 
alto rendimiento para la identificación de compuestos inductores de las bombas de 
expulsión múltiple de drogas (MDR). 
 
III. La vitamina K3 y sus análogos, la vitamina K2 y la plumbagina, así como el 
yodoacetato, el clioquinol y el selenito de sodio, son compuestos inductores de 
smeVWX, lo que sugiere que la reactividad del tiol es la señal que desencadena la 
expresión de smeVWX. 
 
IV. El ácido bórico, la eritromicina, el cloranfenicol y la lincomicina son compuestos 
inductores de smeYZ, lo que indica que la inhibición de la síntesis de proteínas es la 
señal subyacente a la inducción de smeYZ. 
 
V. A excepción de la vitamina K3, que parece ser un substrato de la bomba SmeVWX, 
los restantes compuestos inductores identificados, tanto para la bomba SmeVWX 
como para SmeYZ, no parecen ser expulsados por la bomba que inducen, indicando 
que no todos los inductores de bombas MDR son substratos de estos sistemas. 
 
VI. La sobre-expresión de smeVWX y de smeYZ originada por sus compuestos 
inductores genera una resistencia transitoria a los antibióticos que son substratos de 
uno u otro sistema de bombeo. 
 
VII. El primer paso hacia la adquisición de resistencia a ceftazidima implica dos 
substituciones de aminoácido en la proteína transportadora de la bomba de 
expulsión SmeGH, SmeH, posiblemente debido a modificaciones en las cavidades 
de reconocimiento y de unión del antibiótico.  
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VIII. El fondo genético tiene relevancia en lo que respecta a la contribución de cada una 
de las substituciones de aminoácido de SmeH a la resistencia a ceftazidima, puesto 
que Q663R sólo modifica la susceptibilidad a este antibiótico cuando P326Q está 
ya presente. 
 
IX. La bomba de expulsión SmeGH, de la familia RND es un determinante de relevancia 
en la resistencia intrínseca de S. maltophilia a varios antibióticos, incluyendo beta-
lactámicos, quinolonas, polimixina B y tetraciclina, así como para otros compuestos 
tóxicos. SmeGH también podría regular negativamente la formación de 
biopelículas.  
 
X. El primer paso hacia la adquisición de resistencia a tigeciclina es la sobre-expresión 
de smeDEF, debido a mutaciones en el regulador negativo smeT. Algunos genes 
relacionados con el ribosoma, así como con el lipopolisacárido y con la homeostasis 
de la membrana, también están involucrados en la adquisición de resistencia a 
tigeciclina. 
 
XI. La evolución experimental en presencia de ceftazidima o de tigeciclina implica una 
variación en la sensibilidad a otros antibióticos, de la misma y de diferente familia, 
indicando que los mecanismos de resistencia seleccionados no son específicos del 
antibiótico con el cuál se ha realizado la evolución. 
 
XII. Mientras que las substituciones de aminoácido de SmeH que dan lugar a resistencia 
a ceftazidima no conllevan un coste de fitness en S. maltophilia, las poblaciones que 
han evolucionado en presencia de tigeciclina presentan un fitness más 
comprometido en ausencia de antibiótico. 
 
XIII. Las similitudes presentes en las trayectorias evolutivas de cada una de las 
poblaciones evolucionadas destacan la importancia de las bombas RND en la 
adquisición de resistencia a los antibióticos en S. maltophilia y sugieren que la 
evolución de resistencia a ceftazidima y tigeciclina mediante mutaciones puede ser 
en gran medida predecible.  
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